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General Introduction
Chapter 1
2
OBESITY AND INSULIN RESISTANCE
The global epidemic of overweight and obesity is rapidly becoming a major public
health problem in many parts of the world, with a prevalence of at least 500 million
people worldwide (1). In addition to genetic predisposition, an inactive lifestyle as
well as calorie-dense food consumption are the main causes of excessive weight
gain (2, 3). Together with the obesity epidemic, the prevalence of related disorders,
such as the metabolic syndrome, non-alcoholic fatty liver disease, and type 2
diabetes mellitus (T2DM), is also rising. Insulin resistance plays a crucial role in the
pathogenesis of all these disorders (4). Insulin resistance is defined as an impaired
sensitivity to insulin of its main target organs, i.e. skeletal muscle, liver and adipose
tissue. Since skeletal muscle is a key metabolic tissue, accounting for 70-80% of
total glucose disposal under postprandial conditions, defects in insulin action in this
tissue are central to the pathogenesis of T2DM (5, 6). A reduction of insulin-
mediated peripheral glucose uptake produces an elevation of glucose
concentrations predominantly in the postprandial state (impaired glucose tolerance,
IGT), whereas an impaired insulin-mediated suppression of hepatic glucose output
may importantly contribute to fasting hyperglycemia (impaired fasting glucose,
IFG). Subjects with IFG and/or IGT have a 5-12 times increased risk for developing
T2DM compared to individuals with normal fasting and postprandial glucose (7).
But most obese, insulin-resistant individuals do not develop hyperglycemia. Under
normal conditions, the pancreatic islet -cells increase insulin release sufficiently to
overcome the reduced insulin action, thereby maintaining normal glucose tolerance
(8, 9). However, when insulin-producing pancreatic -cells can no longer
compensate for the decreased tissue insulin sensitivity, glucose homeostasis
deteriorates and the pre-diabetic state and eventually frank T2DM develop (10).
INSULIN ACTION
The metabolic actions of insulin with respect to glucose metabolism are
maintaining glucose homeostasis by promoting glucose uptake in skeletal muscle
and suppressing glucose production in the liver. In skeletal muscle, insulin binds to
the extracellular subunit of the insulin receptor. This causes a conformational
change in the -subunit, which has intrinsic tyrosine kinase activity, resulting in
auto-phosphorylation of insulin receptor tyrosine residues and enhanced tyrosine
kinase activity of the receptor. The activated receptor phosphorylates the insulin
receptor substrate (IRS) proteins. When phosphorylated, IRS-1 activates
phosphatidylinositol 3-kinase (PI3-K). Insulin-activated PI3-K regulates the
activation of PKB/Akt and atypical PKC isoforms λ/ζ, which results in GLUT4
translocation from its intracellular pool to the plasma membrane and glucose
transport into the cell (Figure 1) (11, 12). In adipose tissue, insulin is antilipolytic,
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where it inhibits the release of fatty acids from adipocytes by decreasing the activity
of hormone-sensitive lipase (HSL) and adipose triglyceride lipase (ATGL) (13).
Insulin also stimulates lipoprotein lipase (LPL) activity to enhance triacylglycerol
(TAG) clearance (14). In the liver, insulin decreases the release of glucose from the
liver by inhibiting hepatic glycogenolysis (glycogen breakdown to glucose) and the
expression of key gluconeogenic enzymes (15).
Figure 1. Simplified overview of the insulin signaling cascade involved in stimulating glucose
transport. See text above for more information.
FAT METABOLISM IN THE HEALTHY STATE
Major organs involved in fat metabolism are adipose tissue, skeletal muscle and
the liver (Figure 2). Dietary fat that is absorbed by the enterocytes can be
repackaged into chylomicron (CM) lipoprotein particles for distribution to the body
tissues, stored within the enterocyte or stored or oxidized in other tissues. Once
absorbed and released into the blood, dietary fatty acids carried in CM deliver lipids
to different parts of the body to be metabolized. The release of fatty acids from CM-
TAG occurs through the activity of LPL, which is bound to the capillary endothelium
of major organs in the body (16). LPL activity is regulated according to the
nutritional state in a tissue-specific manner according to the needs of the tissue for
fatty acids. In the postprandial state, LPL is activated in adipose tissue and
downregulated in skeletal muscle to direct fatty acids towards adipose tissue for
storage. The reverse is true in the fasted state since it has been shown that LPL is
activated in skeletal muscle, while it is suppressed in adipose tissue to direct fatty
acids to skeletal muscle for oxidation (17). CM-derived fatty acids are taken up by
muscle and adipose tissue to a greater extent than very low-density lipoprotein
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(VLDL)-TAG fatty acids derived from the liver. This preferential uptake of CM as
opposed to VLDL fatty acids appears strongest in the early postprandial period
(18). Adipose tissue is the main storage depot for lipids in the form of TAG. The
buffer capacity of adipose tissue refers to the capability of clearing circulating CM-
and VLDL-TAG in the postprandial state, while suppressing the release of fatty
acids into the circulation by means of a reduced endogenous lipolysis (19).
Lipolysis of adipose tissue, which liberates free fatty acids (FFA) from adipocytes,
plays another important regulatory role in conditions of increased energy demand.
FFA are an important fuel for skeletal muscle, in particular when chylomicron and
VLDL-TAG levels decrease in the post-absorptive state (20). Once entering the
muscle or liver, fatty acids are directed towards either synthesis of lipid metabolites
or mitochondrial -oxidation (Figure 2). Disturbances in fat metabolism in either of
these organs can contribute to the development of insulin resistance.
Figure 2. Simplified overview of the exogenous and endogenous pathways of fat metabolism.
FAT METABOLISM IN THE INSULIN RESISTANT STATE
As indicated above, adipose tissue plays a crucial role in buffering the flux of fatty
acids in the circulation in the postprandial period. In a state of nutritional overload,
the adipocyte increases in size until it eventually reaches a state where it can no
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longer store additional lipids. When the maximum capacity of adipose tissue
expansion is reached, lipids will remain in the circulation resulting in an increased
flux and storage in non-adipose tissues (21). A dysbalance between fatty acid
uptake and oxidation may lead to ectopic lipid accumulation to occur in tissues like
the liver, skeletal muscle and the -cells in the pancreas (22). This dysbalance may
be explained by an increased supply of lipids from the circulation or a reduced
regulation and/or capacity to oxidize fatty acids (Figure 3). It is still unclear how the
accumulation of lipids becomes toxic to the cell, and much work has focused on
identifying which lipid species are detrimental to insulin signaling and other
metabolic processes. It has been suggested that TAGs themselves are neutral lipid
species, while lipid intermediates such as diacylglycerols (DAGs), ceramides, and
fatty acyl-CoAs are able to inhibit insulin signaling pathways and promote insulin
resistance (23).
Figure 3. Disturbances in the exogenous and endogenous pathways of fat metabolism may
cause lipid overflow. Lipid overload by obesity or a high fat diet contributes to ectopic fat storage. Loss
of the normal buffer capacity of the adipose tissue may increase the flux of fatty acids and
triacylglycerols (TAG) into the circulation. Fatty acids are taken up in peripheral tissues like skeletal
muscle and the liver. An impaired fat oxidation in these tissues may direct these lipids towards storage
and accumulation of lipid metabolites, which may lead to the development of insulin resistance.
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To better understand the inter-organ crosstalk in fat metabolism and the relation
with insulin resistance, the next paragraphs will discuss the role of adipose tissue
function as well as the role of skeletal muscle fat metabolism in the development of
insulin resistance.
ADIPOSE TISSUE FUNCTION AND DYSFUNCTION
Adipose tissue stores TAG during dietary energy consumption and releases fatty
acids when energy expenditure exceeds energy intake during fasting (24). In
humans, dietary fatty acids are taken up by adipose tissue by extracellular lipolysis
of CM- and VLDL-TAG by LPL (25). In adipose tissue, the major activator of LPL is
insulin (26). Therefore, in the fed state, LPL is activated in white adipose tissue and
fatty acids will be directed to adipose tissue for esterification and storage in time of
energy excess (17). However, a significant proportion of the fatty acids from
exogenous lipolysis can also spillover in the circulation and enter the plasma FFA
pool (27). The process of fatty acid trapping in adipose tissue has shown to be
dependent on the concentration gradient of fatty acids between adipocytes and
plasma, generated by the activity of the esterification pathway of fatty acids and by
intracellular lipolysis (19, 27, 28). The principal role of adipose tissue lipolysis is to
provide other tissues with fatty acids in case of increased energy demand. Lipolysis
of TAG to fatty acids and glycerol requires three consecutive steps: the enzyme
ATGL catalyzes the initial step of lipolysis, converting TAG to DAG (29); HSL is
mainly responsible for the hydrolysis of DAG to monoacylglycerols (MAG) and MG
lipase (MGL) hydrolyzes MAG (30). Lipolysis requires that the different lipases can
access the triglycerides, which are coated by perilipin proteins surrounding the lipid
droplet (31). Perilipin A normally prevents lipolysis of TAG by surrounding the lipid
droplet, preventing the access of lipases (32). ATGL requires a coactivator protein,
comparative gene identification-58 (CGI-58), for full hydrolase activity (33).
Recently, Yang et al. discovered a specific peptide inhibitor of ATGL, G0G1 switch
protein 2 (G0S2). G0S2 expression is very low in adipose tissue during fasting but
increases after feeding (34). Lipolysis is under strong hormonal regulation. During
fasting, catecholamines are major hormones that stimulate lipolysis.
Catecholamines like noradrenaline and adrenaline can regulate lipolysis by binding
to different adrenoreceptor subtypes (1–3 and 2) that are coupled with
membrane-bound G proteins. In the fed state, insulin is the most potent antilipolytic
hormone. Insulin can activate phosphodiesterase, reducing the intracellular levels
of cAMP, thus reducing the activation of HSL (35).
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Lipid overflow: circulating FFA
In the obese insulin resistant state, elevated FFA concentrations are thought to
arise from an increased adipose tissue mass. Although an increased adipose
tissue mass can deliver more FFA into the circulation, the differences in FFA
concentrations between obese and lean subjects are generally modest and appear
not to be proportionally increased to the size of fat mass (36). In contrast, the rate
of FFA release per unit fat mass is considerably decreased in the obese. It has
been shown that the rate of FFA release per unit fat mass is almost halved in
obese subjects compared with lean in the basal state (37). Furthermore, a study
performed in 106 lean, overweight and obese non-diabetic subjects with varying
levels of adiposity (7-56% body fat) showed a decrease in the rate of FFA release
from adipose tissue with increasing fat mass. However, this downregulation in the
rate of FFA release per unit of body fat does not completely compensate for the
increase in total body fat, so whole body FFA rate of appearance increased with
increasing amounts of body fat (38). Moreover, the reduced lipolysis per unit fat
mass has been shown to be associated with downregulation of the expression of
key enzymes of fat mobilization, HSL and ATGL in obese subjects (39-41). This
suggests that hyperinsulinemia often present in the obese state may cause a
downregulation of FFA release to prevent an excessive fatty acid outflow and
worsening of the insulin resistant state (42). Furthermore, it is also argued that
adipose tissue lipolysis, normally suppressed by insulin, becomes insulin resistant.
This has been shown by insulin infusion studies in which insulin resistance of
lipolysis was observed in obese subjects (37, 43). However, clamp studies may be
misleading because in subjects with insulin resistance, plasma insulin
concentrations are elevated and the so-called insulin resistance of adipose tissue
lipolysis may simply reflect an adaptation to high ambient insulin concentrations.
Increased systemic FFA concentrations may also be achieved by a reduced fatty
acid trapping of the adipose tissue after extracellular lipolysis of circulating TAG by
LPL. However, two recent studies using a dual fatty acid stable isotope technique
showed that fatty acid spillover derived from the hydrolysis of CM-TAG was not
different between BMI matched insulin resistant and control subjects (18, 44).
These data indicate that an increased spillover from TAG-derived FA most likely
does not contribute to an elevation in circulating FFA in the insulin resistant state.
Lipid overflow: circulating TAG
Elevated TAG concentrations in both the fasting and postprandial state may be
more strongly associated with insulin resistance as compared to increased FFA
concentrations. TAG concentrations have been reported to be increased in the
obese insulin resistant state, which may be attributed to an increased liver VLDL
production or by impairments in TAG clearance from the circulation (18, 45-47).
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A reduced adipose tissue TAG clearance has been reported in obesity due to a
lower functional LPL activity per unit fat mass in combination with a reduced
postprandial upregulation of adipose tissue LPL by insulin (45, 48). Furthermore, in
obese subjects it has been shown that clearance of VLDL-TAG by adipose tissue
was decreased after an overnight fast, whilst in the postprandial state CM-TAG
clearance decreased and VLDL-TAG seemed to be better able to compete with
chylomicrons for clearance by LPL (39, 45). These data indicate that in obesity
CM-TAG are less effective substrates for LPL than VLDL-TAG possibly due to a
greater VLDL particle size reflecting an increased lipid content (49). The studies
mentioned here compared obese with lean subjects, which does not necessarily
imply that these data are representative for the insulin resistant state per se.
Indeed, comparing insulin resistant and control subjects with no or only a slight
difference in fat mass did not show a difference in CM-TAG extraction across
adipose tissue or gives, although CM-TAG extraction was not directly measured,
comparable CM-TAG concentrations in the circulation (44, 50). Obviously, there is
a need for more studies in this area covering the role of TAG concentrations in the
insulin resistant state.
Impaired adipocyte differentiation
An increase in adipose tissue lipid buffering capacity may, on one hand, be
achieved by an increased expansion of mature adipocytes (hypertrophy) and on
the other hand by recruiting new adipocytes (hyperplasia). In adult man,
hypertrophy is the most common form of storing lipids, whereas hyperplasia
predominates in the prepubertal age. However, recently it has been shown that
there is also a continuous turnover of adipocytes in adult men of 10% per year (51).
Hypertrophic obesity is more strongly associated with insulin resistance and its
metabolic complications than hyperplastic obesity (52, 53). A change from
hypertrophic to hyperplastic obesity should ameliorate these metabolic
complications. This is indeed true, since subjects treated with thiazolidindiones
showed an enhanced adipose tissue growth but with an increased number of small
adipocytes and a decrease in large adipocytes. Although adipose tissue mass
increased, insulin resistance as well as the accompanying dyslipidemia were
reduced (54). Individuals with hypertrophic obesity have been shown to possess a
low degree of adipocyte differentiation and the degree of impairment was positively
correlated with adipose cell size (55). Interestingly, this did not appear to be a
consequence of a reduced number of precursor cells. This finding is intriguing and
suggests that excess lipids cannot be stored adequately in the subcutaneous
adipose tissue in hypertrophic obesity and will be directed to non-adipose organs
like liver and skeletal muscle.
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Disturbed adipokine expression and secretion
Adipose tissue is an active secretory organ whose secretion profile is dramatically
changed in overweight and obesity. Plasma adipocytokine levels rise with an
increase in adipose tissue and adipocyte volume, except for plasma adiponectin,
which is lower in obesity (56). Through such secreted products, adipocytes
possess the capacity to influence local adipocyte biology, as well as systemic
metabolism. Leptin and adiponectin are considered to be primary adipocytokines
because they appear to be produced primarily by adipocytes. Leptin is primarily
produced by white adipose tissue and acts at the brain to maintain body weight
homeostasis by suppressing food intake and increasing thermogenesis via
sympathetic nerve activity (57). In tissues such as muscle, leptin has been shown
to stimulate lipid oxidation and reduce lipogenesis, which may contribute to
improvements in insulin sensitivity (58-60). Despite the insulin-sensitizing effects of
leptin, the obese state is characterized by hyperleptinemia, which indicates a state
of central and peripheral leptin resistance (61, 62). Adiponectin has an anti-
inflammatory role, protecting against insulin resistance, T2DM, non-alcoholic fatty
liver disease and atherosclerosis. Adiponectin acts centrally to promote weight loss
and peripherally to enhance fatty acid oxidation and glucose uptake in muscles and
decreases hepatic gluconeogenesis (63, 64). Decreased adiponectin
concentrations may have detrimental effects on fat oxidation, since it has been
demonstrated that adiponectin increases fat oxidation in rat skeletal muscle and
C2C12 myocytes (65-67). Furthermore, a reduction in adiponectin concentration
may decrease skeletal muscle glucose uptake (66, 68, 69) and increase
gluconeogenesis (67). Several inflammatory cytokines like tumor necrosis factor-α
(TNF-), interleukin-6 (IL-6), monocyte chemotactic protein-1 (MCP-1), visfatin,
and plasminogen activator inhibitor-1 (PAI-1) are expressed in adipocytes as well
as activated macrophages and/or other immune cells (70). TNF- increases
lipolysis in human and 3T3-L1 adipocytes (71, 72). In addition, IL-6 has also been
shown to stimulate lipolysis in vivo in humans (73). Therefore, these local effects
on adipose tissue lipolysis may contribute to the development of insulin resistance.
Furthermore, TNF- may impair insulin sensitivity by triggering different key steps
in the insulin signaling pathway (74).
Mechanisms for adipose tissue inflammation
Growing evidence links low-grade inflammation in adipose tissue with obesity and
insulin resistance. During the progression to obesity, the adipose tissue expands
and this may lead to hypoxia in certain parts of the adipose tissue because the
blood supply is insufficient. Local adipose tissue hypoxia is partly responsible for
dysregulated adipokine production and may contribute to adipocyte death (75, 76).
However, there is still a lot of controversy if hypoxia is a trigger of the inflammatory
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response since it has been shown that adipose tissue oxygen tension was
increased rather than decreased in the obese state despite a lower adipose tissue
blood flow, which may be explained by a lower adipose tissue oxygen consumption
in obesity (77). Furthermore, hypertrophic adipocytes are subjected to several
other cytotoxic stressors, including endoplasmic reticulum stress and reactive
oxygen species (78, 79). These cytotoxic stresses activate inflammatory signaling
cascades, which leads to chemokine release and subsequent recruitment of
macrophages into the adipose tissue, where they can form ring-like structures
around large, dying adipocytes (80). The primary purpose of these recruited
macrophages is the removal of cell debris and tissue remodeling. The precise
mechanisms that regulate the recruitment of new macrophages to adipose tissue
are unclear but may involve MCP-1, which is a chemokine that promotes the
recruitment of monocytes to damaged or inflamed tissues, and its receptor
chemokine (C-C motif) receptor 2 (CCR2) (81). Macrophage phenotypes exist
across an M1 to M2 polarization state in which M1 cells are operationally defined
as “classically activated”, pro-inflammatory macrophages, while M2 cells make up
the “alternatively activated”, anti-inflammatory macrophage population (82). In
obesity, the adipose tissue consists mainly of macrophages of the M1 phenotype
(83). Accordingly, because of their pro-inflammatory properties, these
macrophages are implicated in the pathogenesis of insulin resistance (84). In
humans this classification in M1/M2 may be less straightforward and oversimplified
but it provides a useful initial structure for distinguishing macrophage functions.
Adipose tissue macrophages are surrounded by a lipid-rich environment, which can
further induce macrophage inflammatory processes via activation of the pattern
recognition receptors TLR2 and TLR4 (83, 85). In addition to macrophages,
adipose tissue is known to contain other immune cells like CD4+ and CD8+ T cells,
natural killer T cells, B cells, eosinophils, neutrophils, and mast cells, which may
also contribute to adipose tissue inflammation (86-88).
In summary during long-term excessive energy intake, adipose tissue mass
increases, to store the overload of lipids. Hypertrophic obesity, which develops, is
characterized by a low degree of adipocyte differentiation and may further impair
increased fatty acid storage contributing to a limited buffering capacity of the
adipose tissue. This may increase the supply of lipids to non-adipose tissues like
skeletal muscle and result in ectopic lipid accumulation, which is associated with
the development of insulin resistance. Furthermore, expansion of the adipose
tissue is associated with an altered production of adipokines and an increased
inflammatory response. This may also contribute to the insulin resistant state via
modulation of skeletal muscle fat metabolism or interference with the insulin
signaling cascade. Besides the increased supply of lipids to skeletal muscle, also
intrinsic disturbances in skeletal muscle fatty acid handling may play an important
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role in the development of insulin resistance, which will be described in more detail
in the next paragraphs.
SKELETAL MUSCLE FUNCTION AND DYSFUNCTION
Skeletal muscle is responsible for 70-80% of insulin-stimulated whole-body glucose
disposal and plays an important role in the pathogenesis of insulin resistance (6).
Various methods have been used to investigate in vivo fatty acid metabolism in
order to more clearly define the aspects of lipid metabolism that contribute to the
pathogenesis of insulin resistance. Isotope dilution and indirect calorimetry
techniques provide information on rates of whole-body lipid utilization (89, 90).
Regional lipid metabolism has been studied by following changes in the interstitial
glycerol concentration, using semi-permeable microdialysis catheters as well as
arterio-venous (A-V) balance techniques, based upon measurement of metabolite
concentrations of arterial blood and venous blood draining the organ of interest in
combination with tissue blood flow determination (91-93). Disturbances in fatty acid
metabolism have been suggested to contribute to the development of skeletal
muscle insulin resistance. Moreover, increased muscle fat accumulation has been
linked to insulin resistance and may be a consequence of an increased supply of
lipids to skeletal muscle as has previously been described, or intrinsic disturbances
in the regulation of fatty acid uptake, storage and/or oxidation. The next
paragraphs will describe skeletal muscle fat metabolism with respect to fatty acid
uptake and fatty acid partitioning towards either storage or oxidation and how
disturbances in these processes may contribute to the development of the insulin
resistant state. Moreover, an overview will be given of the different paradigms,
which link the intrinsic disturbances in skeletal muscle fat metabolism to insulin
resistance.
Fatty acid uptake in skeletal muscle
Regardless of the debate whether plasma FFA and/or TAG concentrations are
increased in obesity and insulin resistant conditions or not, differences in the ability
to take up fatty acids by skeletal muscle have been reported as well. For many
years, it was believed that the transport of fatty acids across the plasma membrane
in skeletal muscle occurred only via passive diffusion. However in recent years,
many studies have demonstrated that fatty acid uptake into skeletal muscle also
occurs via a protein-mediated process (94-96). The membrane-associated
proteins in skeletal muscle have been identified as fatty acid translocase
(FAT/CD36) (97), fatty acid binding protein (FABPpm) (98) and fatty acid transport
protein (FATP1-6) (99, 100). Inside the cell, fatty acids remain water insoluble and
are bound to one of two proteins: FABPc or acyl-CoA binding protein. FABPc is
abundantly present in the cytosol and likely works together with FAT/CD36 to
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transport long chain fatty acids across the plasma membrane (101). The exact
contribution of these transporters to fatty acid uptake is not clear, but FAT/CD36 is
thought to be the predominant transporter, and is the one most studied (102). In
addition, these transporters may interact with each other to facilitate fatty acid
uptake, as interactions between FAT/CD36 and FABPpm, and between FAT/CD36
and FATP have been identified in controlling fatty acid uptake (103, 104). Thus,
uptake of fatty acids into the skeletal muscle depends on both fatty acid
concentration in the blood and tissue (blood-tissue concentration gradient) and on
the regulation of the transporters (105).
Increased rates of fatty acid uptake across plasma membranes in vitro have been
observed in skeletal muscle of obese individuals and T2DM subjects. The
increased rates of fatty acid transport have been associated with increases in
plasma membrane FAT/CD36, while FAT/CD36 protein expression was not
altered, suggesting that a permanent redistribution of FAT/CD36 to the plasma
membrane occurred (106). Several in vivo human studies showed no effect on
skeletal muscle fatty acid uptake during fasting or postprandial conditions in obese
individuals, insulin resistant subjects or subjects with impaired glucose metabolism
compared with their controls (44, 107-109). Notably, in all of these studies
circulating FFA concentrations were comparable between groups or slightly
elevated in the more insulin resistant group. Two other studies reported a slightly
elevated muscle FFA uptake during fasting conditions despite comparable FFA
concentrations in obese and insulin resistant conditions (18, 110). Thus, there is
not much evidence available from in vivo human studies that skeletal muscle FFA
uptake is increased in the insulin resistant state.
The contribution of TAG-derived FA to skeletal muscle FA uptake is currently not
fully understood but may be equally important as circulating FA (111, 112). The
activity of LPL may be an important contributor to an increased muscle TAG
extraction. Insulin has shown to stimulate LPL activity in adipose tissue but does
not appear to activate LPL in skeletal muscle (113, 114). Downregulation of LPL
increased glucose uptake in L6 muscle cells, while a tissue-specific overexpression
of LPL in skeletal muscle increased cellular stores of TAG and led to insulin
resistance (115, 116). Moreover, in insulin resistant subjects it has been shown
that TAG extraction across the muscle was increased (44, 109). Therefore, it can
be postulated that in insulin resistant conditions, the insulin mediated suppression
of muscle LPL is impaired, resulting in an increased fatty acid supply to the muscle.
This may possibly enhance muscle lipid accumulation, which can interfere with the
insulin signaling cascade.
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Fatty acid partitioning within skeletal muscle
Once fatty acids are transported into the cytosol, fatty acids are esterified to fatty
acyl-CoA by the enzyme acyl-CoA synthetase, which then enters the mitochondria
for oxidation or is partitioned towards the synthesis of intramyocellular lipid (IMCL)
(117).
Fat storage
The synthesis of TAG from fatty acids starts with the sequential addition of
activated fatty acyl-CoAs to a glycerol backbone. The first committed step in TAG
synthesis is catalyzed by glycerol-3-phosphate acyltransferase (GPAT), which
results in the synthesis of lysophosphatidic acid (LPA). In subsequent steps, LPA is
converted to phosphatidic acid (PA), and PA is converted to DAG. The final step in
triglyceride synthesis is the addition of a fatty acyl-CoA to DAG by DAG
acyltransferase (DGAT) (118). This enzyme has dual significance in that it
promotes triglyceride storage but also decreases the TAG precursor DAG, which
may have an inhibitory effect on insulin signaling (119, 120). However, unilateral
DGAT overexpression in skeletal muscle has been shown to increase the storage
of IMCL but remarkably also resulted in an increased DAG content even though an
improvement in insulin sensitivity was observed (121). This may suggest that not
DAG and TAG content per se are related to insulin resistance. Increasing DAG and
TAG turnover and thus a proper balance between supply and oxidation may
prevent insulin resistance. Lipid turnover is not only determined by TAG synthesis
but also by TAG lipolysis. Disturbances in the regulation of skeletal muscle lipolysis
may also contribute to the accumulation of lipids and lipid intermediates. Under
fasting conditions it has been shown that total glycerol release was reduced across
the forearm muscle of obese subjects compared with lean controls (110).
Furthermore, it was shown that HSL protein content was lower and ATGL protein
higher in obese insulin resistant subjects. This difference in muscle lipase content
was accompanied by a lower DAG hydrolase activity and normal TAG hydrolase
activity suggesting incomplete TAG hydrolysis. Surprisingly, no accumulation of
DAG was observed in skeletal muscle (122). This could be partially attributed by a
rapid conversion of DAG back to TAG by DGAT, which may be a protection
mechanism to prevent accumulation of potential lipotoxic DAG. There is still a lot of
controversy about the lipotoxic potential of several lipid metabolites. It may be that
not TAG or lipid metabolite content per se is associated with insulin resistance but
that muscle lipid turnover and lipid metabolite composition, and localization may
play an important role.
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Fat oxidation
The capacity of the body or cells to rapidly switch substrate oxidation from
predominantly lipid oxidation and high rates of fatty acid uptake during fasting
conditions to the suppression of lipid oxidation and increased glucose uptake,
oxidation and storage under insulin-stimulated conditions is defined as metabolic
flexibility (123, 124). In healthy, metabolically normal individuals substrate
switching occurs rapidly and completely. If skeletal muscle cannot match fat
oxidation to lipid supply, fat accumulation will ensue, which will in turn cause insulin
resistance. Fatty acids are the main readily available energy sources during the
transition from the fed to the overnight-fasted condition. Several studies suggest
that fasting respiratory quotient (RQ) is elevated in skeletal muscle from obese
insulin resistant and type 2 diabetic adults, which indicates lower rates of fat
oxidation (107, 125). A reduced fat oxidation in T2DM subjects has also been
reported during exercise (126) and in obese subjects after beta-adrenergic
stimulation (127). Impairments in postprandial fat oxidation possibly play a larger
role in fatty acid-induced insulin resistance, since most individuals are in a
postprandial state for the greatest part of the day. During insulin stimulation,
several studies described an impaired capacity to increase muscle and whole body
glucose oxidation and a blunted suppression of fat oxidation in insulin resistant
subjects (107, 123). After a meal, fuel switching was also disturbed in prediabetic
and T2DM subjects (108, 125). The underlying mechanisms responsible for the
impaired fat oxidation are discussed in the next paragraphs.
FA uptake in mitochondria
The rate-limiting step for -oxidation of long-chain fatty acids is their transport into
the mitochondria via carnitine palmitoyltransferase-I (CPT-1) (128). While short and
medium chain fatty acyl-CoA are believed to diffuse into the mitochondria, long
chain fatty acyl-CoA (LCFA-CoA) require modification before crossing the inner
mitochondrial membrane for oxidation. The LCFA-CoA is transported across the
inner mitochondrial membrane as an acylcarnitine complex, which is synthesized
via CPT-1. Once across the inner mitochondrial membrane, the acylcarnitine is
converted back to the original fatty acyl-CoA and released into the matrix to enter
the -oxidation pathway (129). Two regulatory mechanisms of CPT-1 have been
proposed. One involves malonyl-CoA and the other involves the cytosolic
concentration of carnitine. Malonyl-CoA is an allosteric inhibitor of CPT-1, so any
changes in malonyl CoA concentration can alter mitochondrial uptake of fatty acids
and consequently the rate of fatty acid oxidation in the mitochondria (130, 131).
The concentration of malonyl CoA is controlled by its turnover, in which acetyl CoA
carboxylase (ACC) catalyzes the synthesis pathway, and malonyl CoA
decarboxylase (MCD) controls its degradation (132). In human skeletal muscle it
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has been shown that hyperinsulinaemia increases malonyl-CoA, inhibits functional
CPT-1 activity and shunts fatty acids away from oxidation towards storage (133). A
key determinant of ACC activity is the activity of AMP-activated protein kinase
(AMPK). This is generally called the “fuel sensor’ of the cell that is activated with an
increased AMP:ATP ratio (134). AMPK can phosphorylate and inactivate ACC,
which relieves CPT-1 from malonyl CoA's inhibitory effect, resulting in a stimulation
of fatty acid -oxidation (135). In skeletal muscle, it has also been suggested that
AMPK can directly activate MCD (136). Recently, it has been suggested that the
mitochondrial transport of fatty acyl-CoA may involve other proteins in addition to
CPT-1 (137). It appears that FAT/CD36 works in conjunction with CPT-1, because
they together influence rates of mitochondrial FA oxidation, and are co-localized in
the mitochondria (138, 139). FABPpm is another well-recognized plasma
membrane FA transport protein that has also been found on mitochondria (140,
141). However, the role of FABPpm with respect to mitochondrial FA oxidation
remains unknown.
Mitochondrial function/dysfunction
The mitochondria in obese and insulin resistant individuals have also been
hypothesized to be dysfunctional, this could be due to a decreased number of
normally functioning mitochondria or a defect in individual mitochondria per se
(142, 143). Results on the role of mitochondria in insulin resistant skeletal muscle
have been conflicting. Several studies reported a reduction in mitochondrial
content or reduced oxidative capacity of individual mitochondria in skeletal muscle
(144-147). In other studies, however, no alterations in mitochondrial oxidative
capacity were observed (148, 149). Some but not all studies showed reduced
expression of peroxisome proliferator activated receptor γ coactivator 1  (PGC1)
and PGC1, the main regulators of mitochondrial biogenesis and fatty acid
oxidation in patients with T2DM and their nondiabetic relatives (150-152). The
PGC1 family of coactivators responds to environmental and nutritional stimuli and
is controlled at the post-transcriptional level; normal protein or mRNA levels of
PGC1, therefore, do not exclude impairments in protein activity or binding to
docking sites (153). It still remains to be determined whether this mitochondrial
dysfunction is a direct cause of insulin resistance in obesity or is a secondary
consequence of obesity/insulin resistance and/or reduced physical activity. The
latter may also exacerbate the metabolic disturbances associated with insulin
resistance.
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Recently, an alternative hypothesis connecting fatty acid oxidation to insulin
resistance has been proposed. Insulin resistance in skeletal muscle may be
accompanied by a dysbalance between -oxidation and tricarboxylic acid (TCA)
cycle activity. When -oxidation exceeds the ability of the mitochondria to utilize
acetyl-CoA in the TCA cycle, there is an accumulation of incompletely oxidized,
fatty acid products (i.e. acylcarnitines), which can impair skeletal muscle insulin
sensitivity (154). Accordingly, patients with T2DM and obesity accumulate plasma
acylcarnitines that arise from increased rates of inefficient fatty acid oxidation
(155).
Paradigms relating disturbances in fat metabolism to insulin
resistance
From previous paragraphs it has become clear that disturbances in skeletal muscle
fatty acid metabolism may play an important role in the development of insulin
resistance. Two paradigms will be discussed to explain how fatty acids can impair
glucose uptake and insulin signaling.
Glucose FA cycle
In the 1960s, Randle and colleagues (156) proposed a mechanism by which fatty
acids could impair insulin-stimulated glucose oxidation in muscle. This mechanism
was called the glucose-fatty acid cycle. High levels of fat oxidation increased the
ratios of acetyl coenzyme A to coenzyme A and NADH to NAD+ in the
mitochondria, with subsequent inactivation of pyruvate dehydrogenase. This in turn
causes citrate concentrations to increase, leading to inhibition of
phosphofructokinase. Subsequent increases in intracellular glucose-6-phosphate
may inhibit hexokinase activity, resulting in a reduced glucose uptake and
oxidation. Several studies argue against the mechanism postulated by Randle et
al., showing that the reduced insulin-stimulated glucose uptake and glycogen
synthesis in type 2 diabetic patients were associated with a reduction rather than
an increase in concentrations of glucose-6-phosphate in muscle (157, 158).
Similarly, insulin stimulated concentrations of glucose-6-phosphate and rates of
muscle glycogen synthesis were reduced in lean, normoglycemic, insulin-resistant
first-degree relatives of patients with T2DM (159). Other findings have led to the
proposal of an alternative mechanism whereby increased intramuscular lipids lead
to downregulation of insulin signaling in human skeletal muscle (160). In healthy
individuals, the onset of skeletal muscle insulin resistance was delayed by 3-4
hours after exposure to high concentrations of plasma fatty acids and was
accompanied by increased IMCL (161). Additionally, exposure to high
concentrations of plasma FFA caused insulin resistance associated with an
General Introduction
17
induced defect in either glucose transport or phosphorylation activity, not an
impairment in glycolysis (162). However, as mentioned previously, FFA
concentrations are not necessarily increased in the insulin resistant state.
Ectopic fat accumulation
Accumulation of IMCL in obese skeletal muscle may result from a dysbalance
between muscle fatty acid uptake and oxidation. Despite studies reporting a link
between IMCL and insulin resistance, it is now evident that this is not a simple
cause and effect relationship (163, 164). For example, endurance athletes are
extremely insulin sensitive, yet have elevated IMCL levels (165). This observation,
often referred to as the athlete’s paradox, has led to the insight that IMCL per se
does not lead to insulin resistance.
One hypothesis to explain this paradox is that trained athletes have a higher
muscle oxidative capacity, while increased IMCL levels in obese subjects have
been associated with a decreased oxidative capacity (165). A proper balance
between supply and oxidation may prevent the development of insulin resistance.
Additionally, as long as fatty acids are efficiently directed towards storage as TAG,
there is no interference with insulin signaling. Indeed, it has been shown that the
triglyceride synthesis enzyme DGAT increased in muscle cells in response to
exercise in parallel to an increase in insulin sensitivity (166). From this paradox, it
became evident that not IMCL per se but rather other lipid metabolites like DAG,
ceramide and fatty acyl-CoA may interfere with the insulin signaling pathway and
may contribute to the development of insulin resistance.
Diacylglycerol
DAG is an important second messenger involved in intracellular signaling and it is
thought that DAG may have detrimental effects on insulin action through its ability
to activate PKCθ and PKCε in muscle (167, 168). Inappropriate activation of PKCs
may interfere with insulin action by promoting serine/threonine phosphorylation of
the insulin receptor and/or IRS-1, thus preventing tyrosine phosphorylation of these
proteins that are necessary for the function of the insulin signaling cascade and
stimulation of glucose transport (169). In human studies, accumulation of DAG in
skeletal muscle of obese, and diabetic individuals was positively correlated with the
increased activity of PKCθ (170, 171). Although lipid infusion in humans induces
insulin resistance together with increased intramyocellular DAG levels (172), the
support for a role of skeletal muscle DAG accumulation in the development of type
2 diabetes is inconsistent. Recent evidence proposes that it is not total DAG
content per se but rather specific DAG-subspecies that may be important. Several
DAG-subspecies exist that differ in fatty acid composition and the position of the
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fatty acid on the glycerol backbone. Only 1,2-DAG accumulates in membranes and
is capable of activating PKCs, while 2,3-DAG and 1,3-DAG arises from TAG
hydrolysis at the lipid droplet (173-175). Several studies investigated the fatty acid
composition of intramyocellular DAG and found that saturated DAG had a negative
influence on insulin signaling (176). Van Hees et al. (44) reported similar total DAG
and TAG levels between insulin sensitive and insulin resistant men, but a higher
degree of saturation of skeletal muscle DAG in the latter group. In addition to
composition, the insulin-desensitizing effects of DAG may be governed by its
subcellular location (cell membrane, ER and lipid droplet) (177). The majority of the
studies published in humans report total skeletal muscle DAG concentration,
without measuring compartmentalization within the cell. Since the adverse effects
of PKC are confined to cell membranes, it is likely that only DAGs located in certain
compartments influence insulin signaling. Bergman et al. (178) were the first to
reveal that membrane localization of DAG in skeletal muscle, rather than total
intramuscular concentration, drives insulin resistance in humans and that
especially saturated DAG had a particularly negative impact on insulin sensitivity.
Ceramides
Another group of lipid intermediates whose contribution in the development of
insulin resistance has been proposed are the ceramides, which belong to the
sphingolipids. Ceramides can accumulate in skeletal muscle either by the
hydrolysis of sphingomyelin (a phospholipid located in the lipid bilayer of the cell)
(179), or by de novo synthesis from long-chain saturated fatty acids (180).
Ceramides are important membrane building blocks and intracellular messengers
that are believed to interfere with insulin signaling. It has been postulated that
ceramides inhibit insulin action via the inhibition of Akt phosphorylation, resulting in
an inhibition of GLUT4 translocation (181, 182).
Fatty acyl CoA
Lipid intermediates that have received less attention so far are fatty acyl-CoAs. If
fatty acid uptake exceeds the capacity for directing the fatty acids towards lipid
synthesis or -oxidation, fatty acyl-CoA will accumulate in the cell. Fatty acyl-CoAs
have been proposed as a better predictor of insulin resistance than IMCL (183). It
remains unclear through which mechanism(s) fatty acyl-CoAs may affect insulin
action, but some data suggests that fatty acyl-CoAs may interfere with insulin
signaling through the activation of PKC isoforms (169). It is also possible that fatty
acyl-CoAs act indirectly by acting as a precursor of other lipid intermediates such
as DAG and ceramide.
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CONCLUDING REMARKS
It is clear that the development of insulin resistance is associated with disturbances
in lipid metabolism. Despite intense research, current understanding of
mechanisms underlying lipid-induced insulin resistance remains incomplete. The
majority of evidence supports the concept that a dysbalance between fatty acid
uptake and oxidation may lead to ectopic lipid accumulation, which can interfere
with insulin signaling. It seems that not lipid content per se is associated with
insulin resistance but that rather muscle lipid turnover and lipid metabolite
composition and localization play an important role. Furthermore, the dysbalance
may be explained by an increased supply of lipids from the circulation or an
intrinsic disturbance in fatty acid uptake, storage and/or oxidation. It seems that
elevated TAG concentrations may have a greater contribution to the increased
supply of lipids to skeletal muscle than FFA. These elevated TAG concentrations
may arise from a limited buffer capacity of the adipose tissue or an increased liver
VLDL production. Further studies are needed to improve the knowledge of
mechanisms contributing to lipid induced insulin resistance.
FAT METABOLISM IN RELATION TO BODY WEIGHT
CONTROL
Body composition and body mass can remain stable over time only if the
metabolizable energy ingested matches the energy being expended, so if the
individual remains in energy balance. For weight maintenance, not only energy
balance plays an important role, but also macronutrient intake must balance
macronutrient oxidation. This means that over time, the quantity of carbohydrate,
fat and protein consumed equals the amount of each oxidized (184). Protein intake
is usually around 15% of dietary energy. The daily protein intake is about 1% of the
total protein stores (185). The protein stores increase in size only in response to
growth stimuli, such as growth hormone, androgens, physical training and weight
gain, but not simply from increased dietary protein. Thus, protein stores are tightly
controlled and protein balance is achieved on a day-to-day basis. Carbohydrate is
usually the main source of dietary energy, yet the body stores of glycogen are very
limited to amounts of about 500–1000g (186). Daily intake of carbohydrate
corresponds to about 50–100% of the carbohydrate stores compared with about
1% for protein and fat (187). Excess carbohydrate intake cannot be the basis of
weight gain because the storage capacity is limited and controlled, and conversion
to fat only occurs under extreme conditions in humans (186). In contrast to the
other nutrients, body fat stores are large, and fat intake has no or very little
influence on fat oxidation (187). In response to an increase in dietary fat content,
fat oxidation can take more than 1 week to match fat intake (188). Any excess of
Chapter 1
20
fat in the everyday diet is stored and contributes to an increased adipose tissue
mass (189, 190).  However, there are individual differences in the extent to which a
high dietary fat intake results in increased fat oxidation and body fat gain. There
are indications that obese subjects may have a diminished capacity to oxidize fat
and adapt more slowly to a high dietary fat intake compared with lean subjects
(189, 191). A limited capacity to adjust fat oxidation to fat intake may translate into
a positive fat balance and weight gain in the long term (192).
Flatt postulated a two-compartment model in which it is stated that when the
dietary fat content increases, fat oxidation can be raised by either maintenance of
low glycogen stores or by expansion of the adipose tissue mass (193). Indeed, it
has been shown that obese subjects are capable of rapidly adjusting fat oxidation
to fat intake when glycogen stores are lowered by an exhaustive exercise test
(194). Also, ad libitum consumption of a high fat diet has been shown to expand
body fat stores, which increased fat oxidation until a new equilibrium is reached
between fat intake and fat oxidation.  A 10-kg change in fat mass has been shown
to correspond to a change in fat oxidation of 11 g/d (8- 14 g/d) (195). Weight
maintenance requires that the body’s metabolism oxidizes as much glucose, fatty
acids, and amino acids as are supplied by the diet. The goal is to achieve this
steady state without the need for an undesirable expansion of the adipose tissue
mass. Therefore, dietary interventions that may promote fat oxidation are currently
an area of intense investigation since they may be beneficial for both body weight
control as well as reducing ectopic fat accumulation promoting thereby insulin
sensitivity.
DIETARY INTERVENTIONS FOR IMPROVING INSULIN
SENSITIVITY AND BODYWEIGHT CONTROL
Changes in lifestyle are considered to play an important role in the etiology of
obesity and T2DM. Manipulation of diet and physical activity are the first-choice
treatment for these metabolic diseases. Sustaining a healthy dietary lifestyle to
facilitate weight loss is often difficult in an environment where palatable high-fat
foods are easily available. Dietary approaches to increase the effectiveness of
dietary intervention are being studied. The identification of food and food
ingredients that could influence specific physiological targets like increasing fat
oxidation and restoring metabolic flexibility may be helpful in the prevention and
treatment of obesity as well as diabetes (196).
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CALORIE RESTRICTION
Calorie restriction has consistently been proven to produce weight loss and to have
beneficial health effects like an improved insulin sensitivity (197, 198), possibly
mediated via modulation of fat metabolism. Weight loss showed either an
improvement (199) or no change (107) in fasting fat oxidation. After weight loss,
obese prediabetic subjects have been shown to improve their capacity to switch
from fat oxidation to carbohydrate oxidation after a meal (108). Altogether, there
are clear indications that weight loss is able to partly reverse postprandial
impairments in substrate oxidation, which may be positively associated with insulin
sensitivity, whereas with respect to the fasting condition, improved regulation of fat
oxidation could not be confirmed in all studies. In post-obese women an impaired
postprandial fat oxidation may contribute to weight regain (200). Furthermore,
weight loss induced by calorie restriction has been shown to improve insulin
sensitivity and to reduce IMCL in obese subjects (201, 202). The reduction in IMCL
may be due to an increased lipid oxidation capacity. At the molecular level in
skeletal muscle, the expression of genes involved in the regulation of mitochondrial
biogenesis was increased after calorie restriction. In parallel, mitochondrial content
increased in the calorie restriction group (203). The molecular mechanisms that
underlie the upregulation of mitochondrial mass and function may be related to
Sirtuin-1 (SIRT1) which deacytylates and activates PGC1 suggesting a direct link
between SIRT1 and mitochondrial bioenergetics (204, 205). Surgically-induced
weight loss increased PGC1 expression in previous morbidly obese subjects
(206, 207), while Berggren et al. (208) observed no change in PGC1 expression
after weight loss in obese subjects.
Underlying mechanisms mediating the effects of calorie restriction on insulin
sensitivity may involve changes in skeletal muscle fatty acid handling but this
needs to be further elucidated.
RESVERATROL
Polyphenolic compounds, such as resveratrol have, recently, received wide interest
due to their ability to mimic effects of calorie restriction. Resveratrol is found in
peanuts, grapes and red wine, with potential therapeutic implications including anti-
inflammatory, antioxidant, cardio-protective, anti-aging actions and beneficial
properties against metabolic diseases (209). Although originally the focus was
mainly directed towards anti-oxidant properties of resveratrol (210), more recently
cellular effects on fatty acid metabolism and mitochondrial function have been
described. By reversing disturbances in fat metabolism resveratrol may be able to
improve the success of lifestyle interventions with respect to insulin sensitivity and
body weight control.
Chapter 1
22
Glucose metabolism and insulin sensitivity
Insulin resistance has been linked to IMCL accumulation which may develop
because of an impaired mitochondrial function that directs fatty acids towards
storage, as opposed to oxidation (211, 212). In line with this, resveratrol has shown
to improve both muscle oxidative capacity and insulin sensitivity in high fat-fed
mice (213). The effect of resveratrol on the induction of oxidative phosphorylation
genes and mitochondrial biogenesis was largely explained by the activation of
SIRT1, which decreased PGC1 acetylation and increased PGC1 activity.
Besides the ability of resveratrol to activate SIRT1, recent work has shown that
many of the favourable effects of polyphenols occur in an AMPK-dependent
manner, indicating that AMPK signaling is likely involved in the insulin-sensitizing
effects of these compounds (214). Auwerx and colleagues (215) proposed that
AMPK might be an upstream target of resveratrol or calorie restriction prior to
SIRT1 activation. Some studies have shown that resveratrol can stimulate glucose
uptake independent of the action of insulin as well as enhance insulin dependent
glucose transport (216-218). In the absence of insulin, the effect of resveratrol on
glucose uptake was primarily dependent on AMPK activation, without involving
PI3K. In the presence of insulin, resveratrol also potentiated the effect of insulin on
glucose uptake via AMPK activation, but leading to activation of the PI3K-Akt signal
pathway (218). In T2DM patients it was found that low dosages of resveratrol
decreased blood glucose levels and improved insulin sensitivity, as measured by
the HOMA index (219).
Body weight control
Resveratrol has been shown to markedly attenuate weight gain in association with
induction of mitochondrial biogenesis in skeletal muscle and brown adipose tissue
in high-fat fed mice. In parallel, the resveratrol-treated mice showed increased
endurance capacity, higher oxygen consumption, and improved glucose tolerance
(213). In contrast, Baur et al. (220) reported that although resveratrol
supplementation was beneficial in protecting high-fat fed mice against some of the
negative health consequences of obesity, such as insulin resistance, the
supplementation did not protect them from weight gain. The reason for the
discrepancy is not clear, however, it may be due to the dose of the resveratrol used
and/or to the length of the study. Further research is necessary to investigate the
effect of resveratrol on body weight regulation.
Resveratrol and adipose tissue function
The effect of resveratrol on adipose tissue metabolism is mediated, at least in part,
by a reduction in fatty acid uptake from TAG in circulating lipoproteins caused by a
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reduced LPL activity (221). The effects of resveratrol on lipolysis have been
analysed by Szkudelska et al. (222). They observed an enhanced lipolytic
response to epinephrine induced by resveratrol. No changes were observed in
mRNA levels of ATGL, while HSL mRNA expression was increased in resveratrol-
treated animals, showing that this molecule acts differently on both lipases (222). In
contrast Lasa et al. (223) demonstrated an increased ATGL gene and protein
expression, while HSL expression was not changed. Resveratrol has been shown
to promote fat mobilization through activation of SIRT1 and suppression of
peroxisome proliferator-activated receptor- (PPAR), resulting in decreased TAG
storage and increased secretion of FFA. Furthermore, resveratrol inhibited insulin-
stimulated de novo lipogenesis. This effect was accompanied by the
downregulation of key lipogenic molecules, such as Fatty acid synthase (FAS) and
ACC (224). Overall, resveratrol has been proven to promote lipolysis and inhibit
lipogenesis in murine animals and in vitro experiments. This may lead to a
diminished lipid accumulation in adipocytes and a decrease in adiposity.
Nevertheless, this may increase the supply of FFA and TAG to non-adipose organs
such as liver and skeletal muscle and may possibly contribute to impairments in
insulin sensitivity if fat oxidation is not matched. Therefore, further research is
necessary in order to determine resveratrol’s whole body mechanism of action and
how it affects the balance between adipose tissue lipolysis and muscle fat oxidation.
Resveratrol has also shown to reduce proinflammatory cytokine expression in
cultured adipocytes (225, 226) and in rodent white adipose tissue (227). Because
adipose tissue inflammation is tightly linked to systemic insulin resistance,
resveratrol-induced down-regulation of the adipose expression of cytokines such
as Il-6, MCP-1, TNF and PAI-1 may contribute to the insulin sensitizing effect of
resveratrol supplementation (213, 220, 225-228). In addition, resveratrol has
shown to up-regulate the expression of adiponectin - an adipokine with well-
established antidiabetic and anti-inflammatory action - both in cultured adipocytes
and in WAT of obese Zucker rats (227, 229). In general, it has been established
that resveratrol holds anti-inflammatory properties.
In summary, resveratrol represents the first in a novel class of SIRT1 activators
that are proven to be safe and well tolerated in humans. It might be a good
candidate for drug development because it mimics the metabolic benefits of calorie
restriction like improving mitochondrial function, insulin sensitivity and modulation
of adipose tissue function but human data are still lacking (230).
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DIETARY FATTY ACIDS
In most western countries, energy intake from fat is around 35-40% of total energy.
Through our diet we are exposed to a variety of different fatty acids like saturated
fatty acids (SFA), monounsaturated fatty acids (MUFA) and polyunsaturated fatty
acids (PUFA), which are reflected in lipids of plasma and tissues. An
overconsumption of saturated fats has been implicated as a causative factor for the
development of insulin resistance, whereas certain monounsaturated fats and
PUFAs and, particularly n-6 fatty acids, appear to have no adverse effects or even
fairly positive effects on the action of insulin (231). Epidemiological evidence
suggests that insulin resistance is linked to the ingestion of saturated fats (232-
234). Therefore, it is important to understand the underlying mechanisms how
dietary fatty acids may affect insulin sensitivity in skeletal muscle and adipose
tissue and how the risk or severity of insulin resistance can be modulated by
dietary fat quantity and quality.
Glucose metabolism and insulin sensitivity: evidence from human
dietary interventions
In the KANWU study by Vessby et al. (235), healthy subjects were randomly
assigned to either a diet rich in SFA or a diet with the same amount of calories from
MUFA. A random subsample in each group was also given a supplement of n-3
fatty acids. Decreasing SFA and increasing MUFA, improved insulin sensitivity.
However, a beneficial impact of the fat quality on insulin sensitivity was not seen in
individuals with a high habitual fat intake (> 37E%). The addition of n-3 fatty acids
did not result in any change in insulin sensitivity (235). These data suggest that
dietary fat quality is only of importance for insulin sensitivity with a total fat intake
equal or lower than 35-40 % of total energy intake. Summers et al. demonstrated in
a randomized controlled crossover study that a n-6 PUFA-rich diet improved insulin
sensitivity when substituted for a SFA-rich diet, after only 5 weeks (236). However,
in the LIPGENE study no direct effects on insulin sensitivity were reported after a
12-week dietary intervention with isoenergetic diets differing in both fat quantity and
quality (237). Furthermore, in the RISCK trial, isoenergetic replacement of SFA
with MUFA did not improve insulin sensitivity after a 24-week intervention in
subjects at risk for the metabolic syndrome (238). The data on the effect of diets
differing in fat quality on insulin resistance are inconsistent and further research is
necessary. A possible explanation for the conflicting results may be that a different
habitual intake of subjects may be an important determinant for the effectiveness of
a dietary intervention.
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Underlying mechanisms to explain the effects of dietary fatty acids
Dietary fatty acids may influence insulin sensitivity via different mechanisms. PUFA
have been shown to channel lipids towards inert TAG storage, while saturated fats
preferentially generate “toxic” DAG and promote insulin resistance (239).
Furthermore, oleic acid accumulates to a lesser extent as DAG or TAG than
palmitic acid. Also, T2DM myotubes expressed a reduced palmitate oxidation
whereas oleic acid oxidation was not different between groups (240). Overall, the
order of preference for oxidation appears to be the highest for PUFA, followed by
MUFA and eventually SFA. Piers et al. (241) reported in men that the postprandial
fat oxidation rate is higher after a MUFA than after a SFA meal. Nevertheless,
Casas et al. (242) did not observe any difference in substrate oxidation or satiety
after the consumption of meals high in PUFA, MUFA or SFA. A secondary
hierarchy may exist between fatty acids within the same class of saturation, for
example shorter chain saturated fatty acids may be oxidized to a greater extent
than longer chain fatty acids (243, 244).
Furthermore, different FA subtypes may alter several intracellular pathways by
direct regulatory effects on gene expression. It has been demonstrated that PUFA
suppress the transcription of genes encoding for lipogenic enzymes (FAS, ACC
and SCD1, SREBP), while they induce the transcription of genes encoding proteins
involved in lipid oxidation and fatty acid transport (245). Furthermore, in a
subcohort of the LIPGENE study it was shown that a 12-week MUFA diet and a
low-fat diet supplemented with n-3 PUFA reduced lipogenic gene expression,
which shifted the balance from storage to oxidation in insulin resistant subjects
(246).
There is now considerable evidence linking obesity and insulin resistance to the
fatty acid composition of membrane phospholipids (247). The fatty acid
composition of membrane lipids is influenced by the dietary fatty acid profile.
Membrane composition was found to be most responsive to n-6 and n-3 PUFA
levels in the diet. This is probably due to the fact that both n-6 and n-3 PUFA
classes cannot be synthesized de novo by higher animals (248). A high proportion
of SFAs in the muscle membrane may impair insulin receptor binding and affinity,
by reduced ion permeability, by an altered ability to translocate glucose
transporters or by interaction with second messengers such as DAG within the
muscle cell (249, 250). Highly unsaturated n-3 PUFAs have been shown to
increase insulin receptor function and translocation of the GLUT4 transporter (251,
252).
Chapter 1
26
Dietary fat quality may also differentially affect inflammation. Exposure of myotubes
or adipocytes to SFA increased IL-6 mRNA expression and subsequent protein
production, possibly via activation of NF-κB (253, 254). A human intervention study
feeding diets rich in SFA for 5 weeks showed higher concentrations of CRP,
fibrinogen and IL-6 compared with a diet enriched in MUFA (255). Substantial
increase in the intake of PUFA can decrease low-grade inflammation as indicated
by circulating CRP, IL-6 or soluble adhesion molecules (256).
All these data indicate that both fat quality and quantity play a role in insulin
sensitivity and this should not be neglected in the search for optimal diets to
improve insulin sensitivity.
DIETARY FIBERS
Fiber is a major component of carbohydrate that is generally considered beneficial
for health. Current recommendations suggest an intake of 20–40 g dietary fiber per
day (257). Consumption of diets high in dietary fiber have been reported to result in
a number of beneficial health effects including reduced risk of heart disease (258),
hypertension (259), colon cancer (260), diabetes (261) and obesity (262). Fiber
sources differ in characteristics such as solubility, fermentability, and viscosity, and
it is now well known that different types of fiber exert varying physiological effects
in the body.
Glucose metabolism and insulin sensitivity
Fiber-rich foods usually have lower energy content, which contributes to a
decrease in the energy density of the diet. In the intestine, the incorporation of fiber
may complicate the union between digestive enzymes and their substrate, thus
slowing down the absorption of nutrients (263). The slower nutrient uptake may
result in a decrease in glucose and insulin responses (264-268). These lower
glucose and insulin concentrations may, in turn result in a reduced inhibition of
lipolysis, higher circulating FFA concentrations and consequently increased fat
oxidation (269, 270). A greater postprandial fat oxidation may attenuate fat
accumulation in non-adipose tissues, leading to an improvement in insulin
sensitivity (271). In the Finnish Diabetes Prevention Study, individuals with the
highest level of fiber consumption had a 62% reduction in progression of
prediabetes to diabetes over a 4-year period compared with those with the lowest
fiber intake (272). Short-term studies indicate that dietary fiber intake decreases
postprandial glycemia and insulinemia and enhances insulin sensitivity (273, 274).
Pereira et al. (275) used a euglycemic-hyperinsulinemic clamp to measure insulin
sensitivity in obese hyperinsulinaemic subjects. Their results showed that a whole
grain diet led to a postprandial improvement in insulin sensitivity when compared to
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a refined grain diet (275). Likewise, Weickert et al. (273) used the same method to
measure insulin sensitivity in overweight and obese women and found an increase
in insulin sensitivity after 3 days of a diet containing bread enriched with insoluble
fiber compared to another diet containing white bread.
Body weight control
High dietary fiber intake may promote weight loss and long-term weight
maintenance by reducing energy intake and appetite (276). Greater satiety may
result from several factors. High fiber foods take longer to eat and may slow gastric
emptying thereby increasing feelings of fullness and satiety. They may also
stimulate the release of gut peptides that modify eating behaviour (277, 278).
Fermentation products of dietary fibers like short chain fatty acids may enhance
satiety via various mechanisms (279). A number of human intervention studies
have shown weight reduction with diets rich in dietary fiber or dietary fiber
supplements, however other studies failed to show any effect (280-282). These
conflicting results in humans may be due to the dietary fiber type, dosage and
study population.
Evidence of the health-protective effects of dietary fiber has led to industrial interest
in developing fiber ingredients to increase the fiber content of processed foods.
There is debate as to whether these functional soluble fibers deliver known health
benefits associated with ‘traditional’ dietary fibers (283). Many fibers have been
shown to have the potential for beneficial short-term functional effects but have not
been tested in long-term clinical trials.
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OUTLINE OF THE THESIS
This thesis provides insight in the effects of several dietary interventions on body
weight control as well as the improvement in insulin sensitivity by modulation of the
fat metabolism.
The effects of calorie restriction on insulin sensitivity may be mediated by changes
in skeletal muscle fatty acid handling but the underlying mechanisms need to be
further elucidated. Therefore, in chapter 2 we investigated the effect of a 12-week
weight loss intervention on insulin sensitivity and on skeletal muscle fatty acid
metabolism-related gene expression in obese IGT subjects. The weight loss
program was based on a very low-calorie diet using meal replacements, which
were gradually replaced by normal meals.
Identification of foods and food supplements that influence specific physiological
targets may be helpful to improve overall metabolic health. Polyphenolic
compounds, such as resveratrol are currently an area of intense investigation due
to their ability to mimic effects of metabolic benefits of calorie restriction but human
data are still lacking. Chapter 3 describes the first human study that systematically
examined the metabolic effects of resveratrol in healthy obese men. After 30 days
resveratrol supplementation a combination of in vivo and ex vivo measurements
were conducted to examine the effects on whole-body energy expenditure,
substrate utilization, ectopic lipid storage, mitochondrial function and lipolysis in
adipose tissue and skeletal muscle. Modulation of adipose tissue function may
contribute to a reduced body fat accumulation and improved insulin sensitivity.
However, data on the effects of resveratrol on adipose tissue function in the human
in vivo situation are lacking. Therefore, in chapter 4 the effect of resveratrol on
adipose tissue morphology and the underlying mechanisms involved were
investigated using microarray analysis.
Another dietary intervention to prevent obesity or its metabolic complications is
reducing the amount of fat in the diet. High fat diets have been proposed to lead to
obesity and may affect insulin sensitivity. Dietary fat quality may modulate fat
metabolism, thereby possibly improving insulin sensitivity. Therefore, in chapter 5
we investigated the acute effects of meals with various fatty acid composition on
skeletal muscle fatty acid processing and postprandial insulin sensitivity in obese,
insulin-resistant men using the dual-stable isotope technique. With this technique,
the contribution of dietary fat (CM-TAG) vs. endogenous fat (FFA and VLDL-TAG)
to in vivo skeletal muscle fatty acid metabolism could be investigated. Moreover,
baseline and postprandial skeletal muscle biopsy samples were collected for
assessing intracellular lipid partitioning and examining the transcriptional regulation
of fatty acid metabolism by means of microarray technology.
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Besides fat content also carbohydrates contribute to a large part of the diet. Fiber is
a major component of carbohydrates and has been reported to result in several
health effects. High fiber intake may decrease glycaemic and insulinemic
responses, which favour oxidation and lipolysis of fat rather than storage and may
attenuate fat accumulation in non-adipose tissues leading to improved insulin
sensitivity. A higher postprandial fat oxidation may also translate in a negative
energy balance in the long term. This has led to industrial interest in developing
dietary fibers that can be incorporated in a variety of food products. However, the
question remains if these fibers provide the same health benefits as traditional
dietary fibers. For that reason, we studied in chapter 6 replacement of available
carbohydrates with polydextrose or soluble corn fiber on glycemic and insulinemic
profile, energy expenditure, substrate oxidation and appetite ratings over a period
of 24 hours in overweight men and women.
Finally, in chapter 7 the main findings of the different studies described in this
thesis are discussed in a broader perspective and implications for future research
are addressed.
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Abstract
Background: The impaired glucose tolerant (IGT) state is characterized by insulin
resistance. Disturbances in fatty acid (FA) metabolism may underlie this reduced
insulin sensitivity.
Aim: The aim was to investigate whether the prediabetic state is accompanied by
changes in expression of genes involved in FA handling during fasting and insulin
mediated conditions and, secondly, to study the impact of weight loss.
Methods: Seven IGT and five normal glucose tolerant (NGT) men, comparable for
age and BMI, participated in the study. Five IGT men followed a 12-week weight
loss program. Muscle biopsies were taken and expression of six genes was
investigated.
Results: Subjects had a reduction of 15.5 ± 4.3kg body weight. Baseline gene
expression was not different between NGT and IGT men. After hyperinsulinemic
clamp, there was an overall upregulation of PGC1, SREBP-1c, SREBP-2 and
ACC-2. For SREBP-2, the upregulation was more pronounced in IGT men
(p=0.049). Weight loss significantly increased insulin sensitivity by 71%, which was
not reflected in altered gene expression profiles.
Conclusion: SREBP-2 shows altered insulin responsiveness in IGT men
compared with NGT men, whilst there were no differences in basal gene
expression.
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Introduction
Type 2 diabetes mellitus (T2DM) is one of the major causes of morbidity and
mortality in the world and its prevalence has rapidly been increasing with currently
about 200 million patients worldwide (1). The impaired glucose tolerant (IGT) state
represents an intermediate phase between the normal glucose tolerant (NGT) state
and T2DM (2). Insulin resistance and -cell dysfunction occur very early in the
disease progress (3). Insulin resistant skeletal muscle is characterized by a
reduced ability to oxidize lipids (4), an impaired switch between fat and
carbohydrate oxidation in the postprandial state (metabolic inflexibility) (4, 5),
despite elevated lipids in the circulation (‘lipid overflow’), and by an accumulation of
triglycerides within skeletal muscle (5, 6). This may lead to accumulation of lipid
intermediates, such as diacylglycerols, ceramides and long-chain fatty acyl-CoA,
that can be linked to defects in the insulin signalling cascade (7-9).
The metabolic and molecular mechanisms responsible for the reduced fat oxidation
are not completely understood (10). It has been suggested that enzymes involved
in fatty acid transport and metabolism are altered and that the metabolic profile of
the insulin resistant muscle is oriented more towards fat storage than oxidation (11,
12). Acetyl-CoA carboxylase (ACC)-2 may play an important role in this diminished
lipid oxidation (13). It has been shown that T2DM subjects have a significantly
elevated ACC-2 expression in skeletal muscle (14). Meanwhile, ACC-2 mRNA
expression is significantly reduced as result of lifestyle intervention in impaired
glucose tolerant subjects (15) together with improvements in fat oxidation. Another
potential mechanism controlling intramyocellular triglyceride (IMTG) content is the
lipogenic pathway in muscle. SREBPs are central regulators of lipid biosynthesis
(16). It has been shown that SREBP-1c expression was significantly reduced in the
skeletal muscle of T2DM patients (17). SREBP-2 mainly activates genes involved
in cholesterol synthesis in liver (18). The exact role of SREBP-2 in skeletal muscle
metabolism remains to be elucidated. Furthermore, an impaired mitochondrial
function or reduced content have been proposed as underlying defects in fat
oxidation and insulin resistance (19, 20), although several recent studies shed
doubt on this concept (21, 22). A set of genes involved in oxidative
phosphorylation, including peroxisomal proliferator activator receptor  coactivator
1 (PGC1), has recently been found to be coordinately downregulated in the
skeletal muscle of T2DM patients (23, 24). Finally, several studies have also
indicated important defects in the capability of insulin to regulate gene expression
in peripheral tissues in T2DM (25, 26). The insulin-induced regulation of PGC1
and SREBP-1c mRNA expression has been shown to be impaired in the skeletal
muscle of T2DM patients (14, 25).
Chapter 2
46
There are indications that weight loss is able to improve partly the switch between
fat and carbohydrate oxidation in the postprandial state in obese or IGT subjects
(5, 27), which may be related to the effect of insulin on genes involved in lipid
metabolism. Surgically induced weight loss increased PGC1 (mRNA expression)
in previous morbidly obese subjects (28, 29), whilst Berggren et al. observed no
change in PGC1 expression after weight loss in obese subjects (30).
The current study was undertaken to compare the expression levels of candidate
genes involved in lipid metabolism in muscle biopsies of obese NGT and IGT
subjects during fasting or insulin mediated conditions. Secondly, the impact of
weight loss on fatty acid metabolism-related gene expression was studied in the
obese IGT subjects.
Methods
Subjects
Five obese NGT men and seven obese IGT men, comparable for age and BMI,
participated in the study. Glucose tolerance was measured with a standard oral
glucose tolerance test with capillary plasma sampling at baseline and after two
hours according to the World Health Organization (WHO) guidelines. Additional
inclusion criteria were obesity (Body Mass Index (BMI) > 30 kg/m2), diastolic blood
pressure < 100 mmHg, no major organ dysfunction and no use of lipid and glucose
lowering medication. The NGT men had no family history of diabetes. Subjects
were not involved in any organized sports activities for more than 3 hours a week.
The experimental protocol was approved by the local Medical Ethical Committee of
the Maastricht University. All subjects were informed about the aims of the study
and gave their written informed consent.
Study design
The NGT men and IGT men underwent measurements for body composition,
aerobic capacity and insulin sensitivity. Body weight (BW) was determined on an
electronic scale. Body composition (fat mass (FM) and fat free mass (FFM)) were
determined by hydrostatic weighing with simultaneous correction for lung volume
and body fat percentage was calculated according to the equation of Siri (31).
Waist and hip circumference were measured to the nearest 1 cm. Peak oxygen
uptake (VO2max) was determined during an incremental exhaustive bicycle
ergometer test. Insulin sensitivity was determined with a hyperinsulinemic
euglycemic clamp as described below. Percutaneous needle biopsies were taken,
at the beginning and at the end of the hyperinsulinemic clamp, from the vastus
lateralis muscle under local anesthesia of the skin using the Bergström method
with suction (Figure 1) (32). Biopsies were immediately frozen in liquid nitrogen.
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From five men of the IGT group, we obtained complete data on skeletal muscle
gene expression before and after a 12-week weight loss program (Figure 1).
During the first four weeks, the subjects were provided with a very low calorie diet
(VLCD) (2 MJ/day) based on shakes (Modifast Nutrition et Santé, Breda, the
Netherlands) containing all the essential macro- and micronutrients. From weeks
five to eight, the shakes were gradually replaced by normal meals, increasing the
energy content of the diet up to 4.2 MJ/day. In the last four weeks, the subjects
were kept in energy balance by prescribing detailed weekly menus. After at least 2
weeks of energy balance, the measurements as described above were repeated
(weeks 10-12).
Figure 1. Scheme of the study design.
Euglycemic-hyperinsulinemic clamp
Subjects arrived at the laboratory by car or public transport after an overnight fast
(10-12 hours). Insulin was infused at a constant rate (1 mU*kg BW-1*min-1) with
glucose clamped at 4.5  0.2 mmol/l with an intravenous infusion of 20% w/v
glucose solution. Insulin sensitivity (M-value) was calculated as the glucose
infusion rate per kg FFM (mol*kgFFM-1*min-1) during a steady state of 30 minutes
after at least 120 minutes of insulin infusion.
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Biochemical analysis
The muscle biopsies were homogenized in ice-cold Tris-EDTA buffer at pH 7.4.
The homogenates were subsequently sonicated for 4 × 15 s and were centrifuged
at 10,000 g for 2 min at 4°C to remove cell debris. Citrate synthase (CS) was
determined by the method of Sherpherd and Garland (33), whereas 3-hydroxyacyl-
CoA dehydrogenase (HAD) was assayed according to Bergmeyer (34).
Total RNA preparation
Total RNA was extracted from frozen skeletal muscle specimens using TRIzol
reagent (Invitrogen, Breda, the Netherlands) and purified with the RNeasy Mini Kit
(Qiagen, Venlo, the Netherlands). RNA quantity was measured with the ND-100
spectrophotometer (Isogen Life Science, Ijsselstein, the Netherlands), and RNA
integrity was analysed on an Agilent 2100 BioAnalyzer (Agilent Technologies,
Amsterdam, The Netherlands) using nanochips according to manufacturer’s
instructions. A RNA Integrity Number above 6 has been judged acceptable for this
study.
Quantification of messenger RNAs
Real-time quantitative Polymerase Chain Reaction (PCR) was used to analyze
RNA samples. Total RNA was reverse-transcribed in a 20 l reaction using the
iScript cDNA synthesis Kit (Bio-Rad,Veenendaal, the Netherlands) according to the
manufacturer’s instructions. Primers were designed using Beacon designer or were
obtained by using Primer Bank (Table 1). Real-time PCR was carried out in an
icycler thermal cycler upgraded with an MyIQTM Single Color Real-Time PCR
detection system (Bio-Rad, Veenendaal, the Netherlands). Gene expression levels
were normalized using housekeeping genes Glyceraldehyde 3-phosphate
dehydrogenase (GAPDH) and Ribosomal Protein L13a (RPL13a). GeNorm was
used to test the stability of the housekeeping genes (35).
Table 1. Sequences of the primers used for mRNA quantitation by RT-PCR.
Gene Sense Primer Antisense Primer
GAPDH GAGTCAACGGATTTGGTCGT TTGATTTTGGAGGGATCTCG
RPL13a CCTGGAGGAGAAGAGGAAAGAGA TTGAGGACCTCTGTGTATTTGTCAA
PGC1 CCAGGTCAAGATCAAGGTCTCCAG TTCGGTGCGTGCGGTGTC
PPAR AAAAGCCTAAGGAAACCGTTCTG TATCGTCCGGGTGGTTGCT
SREBP-1c ACACAGCAACCAGAAACTCAAGC GCCGACACCAGATCCTTCAGAG
SREBP-2 GCACCACTCCGCAGACGAG TGGACTTGAGGCTGAAGGACTTG
ChREBP GCCTCAAGGTGAGCAAAGCTA GCTGGCACAGGTTAATGGC
ACC-2 GCAAGAACGTGTGGGGTTACT TCGCCTCGGATGGACAGTT
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Statistical analysis
Using our sample size of 5 NGT subjects and 7 IGT subjects, our study had
enough power (=0.8, =0.05) to detect an effect size of 1.82 as normalized
expression between the NGT and IGT group for all genes. Using our sample size
of 5 IGT subjects, our study had enough power (=0.8, =0.05) to detect an effect
size of 1.68 as normalized expression in IGT subjects before compared to after
weight loss for all genes. Power calculation was performed using G*Power 1.3
(Institute for Experimental Psychology, Heinrich-Heine University Düsseldorf).
Differences between NGT (n=5) and IGT men (n=7) were statistically examined by
two-tailed Student’s t-test for unpaired samples or over time by ANOVA (repeated
measures). IGT men before (n=5) and after weight loss (n=5) were compared with
a two-tailed Student’s t-test for paired samples. Results are given as mean  SEM.
A p-value < 0.05 was considered as statistically significant. Statistical analysis was
performed using SPSS 16.0 for Macintosh.
Results
Subject characteristics
The IGT and NGT men were comparable for age and BMI. They were also
comparable with respect to body composition and peak oxygen uptake (Table 2).
The IGT men tended to be more insulin resistant than NGT men (p = 0.098, Table
3A), had slightly elevated fasting glucose concentrations (not significant) and had
by definition increased 2h glucose concentrations.
The dietary intervention induced a 15.5  4.3 kg reduction in body weight, which
could be attributed to 20% by loss of FFM and by 80% by loss of FM (Table 2).
After weight loss, there was a significant increase in insulin sensitivity (p = 0.02),
(Table 3B). Skeletal muscle CS activity (p = 0.08) tended to increase after weight
loss, whilst the HAD activity did not change (Table 2). The peak oxygen uptake did
not change after weight loss (Table 2).
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Table 2. Clinical characteristics of study subjects.
Values are mean ± SEM. Student’s t-test for unpaired samples NGT vs. IGT, two-tailed. Student’s t-test for paired
samples IGT before weight loss vs. IGT after weight loss. NGT, normal glucose tolerance; IGT, impaired glucose
tolerance; WL, weight loss; BMI, body mass index; FPG, fasting plasma glucose; 2hPG, 2 hour plasma glucose; CS,
citrate synthase activity; HAD, 3-hydroxyacyl-CoA dehydrogenase.
Fasting glucose, insulin and free fatty acids (FFA) were not significantly different
between IGT and NGT men (Table 3A). After weight loss, IGT men had a
significantly lower insulin concentration during fasting (p = 0.03) and during steady
state at the end of the clamp (p = 0.04). Furthermore, the FFA concentration
tended to be lower in the IGT men after weight loss in the steady state period at the
end of the clamp compared to before weight loss (p = 0.07) (Table 3B).
Table 3A. M-value and plasma metabolites during fasting and during the steady state of the
euglycemic hyperinsulinemic clamp.
NGT (n=5) IGT (n=7)
Fasting SS Fasting SS
Glucose (mmol/l) 5.9 ± 0.1 4.5 ± 0.1 6.2 ± 0.2 4.4 ± 0.1
Insulin (mU/l) 12.3 ± 2.3 106.8 ± 6.9 15.5 ± 2.8 94.5 ± 7.2
FFA (mol/l) 629 ± 120 162 ± 28 652 ± 139 149 ± 19
Insulin sensitivity n.a. 34.2 ± 6.7 n.a. 20.8 ± 4.1
#
(M-value, mol*kg FFM-1 * min-1)
Values are mean ± SEM. Student’s t-test for unpaired samples NGT vs. IGT, two-tailed; # p < 0.10; NGT, normal
glucose tolerance; IGT, impaired glucose tolerance; SS, steady state at the end of the clamp; FFA, free fatty acids.
NGT (n=5) IGT (n=7) P-value
IGT P-
valuebefore WL
(n=5)
after WL
(n=5)
Age (years) 59.8 ± 1.9 57.1 ± 3.5 0.57
Body weight (kg) 99.8 ± 6.5 92.9 ± 3.4 0.33 95.5 ± 4.0 80.0 ± 3.7 0.001
BMI (kg/m2) 33.8 ± 1.7 32.2 ± 0.7 0.34 32.3 ± 0.6 27.0 ± 0.8 0.001
Body fat (%) 35.9 ± 2.2 32.5 ± 1.3 0.18 34.0 ± 1.1 25.0 ± 1.8 0.002
Fat free mass (kg) 63.6 ± 3.3 62.6 ± 1.3 0.75 62.9 ± 1.7 59.7 ± 1.9 0.04
Fat mass (kg) 36.2 ± 4.2 30.5 ± 2.2 0.23 32.6 ± 2.3 20.2 ± 2.1 0.001
Waist-hip ratio 1.02 ± 0.03 1.03 ± 0.01 0.62 1.05 ± 0.01 0.98 ± 0.01 0.01
VO2max
(ml O2 * kg FFM-1 * min-1)
40.3 ± 2.7 39.5 ± 1.8 0.82 41.4 ± 2.2 42.6 ± 3.8 0.96
FPG (mmol/l) 5.8 ± 0.3 6.6 ± 0.3 0.12
2h PG (mmol/l) 7.5 ± 0.5 11.7 ± 0.7 0.001
CS (U/g wet weight) 3.0 ± 0.8 4.2 ± 0.4 0.20 4.3 ± 0.5 7.4 ± 1.2 0.08
HAD (U/g wet weight) 4.5 ± 1.0 5.0 ± 0.5 0.66 5.0 ± 0.8 3.7 ± 1.0 0.43
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Table 3B. M-value and plasma metabolites during fasting and during the steady state of the
euglycemic hyperinsulinemic clamp.
IGT
Before WL (n=5) After WL (n=5)
Fasting SS Fasting SS
Glucose (mmol/l) 6.2 ± 0.3 4.5 ± 0.1 5.4 ± 0.2 4.5 ± 0.1
Insulin (mU/l) 14.2 ± 2.0 99.2 ± 9.5 8.6 ± 0.6* 69.6 ± 1.4*
FFA (mol/l) 652 ± 278 141 ± 45 562 ± 59 72 ± 14#
Insulin sensitivity n.a. 21.7 ± 5.0 n.a. 37.1 ± 5.7*
(M-value, mol*kg FFM-1 * min-1)
Values are mean ± SEM. Student’s t-test for paired samples IGT before weight loss vs. IGT after weight loss; * p <
0.05, # p < 0.10. IGT, impaired glucose tolerance; WL, weight loss; SS, steady state at the end of the clamp; FFA, free
fatty acids.
Skeletal muscle gene expression during fasting and during a
euglycemic hyperinsulinemic clamp
To determine fasting gene expression and the effect of insulin on skeletal muscle
gene expression, six genes involved in fatty acid partitioning and oxidation were
investigated. Fasting gene expression was not significantly different between the
NGT and IGT men for all the genes tested. After the hyperinsulinemic clamp there
was an overall upregulation of PGC1 (p = 0.003), SREBP-1c (p = 0.005), SREBP-
2 (p = 0.005) and ACC-2 (p = 0.03) (Figures 2A, C, D and F). For SREBP-2, the
upregulation was more pronounced in IGT vs. NGT men (∆0.23  0.15 vs. ∆0.07 
0.18 respectively, p = 0.049) (Figures 2D and 3). 2h-insulin infusion did not affect
PPAR and ChREBP expression (Figures 2B and E).
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Figure 2. Effect of insulin on skeletal muscle gene expression. The mRNA levels of the various
genes were determined by quantitative real-time PCR in skeletal muscle biopsies of NGT (n=5) and IGT
(n=7) subjects before and after a 2h euglycemic-hyperinsulinemic clamp. Results are presented as
means ± SEM.
Figure 3. The change in SREBP-2 expression in NGT vs. IGT men induced by a 2h euglycemic-
hyperinsulinemic clamp. *P<0.05 significantly different between NGT and IGT men. Data are
presented as values after clamp minus values before clamp.
Effect of weight loss on skeletal muscle gene expression
We investigated in IGT men whether weight loss could induce changes in mRNA
level of the six target genes. Although the IGT men had improved insulin sensitivity
after weight loss (p = 0.02), this effect could not be detected on a transcriptional
level (Figure 4). Both PGC1 and PPAR, genes thought to be involved in skeletal
muscle fat oxidation, showed no increased expression after weight loss (Figures
4A and B). There was also no effect of weight loss on the expression of SREBP-
1c, SREBP-2, ChREBP and ACC-2 (Figures 4C-F).
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Figure 4. Skeletal muscle gene expression in IGT men before and after weight loss.
The mRNA levels of the various genes were determined by quantitative real-time PCR in skeletal
muscle biopsies of IGT (n=5) subjects before and after weight loss. Paired Student’s t-test, two-tailed.
Discussion
In the present study, we have demonstrated that SREBP-2 may play an important
role in skeletal muscle fatty acid handling since it was differentially expressed
between NGT and IGT men after insulin infusion. The basal level of SREBP-2 in
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the IGT subjects was lower than in the NGT subjects, although not significantly
different. An infusion of insulin in the IGT men, acutely upregulated SREBP-2
expression to levels comparable in NGT subjects. The lower baseline expression
could have contributed to the more pronounced increase of SREBP-2 expression in
IGT men compared with NGT men. SREBP-2 is a member of the SREBP family, a
group of membrane-bound transcription factors, which are synthesized as inactive
precursor proteins. They undergo posttranslational cleavage in order to enter the
nucleus and stimulate transcription of numerous target genes (36). In liver,
SREBP-2 mainly activates genes involved in cholesterol synthesis (18). The exact
role of SREBP-2 in skeletal muscle metabolism remains to be elucidated. Recent
studies have demonstrated that SREBPs are central regulators of membrane lipid
biosynthesis (16, 37). Mahoney et al. report an upregulation of SREBP-2 in skeletal
muscle after eccentric exercise (38). They suggest that SREBP-2 may activate a
transcriptional program for de novo membrane synthesis since eccentric exercise
can induce membrane damage. Based on these findings, it can be speculated that
in our study SREBP-2 is more upregulated in IGT men after insulin infusion to
repair the mitochondrial membrane damage possibly induced by lipid peroxidation.
However, the present study has no data to address this hypothesis. From literature,
it is known that IGT men suffer from oxidative stress, deﬁned as a persistent
imbalance between the production of highly reactive oxygen/nitrogen species (39).
Mitochondria are a major source of reactive oxygen species. Accumulation of fatty
acids in the vicinity of the mitochondrial matrix makes them prone to lipid
peroxidation, which eventually may result in damaged mitochondrial proteins and
reduced oxidative capacity (40, 41). SREBP-2 showed altered insulin
responsiveness in IGT men compared with NGT men and may thus be an
interesting candidate for further research to elucidate its exact role in skeletal
muscle.
Besides SREBP-2, several other genes were upregulated after the euglycemic-
hyperinsulinemic clamp, including PGC1, SREBP-1c and ACC-2. Our data are
consistent with Ling et al. who found that insulin increased the mRNA level of
PGC1 in muscle biopsies from healthy young and elderly twins before and after a
clamp (42). This increase can mediate the expression of GLUT-4 in large part by
binding to and coactivating the muscle-selective transcription factor myocyte-
specific enhancer factor 2C (MEF2C) (43, 44). Many groups have established that
insulin upregulates SREBP-1c mRNA and mature SREBP-1 protein and is
accompanied by increases in FA biosynthetic gene expression (17, 25). ACC-2 is
one of these genes that catalyzes the synthesis of malonyl-CoA from acetyl-CoA.
Increased levels of malonyl-CoA lead to the inhibition of CPT-1 and, subsequently,
to the inhibition of mitochondrial fatty acid oxidation (45, 46). Our results, indeed,
show an upregulation of SREBP-1c and, subsequently, an upregulation of ACC-2
after insulin stimulation.
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Previous studies indicated that the transcriptional profile in the insulin resistant
muscle might be more directed towards fat storage than oxidation. Although Morino
et al. have reported similar gene expression levels in insulin resistant and healthy
controls (47), other studies indicate a reduced expression of PGC1 and oxidative
genes as early factors in the etiology of T2DM (14, 23, 24, 48). Moreover, an
upregulation of ACC-2 has been observed in T2DM patients compared with lean
subjects (14).  This could not be confirmed in the present study, which did not show
a decreased expression of PGC1 and an increased expression of ACC-2 in IGT
men compared to NGT men in the fasted state. Although we cannot exclude that
we missed small differences between groups (effect size smaller than 1.82 as
normalized expression), this does not explain most discrepancies between our data
and several previous studies. Possibly, differences in the degree of insulin
resistance between the subject groups of the individual studies may have played a
role. In most studies, more extreme phenotypes are compared. In our study,
differences in insulin resistance were less extreme and subjects were comparable
for obesity, which may explain the absence of relevant numerical differences in
baseline gene expression that were observed.
The second objective of the present work was to define whether weight loss could
have an impact on the expression of genes involved in FA handling. Weight loss
significantly increased insulin sensitivity (by 71%) and tended to improve muscle
oxidative capacity as evidenced by CS activity. Nevertheless, our data do not
support an improvement on transcriptional level of the genes examined here. This
is consistent with Simoneau et al. who also did not detect changes in several
different markers of skeletal muscle FA metabolism in obese NGT men after a
weight loss intervention based on a VLCD (11), but not with all other studies
showing an upregulation of genes involved in lipid oxidation (28, 29, 49). This may
be explained by the finding that no apparent disturbances at basal transcriptional
level were present between NGT and IGT men and that, possibly, the expression
of these genes is not regulated by obesity per se. Small differences after weight
loss may have been missed because of the relatively small sample size, and the
results will need confirmation from other studies.
In conclusion, insulin could acutely increase the expression of PGC1, SREBP-1c,
SREBP-2 and ACC-2 in obese subjects. Accumulating data indicate that defects in
insulin-regulated gene expression may be involved in the etiology of insulin
resistance and T2DM. In the present work, SREBP-2 was identified as a potential
novel candidate because of its altered insulin responsiveness in IGT men
compared with NGT men.
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Abstract
Background: Resveratrol is a natural compound that affects energy metabolism
and mitochondrial function and serves as a calorie restriction mimetic, at least in
animal models of obesity.
Methods: Here we treated 11 healthy, obese men with placebo and 150 mg/day
resveratrol in a randomized double-blind cross-over study for 30 days.
Results: Resveratrol supplementation significantly reduced sleeping- and resting
metabolic rate. In muscle, resveratrol activated AMPK, increased SIRT1 and
PGC1 protein levels, increased citrate synthase activity without change in
mitochondrial content, and improved muscle mitochondrial respiration on a fatty
acid-derived substrate. Furthermore, resveratrol elevated intramyocellular lipid
levels, and decreased intrahepatic lipid content, circulating glucose, triglycerides,
alanine-aminotransferase, and inflammation markers. Systolic blood pressure
dropped and HOMA index improved after resveratrol. In the postprandial state,
adipose tissue lipolysis and plasma fatty acid and glycerol decreased.
Conclusion: We demonstrate that 30 days of resveratrol supplementation induces
profound metabolic changes in obese subjects, mimicking the effects of calorie
restriction.
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Introduction
In our western society, the number of age-related chronic diseases such as
obesity, diabetes and cancer increases progressively (1). The only non-
pharmacological intervention known to date to alleviate these deleterious
conditions is calorie restriction. Reduction of calorie intake to 30-50% below ad
libitum levels, or every-other-day feeding, can delay the onset of age-related
diseases, improve stress resistance, and decelerate functional decline (2-4).
Although short-term dietary restriction has metabolic effects in humans such as
lowering metabolic rate (5), improving insulin sensitivity (6, 7) and reducing
cardiovascular risk factors (8), eating less for the sake of creating a desirable
metabolic profile is unlikely to gain widespread compliance. As such, the focus has
been on the development of calorie restriction mimics that evoke some of the
benefits of calorie restriction without an actual reduction in calorie intake. In that
respect, sirtuins are considered an important molecular target (9). Indeed, it was
suggested that the yeast Sir2 gene (10) or its worm (11) and fly (12) orthologues
are required for the effects of calorie restriction, although the relevance of the role
of Sir2/SIRT1 as a strictu sensu longevity regulator is debated (13). What is clear,
however, is that mammalian SIRT1 plays a context-dependent role in health span
regulation, for instance by mediating effects in metabolic stress situations, such as
high-fat diet-induced obesity (14-16). As such, SIRT1 confers protection against
ageing-associated metabolic diseases such as glucose intolerance and cancer (16-
18). In light of the growing number of patients suffering from metabolic diseases,
compounds that activate SIRT1 directly or indirectly, might offer protection against
the onset of metabolic damage, and promote healthy ageing.
To this end, Howitz and colleagues performed an in vitro screen to identify small
molecule activators of SIRT1 (19). Resveratrol, a natural polyphenolic compound
present in various dietary components such as mulberries, peanuts, grapes and
red wine, was identified as the most potent activator of SIRT1 (19). Recently, it was
shown, however, that resveratrol may not activate SIRT1 directly (20, 21), but
rather exerts its effects on SIRT1 through activation of AMPK (14, 22-26), although
additional direct SIRT1 activation is not completely excluded (27). Regardless of
the mode of activation, resveratrol treatment in mice fed a high calorie diet
consistently improved various health parameters including glucose homeostasis,
endurance and survival (14-16, 28), and has therefore been suggested to act as a
calorie restriction mimetic. However, so far, no human studies have been reported
that have systematically examined the metabolic effects of resveratrol in vivo.
Here, we gave obese subjects a dietary supplement containing 99% pure trans-
resveratrol (resVidaTM), during 30 days and examined whole-body energy
expenditure, substrate utilization, ectopic lipid storage, mitochondrial function, and
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lipolysis in adipose tissue and skeletal muscle using a combination of in vivo and
ex vivo measurements. Our data show that like calorie restriction, resveratrol
supplementation lowers energy expenditure, improves metabolic flexibility, as well
as global health parameters.
Methods
The study protocol was reviewed and approved by the Medical Ethical Committee
of Maastricht University Medical Centre (MUMC+). All study participants gave
written informed consent before initiation of the study.
Subject characteristics
Eleven healthy, obese, male volunteers without family history of diabetes or any
other endocrine disorder participated in this study (Table 1). None of the subjects
were on medication or were engaged in sports activities for more than two hours
per week. Body composition was determined by a dual-energy X-ray
absorptiometry scan (DXA, Discovery A; Hologic Corp, Bedford, MA) and maximal
aerobic capacity was measured as described (29).
Table 1. Subjects baseline characteristics.
Placebo Resveratrol P-value
Age (years) 52.5  2.1 52.5  2.1 -
Body weight (kg) 100.1  3.5 99.6  3.7 0.50
BMI (kg/m2) 31.59  0.74 31.45  0.82 0.48
Fat (%) 26.44  0.53 26.44  0.53 -
VO2max (ml.kg-1.min-1) 24.96  1.30 24.80  1.00 0.83
Systolic blood pressure (mmHg) 131  3.1 132  3.0 0.22
Diastolic blood pressure (mmHg) 82  2.5 83  2.6 0.20
Glucose (mmol/l) 5.44  0.10 5.44  0.13 0.96
Insulin (mU/l) 16.37  1.76 15.38  2.05 0.67
Triglycerides (mmol/l) 1.86  0.19 1.92  0.21 0.80
Non-esterified fatty acids (mol/l) 357  69 320  31 0.56
Subject characteristics at the start of the intervention (day 0). Values are given as means ± SEM (n=11).
Clinical study design
Subjects participated in two experimental trials: a placebo and a resVidaTM
(150mg/day trans-resveratrol (99.9%)) (provided by DSM Nutritional Products, Ltd)
condition, in a randomized double-blind crossover design with a four-week wash-
out period. Subjects were instructed to take the first supplement on the day after
baseline measurements (d1) and the last supplement in the evening on day 29.
The subjects were instructed to abstain from alcoholic beverages and foods
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containing substantial amounts of resveratrol (e.g. wine, red grapes, peanuts and
berries) and were advised not to take any other food supplements during the study
period. Compliance with these instructions was confirmed by verbal declaration of
the subjects. Subjects were advised to maintain their normal living-, activity-, and
sleeping-pattern during the intervention period. At the start (day 0) and end (day
30) of both intervention periods (resveratrol and placebo), blood samples were
analyzed for general safety parameters including clinical chemistry, hematology
and coagulation values. A twelve lead electrocardiogram (ECG) (Laméris,
Veenendaal, The Netherlands) was performed at the beginning and end of both the
resveratrol and placebo intervention. Each experimental trial lasted four weeks
during which the subjects came on a weekly basis (day 0, 7, 14, 21, 30) to the
university. The weekly check-up took place in the morning after an overnight fast,
and included a measurement of body mass and withdrawal of a small blood sample
for the analysis of resveratrol (original and metabolites) to confirm compliance to
the protocol. On day 28 in the evening, subjects came to the university for 1H-MRS
measurements of the liver, to quantify intrahepatic lipid content, and post-exercise
PCr recovery rate was examined by 31P-MRS to estimate in vivo mitochondrial
function (30). To standardize food intake, subjects had lunch with the same food
items in the two conditions and after lunch stayed fasted until the start of the
measurement at 17 h.
After the MRS measurements on day 28, subjects stayed in the respiration
chamber during 36 h to allow measurement of 24 h substrate oxidation and energy
expenditure (31). Before their stay in the respiration chamber, a standardized
evening meal was provided. In the respiration chamber subjects were fed in energy
balance (2332.5 kcal/day, 13.1 g of protein, 54.0 g of carbohydrate, 32.9 g of fat)
and followed an activity protocol as described (32). In the morning of day 30, after
subjects left the respiration chamber, a muscle biopsy was taken to investigate ex
vivo mitochondrial respiration, which was followed by the withdrawal of a fasting
blood sample for the analysis of the effect of resveratrol on circulating substrates.
Hereafter, adipose tissue and skeletal muscle lipolysis was examined by means of
microdialysis.
Plasma biochemistry
To check compliance, resveratrol metabolites were measured by mass
spectrometry in plasma on day 0, 7, 14, 21, 29 and 30 as described in the
supplemental methods.
In the morning of day 30 -after a standardized overnight fast for 12 hours- and
during the postprandial microdialysis test, blood samples were withdrawn for the
determination of plasma metabolites according to standard procedures. Full
experimental detail is described in the supplemental methods.
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Blood pressure
On day 0 and day 30, blood pressure was measured after an overnight fast. By
placing an automatic inflatable cuff (Omron Healthcare, Hamburg, Germany) on the
non-dominant arm in the resting condition, systolic and diastolic blood pressure
was measured in triplicate. Mean systolic and diastolic blood pressure values were
used to calculate the mean arterial pressure.
Lipid accumulation in liver
On day 28, before subjects underwent the respiration chamber measurement,
proton magnetic resonance spectroscopy (1H-MRS) was used to quantify hepatic
lipid content (IHL) on a 3 T whole body scanner (Achieva; Philips Healthcare, Best,
The Netherlands) using a five-element coil as described (33), however with a
repetition time = 4000 msec, echo time = 37 msec, and number of averages = 64.
To minimize motion artifacts, subjects were asked to breathe in the rhythm of the
measurement and to be at end-expiration during acquisition of spectra. To
determine the intensity of the lipid peak, the water signal was suppressed using
frequency-selective prepulses. The unsuppressed water resonance was used as
internal reference (number of averages=32) and spectra were fitted with AMARES
(34) in the jMURI software (35). Values are given as T2-corrected ratios (according
to (33)) of the CH2 peak, relative to the unsuppressed water resonance (as
percentage).
31P-MRS-based measurement of mitochondrial function
On day 28, 31P-MRS measurements were performed in vastus lateralis muscle on
a 1.5 T whole-body scanner (Intera; Philips Health Care, Best, The Netherlands)
essentially according to an established methodology (30).
Muscle biopsy
On day 30, when subjects left the respiration chamber, a muscle biopsy was taken
from the vastus lateralis muscle under local anesthesia (2% lidocaïne), as
previously described (36). A portion of the muscle tissue was directly frozen in
melting isopentane and stored at -80C until assayed. Another portion (30 mg)
was immediately placed in ice-cold preservation medium for determination of ex
vivo mitochondrial respiration (36).
Molecular and protein expression
Mitochondrial DNA copy number, gene expression by microarray, and protein
expression by Western blot, were performed according to standard procedures as
described in the supplemental methods.
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High resolution respirometry
Permeabilized muscle fibers were immediately prepared from the muscle tissue
collected in the preservation medium, as described elsewhere (36, 37).
Subsequently, the permeabilized muscle fibers (2.5 mg wet weight) were
analyzed for mitochondrial function using an oxygraph (OROBOROS Instruments,
Innsbruck, Austria) (38).
Intramyocellular lipids
Fresh cryosections (5 m) were stained for intramyocellular lipids (IMCL) by Oil
Red O staining combined with fibertyping and immunolabeling of the basal
membrane marker laminin to allow quantification of IMCL, as described (39).
Postprandial substrate utilization and tissue lipolysis
In 10 subjects, the lipolytic effects of resveratrol in adipose tissue and skeletal
muscle were successfully determined by microdialysis, essentially according to
(40). A full description of the microdialysis method is provided as supplemental
information.
Statistical analysis
Kolmogorov-Smirnov normality test was performed to evaluate normality
distribution. Student’s paired t-test was used to compare placebo and resVida
supplementation in normally distributed data, otherwise Wilcoxon signed-rank test
was used. For the microdialysis test day, postprandial area under the curve (AUC)
of plasma and interstitial metabolites and indirect calorimetry data were calculated
using the trapezium rule. In addition to the total AUC (0h-6h after meal ingestion),
also the early (0h-2h), mid (2h-4h) and late (4h-6h) AUCs were calculated to obtain
more detailed information about the time course of postprandial responses. A P-
Value < 0.05 was considered statistically significant. Data are reported as mean ±
SEM. Statistical analyses were performed using the statistical program SPSS 16.0
for Mac OS X.
Results
Study design and plasma biochemistry
Eleven obese but otherwise healthy male volunteers without a family history of
diabetes or any other endocrine disorder participated in this study. Baseline
characteristics of the subjects are included in Table 1. Subjects participated in two
experimental trials: (1) a placebo and (2) a resveratrol (150 mg/day (99%);
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resVidaTM) (provided by DSM Nutritional Products, Ltd) condition, in a randomized
double-blind crossover design with a four-week wash-out period. Subjects were
instructed to take the first supplement on the day after the baseline measurements
(day 1) and the last supplement in the evening on day 29.
To ensure that the subjects adhered to the study protocol and to confirm systemic
conversion of resveratrol to dihydroresveratrol (DHR), total (sum of conjugated and
unconjugatd resveratrol) and free plasma levels of both compounds were analyzed
each week during the 30-day period of resveratrol or placebo supplementation.
Whereas no resveratrol or DHR could be detected in the placebo group, both
compounds were present in plasma of resveratrol-supplemented subjects (Table 2,
levels at day 30 are shown and representative for the whole intervention period).
Whereas measurement of plasma resveratrol demonstrated compliance to the
study protocol and indicated that the compound was well absorbed, measurement
of DHR confirmed that resveratrol was efficiently metabolized, especially as the
plasma levels of DHR exceeded those of resveratrol after an overnight fast. No
detectable levels of free resveratrol and free DHR were observed in the plasma in
both the resveratrol and placebo period, also confirming efficient metabolism. It is
important to note that, although the dosage of 150 mg of resveratrol per day is
around 133-266 lower compared to the high doses of 200 to 400 mg/kg/day used
to supplement mice (14, 15), plasma resveratrol levels in our human intervention
(231.01 ng/ml on average during the 30 days) are even higher than those obtained
in the mice (10-120 ng/ml) (15). These differences may be due to different
metabolic rates of resveratrol between humans and mice, and therefore suggest
that resveratrol may exert its effects at different concentration ranges in different
mammals.
To ensure that resveratrol supplementation did not cause adverse effects, we
screened plasma and blood of the subjects for several general health parameters.
Clinical chemistry, hematology and coagulation analysis revealed no adverse
effects after 30 days of resveratrol (see Table S1 available online). Plasma ALAT
concentrations were significantly lower after resveratrol compared to placebo
(Table 2). Also, leptin levels and leukocytes in the plasma were significantly lower
in resveratrol-treated subjects (Table 2). In line with the reduced leukocyte count,
resveratrol also lowered some markers of systemic inflammation, for instance, IL-6
and TNF- (Table 2). ECGs were inconspicuous and did not raise clinical concern
in any subject. No clinical adverse events were reported during the resveratrol
supplementation.
Next, we assessed whether resveratrol also exerted positive effects on plasma
markers that predict the metabolic risk for development of diabetes and shorter
lifespan. After 30 days of resveratrol, plasma glucose and insulin concentrations
were lower compared to placebo (Table 2), resulting in a lower HOMA-index,
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indicative of improved insulin sensitivity (Table 2). Plasma triglyceride (TG)
concentrations were significantly lower after resveratrol compared to placebo. No
differences were observed in plasma non-esterified fatty acids (NEFA) (Table 2).
Table 2. Plasma biochemistry.
Placebo Resveratrol P-value
Resveratrol (ng/ml) Not detectable 182.59 ± 30.33 -
Dihydroresveratrol (ng/ml) Not detectable 289.14 ± 93.57 -
Glucose (mmol/l) 5.28 ± 0.15 5.06 ± 0.13 0.05
Insulin (mU/l) 11.94 ± 1.11 10.31 ± 1.25 0.04
HOMA index 2.80 ± 0.20 2.43 ± 0.24 0.03
Triglycerides (mmol/l) 2.29 ± 0.23 2.16 ± 0.21 0.03
Non-esterified fatty acids (mol/l) 572 ± 77 621 ± 38 0.59
Leptin (ng/ml) 14.28 ± 1.98 12.91 ± 1.84 0.04
Adiponectin (g/ml) 6.47 ± 0.55 6.45 ± 0.56 0.95
CRP (ng/ml) 1.52 ± 0.35 1.33 ± 0.31 0.11
IL-1β (pg/ml) 1.33 ± 0.27 0.94 ± 0.15 0.20
IL-6 (pg/ml) 3.13 ± 0.67 2.42 ± 0.38 0.09
IL-8 (pg/ml) 4.94 ± 0.59 4.28 ± 0.25 0.19
TNF- (pg/ml) 16.15 ± 2.27 15.14 ± 2.03 0.04
Leukocytes (109/l) 7.03 ± 0.44 6.48 ± 0.39 0.03
ALAT (U/l) 31.91 ± 2.21 28.09 ± 1.54 0.02
Plasma values after 30 days of resveratrol or placebo supplementation. Values are given as means  SEM (n=11).
Clinical improvement after resveratrol supplementation
As calorie restriction was described to associate with reduced absolute 24-hour
energy expenditure and sleeping energy expenditure (5), we sought to investigate
whether resveratrol treatment induced similar metabolic adaptations. Indeed,
resveratrol supplementation for a period of 30 days had a profound effect on
resting energy expenditure (Table 3). Subjects had a significantly lower sleeping
metabolic rate (SMR) compared to placebo, even though 24-hour energy
expenditure was similar between resveratrol and placebo (Table 3). Although
calorie restriction is known to cause metabolic adaptations in part through weight
loss, we found no effect on body mass (99.9  3.9 vs. 99.6  2.5 kg, in resveratrol
vs. placebo, p=0.43). Respiratory quotient (RQ) values over 24 hours tended to be
higher after resveratrol supplementation, which was largely accounted for by higher
RQ values during the daytime (Table 3, the complete time-course for the RQ and
the energy expenditure over 24 hours is shown in Table S2). The higher RQ in the
resveratrol group, are especially apparent after periods of feeding, and suggest
improved metabolic flexibility, i.e. the ability to switch between energy substrates.
No differences were observed in diet-induced thermogenesis (DIT) or physical
activity index (PAI).
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Next, we investigated whether resveratrol also exerted favorable effects on other
general health parameters. As long-term calorie restriction in humans (8, 41) and
resveratrol treatment in mice (15) was shown to ameliorate cardiac function, we
examined whether resveratrol also exerts beneficial effects on blood pressure.
Resveratrol significantly lowered systolic blood pressure by ~ 5 mmHg, while
resveratrol had no effect on diastolic blood pressure (Table 3). Mean arterial
pressure was significantly lower after resveratrol supplementation (Table 3).
Table 3. Clinical improvement after resveratrol.
Placebo Resveratrol P-value
24h Respiratory Quotient 0.89 ± 0.007 0.91 ± 0.006 0.09
Respiratory Quotient daytime 0.89 ± 0.004 0.91 ± 0.003 0.001
Respiratory Quotient nighttime 0.87 ± 0.007 0.88 ± 0.009 0.18
24h Energy Expenditure (MJ/d) 11.86 ± 0.29 11.91 ± 0.29 0.64
Sleeping Metabolic Rate first night (MJ/d) 8.09 ± 0.24 7.75 ± 0.23 0.007
Sleeping Metabolic Rate second night (MJ/d) 8.06 ± 0.22 7.90 ± 0.18 0.06
Diet-induced Thermogenesis (MJ/d) 1.02 ± 0.13 1.14 ± 0.17 0.33
Physical Activity Index 1.49 ± 0.02 1.50 ± 0.01 0.37
Systolic blood pressure (mmHg) 130.5 ± 2.7 124.7 ± 3.1 0.006
Diastolic blood pressure (mmHg) 81.6 ± 2.8 80.0 ± 2.9 0.18
Mean arterial pressure (mmHg) 97.9 ± 2.7 94.9 ± 2.9 0.02
Energy metabolism (n=10), and blood pressure (n=11) after 30 days of resveratrol or placebo supplementation. Values
are given as means  SEM.
Postprandial substrate utilization and tissue lipolysis
Mounting evidence implicates SIRT1 as a switch in substrate utilization, for
instance from glucose to fatty acid oxidation under low-nutrient conditions (9, 24).
Therefore, we next investigated whether resveratrol is capable to increase fat
oxidation in adipose tissue and skeletal muscle after a mixed meal, by stimulating
tissue lipolysis. The peak glucose and insulin responses after consuming a liquid
test meal were reached after 30 min for placebo and after 60 min for resveratrol
(Figure 1A,B). There was a tendency for NEFA (AUC 4h-6h, p=0.097) and free
glycerol (AUC 4h-6h, p=0.06) to be lower in the late postprandial phase after
resveratrol (Figure 1C,D). Resveratrol did not alter postprandial TG and lactate
responses (data not shown). Using the microdialysis technique, ethanol out/in
ratios were determined to measure blood flow. At baseline, ethanol out/in ratios
were not different after resveratrol supplementation compared to placebo, both in
adipose tissue (0.81 ± 0.02 vs. 0.81 ± 0.02, respectively) and skeletal muscle (0.46
± 0.02 vs. 0.49 ± 0.02, respectively). Furthermore, resveratrol did not affect
postprandial adipose tissue and skeletal muscle blood flow (data not shown). The
interstitial glycerol concentration in adipose tissue was slightly lower in the
resveratrol condition in the mid- and late postprandial phase, although it did not
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reach statistical significance (AUC 2h-4h, p=0.14; AUC 4h-6h, p=0.13) (Figure 1E).
There were no differences in interstitial glucose, pyruvate and lactate responses in
adipose tissue between placebo and resveratrol (data not shown). For skeletal
muscle, there were no differences in interstitial glucose, pyruvate, lactate and
glycerol concentrations (glycerol data shown Figure 1F). Interestingly, energy
expenditure in the postprandial period was significantly lower after resveratrol
supplementation (AUC, p=0.02) (Figure 1G). During the late postprandial phase
(4h-6h), RQ tended to be higher (AUC 4h-6h, p=0.07) (Figure 1H) and fat
oxidation was decreased in the resveratrol condition (AUC 4h-6h, p=0.007) (Figure
1I), again suggesting improved metabolic flexibility.
Figure 1. Resveratrol decreases postprandial energy expenditure and lowers adipose tissue
lipolysis. Data are obtained on whole body (A-D), by microdialysis (E-F) and indirect calorimetry (G-I).
Plasma metabolites during the postprandial microdialysis test after 30 days of placebo or resveratrol
supplementation: (A) glucose response (B) insulin response (C) NEFA response (D) free glycerol
response. Interstitial glycerol responses in (E) adipose tissue and (F) skeletal muscle during the
postprandial microdialysis test. Indirect calorimetry results during the postprandial microdialysis test: (G)
energy expenditure (H) respiratory quotient (I) fat oxidation. Open squares, placebo; Black squares,
resveratrol. Values are given as means  SEM (n=10).
Molecular mechanism of resveratrol treatment
To clarify the mechanism of action of resveratrol, we performed microarray analysis
on vastus lateralis muscle biopsies. We found 469 genes differentially expressed
between placebo and RSV-supplementation, 219 of which were increased and 250
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decreased (Figure 2A). We performed gene set enrichment analysis (GSEA) to
define the pathways that were affected by resveratrol, and to compare the
expression profile with previous studies in mouse (15). Several gene sets related to
mitochondrial oxidative phosphorylation were upregulated, whereas pathways
linked to inflammation were downregulated upon resveratrol supplementation.
Indeed, when analyzing expression of the individual genes in the oxidative
phosphorylation-related gene sets, we observed a marked increase (Figure 2B).
Importantly, these effects are highly similar to the effects observed in mice treated
with resveratrol (Figure 2C), even though the effects in the latter are more
pronounced, probably due to longer treatment time and their identical genetic and
environmental background.
Since resveratrol was shown to activate AMPK, we measured levels of
phosphorylated AMPK on the Thr172 residue of the -subunit—a marker for its
activation. Indeed, increased AMPK phosphorylation was observed in muscle
biopsies of the resveratrol-treated subjects (Figure 3A, S1A).
Figure 2. Resveratrol increases oxidative phosphorylation gene expression in man and mice. (A)
One-way hierarchical clustering of genes significantly changed in a microarray of vastus lateralis of
subjects receiving resveratrol (RSV) or placebo. In muscle, 469 genes were differentially expressed
between placebo and RSV (n=10). (B) Gene set enrichment analysis (GSEA) of muscle microarray
revealed that gene sets related to mitochondrial oxidative phosphorylation were significantly enriched
following resveratrol supplementation in humans. (C) Previously published microarray data of mice
treated with 400 mpkd RSV (15) were reanalyzed by GSEA, showing a marked enrichment of oxidative
phosphorylation genes.
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Mitochondrial metabolism
Our microarray data clearly suggest strong involvement of mitochondrial function in
the beneficial effects of resveratrol. We hence performed some more detailed
analyses of mitochondrial function. Mitochondrial DNA copy number in the
resveratrol condition was similar to the values obtained after placebo (994.8 
101.4 vs. 1074.7  109.9 AU in resveratrol vs. placebo, p=0.20). Also, neither the
protein content of the individual structural components of the individual OXPHOS
complexes nor the mean of all these complexes revealed differences in
mitochondrial density in resveratrol compared to placebo supplementation (Figure
3B, S1B). On the other hand, protein content of the AMPK downstream effector
SIRT1 (22), as well as the mitochondrial master regulator PGC1 was significantly
increased after 30 days of resveratrol (Figure 3C, S1C), as was citrate synthase
activity (Figure 3D)—a common marker for mitochondrial activity.
Mitochondrial function can also be assessed in vivo by measurement of
phosphocreatine (PCr) recovery rate after exercise (30). To this end, single leg
extension exercise was performed for 5 min with a weight corresponding to 60% of
maximal capacity, which was determined with an incremental maximal test on the
same ergometer on a different day. Low- to medium- intensity exercise was chosen
to prevent acidification of the muscle, which is known to affect PCr recovery.
Spectra were acquired 2 minutes before, during the 5 minutes of knee extension
exercise and during the subsequent 5 minutes of recovery (rest). As targeted, PCr
levels decreased during the knee-extension exercise until a steady state was
reached. However, mean PCr recovery half time (PCr-t1/2) was unchanged by
resveratrol compared to placebo (Figure 3E).
To functionally characterize mitochondrial oxidative phosphorylation in more detail,
we measured mitochondrial respiration using different substrate combinations.
State 2 respiration (i.e., respiration in the presence of exogenous substrates alone)
was not different between resveratrol versus placebo on any of the substrate
combinations studied (data not shown). ADP-stimulated (state 3) respiration on a
lipid substrate (malate + octanoyl-carnitine, MO) tended to be higher after
resveratrol supplementation (p=0.075, Figure 3F). State 3 respiration upon the
Complex I-linked substrates malate + glutamate (MG) was unaffected (Figure 3G).
Respiration upon parallel electron input to both Complex I and II was ~10% higher
upon resveratrol. Thus, state 3 respiration upon malate + octanoyl-carnitine +
glutamate (MOG) was significantly higher in subjects receiving resveratrol (Figure
3H). Similar differences were observed for state 3 respiration upon malate +
octanoyl-carnitine + glutamate + succinate (MOGS) (Figure 3H), but not in the
absence of octanoyl-carnitine (malate + glutamate + succinate, MGS) (Figure 3H).
Maximal FCCP-induced uncoupled respiration, measured in the presence of
octanoyl-carnitine, reflecting the maximal capacity of the electron transport chain,
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was also higher after 30 days of resveratrol (Figure 3I). State 4o respiration
(reflecting mitochondrial proton leak) was similar between resveratrol and placebo
condition (Figure 3J). Similar results were obtained if respiration rates were not
corrected for mtDNA copy number.
Figure 3. Resveratrol increases AMPK activity, increases mitochondrial efficiency and
respiration on fatty acid substrates. After 30 days of resveratrol or placebo, a muscle biopsy was
obtained from the vastus lateralis muscle. Of total protein extracts from the vastus lateralis muscle, 50
g of protein was used to check the expression levels of several proteins by western blotting. (A) The
level of phosphorylation of residue Thr172 of the AMPK subunit (top panel), indicative of AMPK activity,
by Western blotting in a total of 9 subjects per group (representative subset is shown). Total level of the
AMPK protein are shown in the bottom panel. The ratio resveratrol / placebo is shown on the right of
panel A. Relative quantification of the ratio of pAMPK/ AMPK is shown in S1A. (B) The protein content
of the individual complexes of the electron transport chain are quantified by Western blotting in vastus
lateralis muscle of 11 subjects per group. An antibody cocktail that detects all five complexes is used,
and the data are represented as mean  SEM for the individual complexes as well as for the average
expression of all the complexes. A representative Western blot is included in S1B.
(C) SIRT1 and PGC1 protein levels in vastus lateralis muscle by Western blotting (n=8 for SIRT1 and
n=11 for PGC1, a representative subset is shown). The relative expression of both proteins is
corrected for the loading control, tubulin for SIRT1 and actin for PGC1. The ratio of resveratrol /
placebo is shown of the right of panel C. The relative quantification of the western blots is shown in
S1C. (D) Citrate Synthase activity was significantly increased in vastus lateralis muscle of resveratrol
(RSV)-treated subjects (n=11), * p<0.05. (E) In vivo mitochondrial function expressed as PCr half-time
(n=11). Evaluation of ex vivo mitochondrial function in vastus lateralis muscle: (F) ADP-stimulated
respiration (state 3) upon a lipid substrate. (G) State 3 respiration fueled by Complex I-linked substrates.
(H) State 3 respiration upon parallel electron input into Complex I and II, * p<0.05. (I) Maximally
uncoupled respiration upon FCCP, * p<0.05. (J) Mitochondrial respiration uncoupled from ATP
synthesis (state 4o). White bars, placebo; black bars, resveratrol. Values are given as means  SEM
(n=10). M, malate; O, octanoyl-carnitine; G, glutamate; S, succinate.
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Lipid accumulation in liver and skeletal muscle
Since our data show that resveratrol clearly induced a shift in mitochondrial
substrate usage, we tested whether this also reflected in liver and skeletal muscle
lipid accumulation. Intrahepatic lipid (IHL) content was lower after 30 days of
resveratrol supplementation in comparison to placebo (Figure 4A). This was
paralleled by lower plasma ALAT values, as mentioned before, both indicating
improved liver function. The mean intramyocellular lipid (IMCL) area fraction was
2-fold higher in the resveratrol group (Figure 4B). The increase in lipid
accumulation was more pronounced in fibers identified as slow, oxidative (type 1)
fibers than in type 2 muscle fibers (Figure 4B).
Figure 4. Resveratrol decreases intrahepatic lipid content but increases intramyocellular lipid
content. Ectopic lipid deposition after 30 days of placebo or resveratrol supplementation. (A) Typical
lipid regions of hepatic 1H-MR spectra from a subject receiving placebo (left) and resveratrol (right) at
3T, scaled to the water resonance (reference). The CH2 peak is used for quantification, the area under
the curve is proportional to the lipid content in the liver. Quantification revealed that intrahepatic lipid
content was reduced by resveratrol (n=9), * p<0.05. (B) Images of representative cross section of the
vastus lateralis muscle from a subject receiving placebo (top) and resveratrol (bottom). Sections are
stained for intramyocellular lipids with Oil Red O staining (in red), muscle laminin (in blue) and type 1
muscle fibers (in green) (400x magnification). IMCL content significantly increased by resveratrol
treatment in muscle fibers, which was mostly accounted for by an increased lipid storage in type I
muscle fibers (n=10), * p<0.05. White bars, placebo; black bars, resveratrol. Values are given as means
 SEM.
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Discussion
Resveratrol, which was discovered in a small-molecule screen as a potent SIRT1
activator (19), has been extensively studied in animal and cellular studies with
promising results (14, 15). Here, we show that resveratrol supplementation in
humans exerted favorable metabolic adaptations that in many aspects mimic the
effects of calorie restriction and/or endurance training (5, 6, 8, 42, 43). These
metabolic adaptations include a reduction in sleeping metabolic rate, blood
pressure and hepatic lipid content, an improvement in skeletal muscle intrinsic
mitochondrial function and several plasma markers of general health, an increase
in intramyocellular lipid content, as well as an increase in skeletal muscle PGC1
protein content. These data extend findings, which so far have only been observed
in cell and rodent models, to the human situation, showing that resveratrol has
promising beneficial metabolic effects, and suggests that resveratrol has the
potential to improve metabolic health in subjects at risk for developing the
metabolic syndrome.
Resveratrol exerts significant effects on energy metabolism. Sleeping metabolic
rate (SMR) was significantly lower following 30 days of resveratrol
supplementation, without changing 24-hour energy expenditure. It should be noted
that SMR is the component of human energy metabolism that is most sensitive to
metabolic changes—as it is not affected by physical activity—and small differences
in sleeping energy expenditure can be detected with high accuracy. In line, we
observed that basal and postprandial energy expenditure was also lower after 30
days of resveratrol supplementation. The 2-4% reduction in energy expenditure
upon resveratrol treatment is consistent with the effects observed after calorie
restriction (6% reduction) (5, 44).
It is important to note that basal and postprandial energy expenditure was reduced
by resveratrol in our human study rather than increased, as was true for mice (15).
Although our energy expenditure data are opposite to the effects seen in mice, a
lowering of resting and sleeping metabolic rate is likely a reflection of improved
metabolic efficiency, and completely in line with the endurance training or calorie
restriction-like effects of resveratrol (5, 44). Although the dose used in our human
study was ~200 fold lower than doses used in the mouse studies, we reached
similar plasma resveratrol concentrations. We cannot exclude, however, that
metabolism of resveratrol is different between mouse and man, and, possibly more
importantly, that timing of treatment (30 days in our study vs 4-6 months in mice
(14, 15)) significantly impacts physiological outcome.
Prolonged calorie restriction, during six months, has also been suggested to
increase the expression of genes encoding proteins involved in mitochondrial
biogenesis and function (43). Similarly, our microarray data indicate increased
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mitochondrial gene expression in muscle following resveratrol supplementation. In
fact, we showed that this induction is likely to be mediated by AMPK—which is
activated by resveratrol—and resulted in increased SIRT1 and PGC1 protein
content, accompanied by increased citrate synthase activity, suggesting that
mitochondrial activity was effectively improved. Moreover, detailed mitochondrial
characterization revealed that resveratrol had beneficial effects on mitochondrial
respiration when octanoyl-carnitine was used a substrate, but not when only
glutamate was used. These data suggest that resveratrol specifically improves
muscle fat oxidative mitochondrial capacity. Interestingly, we have recently found
comparable effects in PGC1 overexpressing mice, showing an improved intrinsic
mitochondrial function (i.e. respiration per mitochondrion) but only when fatty acids
are used as a substrate (45). The fact that mtDNA copy number, OXPHOS protein
content, and PCr recovery were not changed in resveratrol-treated subjects
suggests that 30 days resveratrol treatment mostly affects mitochondrial efficiency,
not abundance. It is well possible that more long-term treatment would cause these
parameters to change as well.
Interestingly, IMCL content was markedly increased after 30 days of resveratrol
supplementation. Together with the improvement in muscle fat oxidative capacity,
and the other beneficial metabolic adaptations like lowering of circulating TG and
glucose levels, the present data hint towards endurance training-like effects of
resveratrol (46, 47). Consistent with data in rats, where resveratrol has been shown
to reduce hepatic lipid synthesis (48, 49), we observed reduced IHL content.
Recent data suggest that endurance training is also able to lower IHL content (50),
as was calorie restriction, although this effect was mainly attributed to a reduction
in body weight (6, 7). Taken together with the reduced plasma TG and increased
muscle fatty acid oxidation, we hypothesize that fat is liberated from peripheral
depots, to be metabolized by the muscle. Again, here our data suggest that
resveratrol mimics the effect of calorie restriction and endurance training. Also, we
have investigated postprandial metabolism, but only found a reduction in total
energy expenditure that was reflected by a lower fat oxidation during the late
postprandial phase—a change that is reminiscent of the role of SIRT1 in regulating
the efficient switch in energy substrate utilization (22, 23). Although postprandial
lipolysis tended down, this does not refute our hypothesis of increased fat
mobilization, but rather confirms the idea of improved metabolic flexibility.
A striking finding in our study was the resveratrol-induced reduction of systolic
blood pressure by 5 mmHg. In rodents, resveratrol is also vasoactive and has been
shown to cause vasodilatation and to improve aortic endothelial function in diabetic
mice (51), to reduce heart rate (15) and even to lower blood pressure (52). Also in
human obese subjects endothelial function and cardiovascular health, dose-
dependently improved after one week of resveratrol supplementation (53).
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Similarly, healthy non-obese individuals also improved their cardiovascular risk
after six months of calorie restriction as evidenced by a reduction in blood pressure
(8). Another indication that global health was improved upon resveratrol treatment
was the decreased expression levels of genes of inflammatory pathways, as were
plasma levels of several inflammatory markers, and leukocyte numbers.
Our data also point towards favorable metabolic adaptations after 30 days of
resveratrol supplementation in obese subjects. Indeed, HOMA-index was improved
after resveratrol, suggesting favorable effects on insulin sensitivity. These
beneficial effects of resveratrol on metabolism are in concordance with several
findings of resveratrol supplementation in animals (14-16, 22, 28).
In conclusion, we demonstrate beneficial effects of resveratrol supplementation for
30 days on the metabolic profile in healthy obese males, which seems to reflect
effects observed during calorie restriction (Table S3). Although most of the effects
that we observed were modest, they were very consistently pointing towards
beneficial metabolic adaptations. Furthermore, there were no effects on safety
parameters and no adverse events were reported. Therefore, resVida was safe
and well tolerated at the tested concentration. Future studies should investigate the
long-term and dose-dependent metabolic effects of resveratrol supplementation in
order to further establish whether resveratrol supplementation has the potential to
overcome the metabolic aberrations that are associated with obesity in humans.
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Supplementary information
Supplementary methods
Analysis of resveratrol and dihydroresveratrol
To check compliance, the analytics of resveratrol (original and metabolites) were
processed in a blinded fashion by a liquid chromatography mass spectrometry (LC-
MS) system in both the resveratrol- and placebo-supplemented period by DSM
Nutritional Products, Ltd. Kaiseraugst, Switzerland. Plasma collected on day 0, 7,
14, 21, 30 and during the stay in the respiration chamber (day 29) was processed
for the determination of “free” trans-resveratrol and dihydroresveratrol (aglycone)
and “total” trans-resveratrol and dihydroresveratrol (aglycone + glucuronide
conjugates). After addition of an internal standard and liquid-liquid extraction (“free”
analyte) or pre-digesting by -glucuronidase followed by liquid-liquid extraction
(“total” analyte), the samples were injected in a C18 column. Detection was
performed using MS in the SIM mode.
Plasma biochemistry
In the morning of day 30 -after a standardized overnight fast for 12 hours- and
during the postprandial microdialysis test, blood samples were withdrawn for the
determination of plasma glucose, insulin, non-esterified fatty acids (NEFA) and
triglycerides (TG) levels as described (1). Glycerol and lactate levels during the
microdialysis test were analyzed enzymatically on a Cobas Mira automated
spectrophotometer. The concentration of leptin and adiponectin in plasma were
analyzed by radioimmunoassay using commercial kits (Millipore Corporation,
Billerica, MA, USA) in accordance with the manufacturer’s instructions. High-
sensitivity C-reactive protein was measured with a commercially available kit
(Horiba ABX, Montpellier, France). Plasma inflammatory markers (IL-1b, IL-6, IL-8
and TNF-) were measured with a commercially available Multi Spot ELISA kit
(Meso Scale Discovery, Gaithersburg, MD, USA).
Molecular and protein expression
Mitochondrial DNA (mtDNA) copy number, the ratio of NADH dehydrogenase
subunit one (ND1) to lipoprotein lipase (LPL) (mtDNA/nuclear DNA) was
determined as described (1).
Oxidative phosphorylation (OXPHOS), SIRT1, and PGC1 protein levels were
measured in whole muscle by western blotting as an additional reflection of
mitochondrial density, as described (2). OXPHOS proteins were detected using a
monoclonal antibody cocktail of five monoclonal antibodies directed against the
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different OXPHOS complexes (MS601, MitoSciences, Eugene, OR). SIRT1 was
detected using a polyclonal antibody (#2493 Cell Signaling, Technology, Inc.,
Beverly MA, USA). PGC1 was measured using a polyclonal antibody (Santa
Cruz, Heidelberg, Germany). Total and the phosphorylated subunit  of AMPK
(#2531 and #2532 Cell Signalling Technology, Inc., Beverly MA, USA) were
detected as described (3).
Postprandial substrate utilization and tissue lipolysis
In 10 subjects, the lipolytic effects of resveratrol in adipose tissue and skeletal
muscle were successfully determined by microdialysis, essentially according to (4).
To study the response of tissue lipolysis on a mixed meal, subjects were instructed
to consume a liquid meal within 5 minutes. The total energy content of the shake
was 2.6 MJ and consisted of 32.6 En% carbohydrates, 61.2 En% fat and 6.3 En%
protein. Blood samples were taken before ingestion of the liquid test meal (t= -30
and 0 min) and for 6h after meal ingestion at t= 30, 60, 90, 120, 180, 240, 300 and
360 min to determine glycerol, glucose, pyruvate and lactate in the plasma.
Microdialysate was collected from the probes in 30 min fractions during the
baseline period and during the early postprandial period (0-120 min) and at 1h
fractions during the last 4h postprandially (120-360 min) to determine glycerol,
glucose, pyruvate and lactate levels. Microdialysates were measured by Pronexus
Analytical AB (Stockholm, Sweden) on a CMA 600 Microdialysis Analyzer (CMA
Microdialysis AB, Solna, Sweden). Energy expenditure and substrate utilization
were measured, before and for 6h after ingestion of the liquid test meal, using a
ventilated hood system that analyses gasses every 15 seconds (Omnical,
Maastricht University, The Netherlands) (5). Metabolic rate was calculated from
VO2 (L/min) and VCO2 (L/min) according to the equations of Frayn (6). Nitrogen
excretion was calculated based on the assumption that protein oxidation
represents ~15% of total energy expenditure. Energy expenditure was calculated
using the formula of Weir (7).
Microarray
Total RNA was prepared from human muscle using Trizol reagent (Invitrogen,
Breda, The Netherlands), treated with DNase and purified on columns using the
RNeasy Mini Kit (Qiagen, Venlo, The Netherlands). RNA quantity and quality was
assessed spectrophotometrically (ND-1000, NanoDrop Technologies, Wilmington,
USA) and with 6000 Nano chips (Bioanalyzer 2100; Agilent, Amstelveen, The
Netherlands), respectively.
The Ambion WT Expression kit (Life Technologies, P/N 4411974) and the
Affymetrix GeneChip WT Terminal Labeling kit (Affymetrix, Santa Clara, CA; P/N
900671) were used for the preparation of labeled cDNA from 100ng of total RNA.
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Labeled samples were hybridized on Affymetrix GeneChip human Gene 1.1 ST
arrays, provided in plate format. Hybridization, washing and scanning of the array
plates was performed on an Affymetrix GeneTitan Instrument, according to the
manufacturer’s recommendations. Detailed protocols can be found in the
Affymetrix WT Terminal Labeling and Hybridization User Manual (P/N 702808
revision 4), and are also available upon request.
Quality control of the datasets obtained from the scanned Affymetrix arrays was
performed using Bioconductor (8) packages integrated in an on-line pipeline (9).
Various advanced quality metrics, diagnostic plots, pseudo-images and
classification methods were applied for selection of ascertain only excellent quality
arrays were used in the subsequent analyses (10). An extensive description of the
applied criteria is available upon request.
The more than 803000 probes on the Human Gene 1.1 ST array were redefined
according to Dai et al. (11) utilizing current genome information, yielding 19738
unique genes. Probes were reorganized based on the Entrez Gene database, build
37, version 2 (remapped CDF v14).
Normalized expression estimates were obtained from the raw intensity values
using the robust multiarray analysis (RMA) preprocessing algorithm (12). All genes
represented on the array were considered for the unbiased Gene Set Enrichment
Analysis (GSEA) (13).
GSEA was run using 1000 permutations per gene set. Unsupervised hierarchical
clustering was performed using complete linkage and Pearson rank correlation
distance on the normalized transcripts using software implemented in Genepattern
(http://www.broadinstitute.org/cancer/software/genepattern/) (14, 15). The z-score
was calculated by subtracting the mean expression value for each transcript from
each of the values and then dividing the resulting values by the standard deviation.
Color in the heat-maps reflects the relative transcript abundance level with red
being higher and blue lower than the mean transcript abundance value. Transcript
ordering is determined as in hierarchical clustering using the distance function 1-
correlation. Mouse microarray data (16) were reanalysed using KEGG pathway
gene sets in the GSEA software (Broad institute) (17).
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Supplementary Tables and Figures
Table S1. Blood safety parameters.
Placebo Resveratrol p-value
Erythrocytes (1012/l) 4.85 ± 0.09 4.81 ± 0.09 0.52
Hemoglobin (mmol/l) 9.07 ± 0.17 8.95 ± 0.15 0.17
Hematocrit (%) 44.00 ± 1.00 43.00 ± 1.00 0.35
MCV (fl) 90.18 ± 1.73 89.73 ± 1.72 0.10
MCHC (mmol/l) 20.77 ± 0.10 20.81 ± 0.11 0.79
Trombocytes (109/l) 237.55 ± 11.88 228.90 ± 10.60 0.10
RDW (%) 13.25 ± 0.15 13.48 ± 0.26 0.40
Leucocytes (109/l) 7.03 ± 0.44 6.48 ± 0.39 0.03
PT (sec) 10.62 ± 0.06 10.58 ± 0.09 0.65
aPTT (sec) 29.00 ± 0.83 30.63 ± 1.88 0.48
INR 1.00 ± 0.01 1.00 ± 0.01 0.90
Sodium (mmol/l) 140.18 ± 0.35 139.64 ± 0.58 0.40
Potassium (mmol/l) 4.26 ± 0.07 4.18 ± 0.07 0.57
Phosphate (mmol/l) 0.88 ± 0.03 0.92 ± 0.04 0.08
Chloride (mmol/l) 106.36 ± 0.94 106.18 ± 0.60 0.83
Urea (mmol/l) 4.50 ± 0.24 4.37 ± 0.21 0.15
Creatinine (mol/l) 76.10 ± 3.83 75.82 ± 3.28 0.83
Alkaline phosphatase (U/l) 79.00 ± 4.11 76.55 ± 3.81 0.30
Gamma GT (U/l) 29.60 ± 3.71 28.00 ± 2.61 0.44
ASAT (U/l) 19.00 ± 1.46 18.91 ± 1.11 0.93
ALAT (U/l) 31.91 ± 2.21 28.09 ± 1.54 0.02
Bilirubin (mol/l) 14.25 ± 1.00 13.86 ± 1.07 0.42
Total protein (g/l) 66.55 ± 1.24 65.39 ± 0.80 0.14
Albumin (g/l) 38.02 ± 0.79 37.33 ± 0.55 0.18
Blood of the subjects was analyzed for several clinical chemistry, hematology and coagulation markers in order to
confirm that resveratrol supplementation did not cause adverse effects. Values on day 30. Values are given as means
± SEM (n=11).
Metabolic effects of resveratrol in humans
87
Table S2. Time course RQ and EE.
Placebo Resveratrol Placebo Resveratrol
Time (h:min) Activity RQ P-
value
EE (MJ/d) P-
value
- SMR 0.87 ± 0.01 0.89 ± 0.01 0.09 8.09 ± 0.24 7.75 ± 0.23 0.007
9.00-10.00 breakfast 0.87 ± 0.01 0.89 ± 0.01 0.17 11.86 ± 0.57 11.11 ± 0.46 0.05
10.00-13.00 stepping + snack 0.91 ± 0.01 0.94 ± 0.01 0.02 14.40 ± 0.32 13.86 ± 0.32 0.07
13.00-15.30 lunch 0.89 ± 0.01 0.89 ± 0.01 0.44 11.75 ± 0.44 11.65 ± 0.47 0.44
15.30-18.00 stepping + snack 0.90 ± 0.01 0.93 ± 0.01 0.01 14.85 ± 0.31 14.55 ± 0.25 0.24
18.00-20.00 diner 0.89 ± 0.01 0.90 ± 0.01 0.35 12.62 ± 0.39 12.26 ± 0.43 0.16
20.00-24.00 stepping + snack 0.91 ± 0.01 0.92 ± 0.01 0.33 13.16 ± 0.21 13.49 ± 0.23 0.27
- SMR 0.88 ± 0.01 0.90 ± 0.01 0.21 8.06 ± 0.22 7.90 ± 0.18 0.06
Detailed time course of RQ and energy EE over the last 24h of resveratrol or placebo supplementation. Values on day
30. Values are given as means  SEM (n=10).
Table S3. Comparison of calorie restriction with resveratrol.
Calorie restriction Resveratrol
Rodents Humans Rodents Humans
Body weight    
Insulin    
Energy expenditure
Total    
Postprandial   ? 
Sendentary/Sleep   ? 
Fat mass and fat-free mass    ?
Liver fat    
Intramyocellular lipids    
Insulin sensitivity    
Inflammation markers    
Mitochondrial efficiency    
Comparison of chronic calorie restriction in rodents and overweight humans to the effects of 30 days of resveratrol
supplementation in obese humans on markers of ageing. The measured effects of calorie restriction and resveratrol on
the above markers of ageing were obtained from the following references for rodents and for humans: (16, 18-99). 
decrease,  increase,  similar, ? currently unknown
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Figure S1. Western blot analysis. (A) Quantitative analysis of the effect of resveratrol (RSV) on the
phosphorylation of AMPK on Thr172 of the -subunit in vastus lateralis muscle. Data are presented as
the ratio of pAMPK/AMPK (n=9). (B) Representative Western blot for the individual complexes of the
electron transport chain (n=11, a subset of 3 subjects is shown). (C) Quantitative analysis of the
Western blots of PGC1 and SIRT1. Data are normalized for the loading control, actin for PGC1 and
tubulin for SIRT1. Values are given as means ± SEM (n=11 for PGC1, n=8 for SIRT1), * p<0.05.
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Abstract
Background: Polyphenolic compounds, such as resveratrol have recently received
widespread interest due to their ability to mimic effects of calorie restriction.
Aim: The objective of the present study was to gain more insight into the effects of
30 days resveratrol supplementation on adipose tissue morphology and underlying
processes.
Methods: Eleven healthy obese men were supplemented with placebo and
resveratrol for 30 days (150 mg/day), separated by a 4-week washout period in a
double-blind randomized crossover design. A postprandial abdominal
subcutaneous adipose tissue biopsy was collected to assess adipose tissue
morphology and gene expression using microarray analysis.
Results: Resveratrol significantly decreased adipocyte size, with a shift towards a
reduction in the proportion of large and very large adipocytes and an increase in
small adipocytes. Microarray analysis revealed downregulation of Wnt, Notch and
BMP/TGF- signaling pathways and upregulation of pathways involved in cell cycle
regulation after resveratrol supplementation, suggesting enhanced adipogenesis.
Furthermore, the lysosomal/phagosomal pathway and the transcription factor EB
(TFEB) were upregulated reflecting an alternative pathway of lipid breakdown by
autophagy.
Conclusion: These data suggest that adipose tissue is an important target tissue
for the effects of resveratrol in humans, but further research is necessary to
investigate whether it translates into an improved adipose tissue function.
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Introduction
Obesity is reaching epidemic proportions and is associated with insulin resistance
and an increased risk for type 2 diabetes (1). Polyphenolic compounds, such as
resveratrol are currently an area of intense investigation due to their ability to mimic
effects of calorie restriction. Resveratrol (trans-3,5,4’-trihydroxystilbene) is
synthesized in a large number of plant species including some components of the
human diet, such as mulberries, peanuts, grapes, and red wines. Pronounced
effects of resveratrol have been reported on lipolysis, adipogenesis and
inflammation in isolated adipocytes and on adipose tissue of murine animals (2).
These effects may possibly modulate adipose tissue function and contribute to a
reduced body fat accumulation and improved insulin sensitivity (3, 4). However,
data on the effects of resveratrol on adipose tissue function in the human in vivo
situation are lacking. Previously, we demonstrated beneficial effects of 30 days
resveratrol supplementation on the whole body metabolic profile, mimicking effects
of calorie restriction, in healthy obese men (5).
The general aim of the present work was to gain more insight into the effects of 30
days resveratrol supplementation on adipose tissue morphology and to investigate
the underlying mechanisms using microarray analysis in healthy obese men.
Methods
Study design
The current work was conducted as part of a previously published randomized
double-blind crossover study (5). Eleven obese, healthy men participated in two
experimental trials for 30 days: a placebo and a resVida (150 mg/day trans-
resveratrol [99.9%; DSM Nutritional Products, Ltd.]) condition, with a 4-week
washout period. At the end of both intervention periods (resveratrol and placebo), a
subcutaneous adipose tissue biopsy was taken 6 hours after ingestion of a high-fat
liquid test meal (5). The original study protocol was reviewed and approved by the
Medical Ethical Committee of Maastricht University Medical Center and written
informed consent was obtained before study participation.
Abdominal subcutaneous adipocyte size
Processing and analysis of abdominal subcutaneous adipose tissue biopsies for
adipocyte size have been described in detail previously (6). Briefly, an adipose
tissue needle biopsy (~1g) was collected 6-8cm lateral from the umbilicus under
local anaesthesia. Part of the adipose tissue was fixed overnight in 4%
paraformaldehyde and embedded in paraffin for histological sections (8m),
Chapter 4
98
whereas the other part of the biopsy was snap frozen in liquid nitrogen and stored
at -80°C. Sections were stained with hematoxylin and eosin (HE). Digital images
were captured and computerized morphometric analysis of individual adipocytes
was performed in a blinded fashion.
Adipose tissue gene expression
Microarray processing
Total RNA was extracted from frozen adipose tissue specimens using TRIzol
reagent (Invitrogen, Breda, the Netherlands) and puriﬁed on columns using the
Qiagen RNeasy Micro Kit (Qiagen, Venlo, Netherlands). Total RNA (100
ng/sample) was labeled by Whole Transcript Sense Target Assay and hybridized to
human whole-genome Affymetrix Gene 1.1 ST arrays targeting 19,793 unique
genes (Affymetrix, Santa Clara, CA).
Microarray data analysis
Quality control and data analysis has been described in detail previously (5).
Individual genes were deﬁned as changed when comparison of the normalized
signal intensities showed a P value <0.05 in a 2- tailed paired intensity-based
moderated t-statistics (IBMT) (PMID:17177995 ). These analysis were performed
within MADMAX system (PMID:21778530). Further functional data analysis was
performed on the filtered dataset with Gene Set Enrichment Analysis
(http://www.broad.mit.edu/gsea/) and on the differentially expressed genes with
Ingenuity Pathway Analysis (June 2012, Ingenuity Systems, Redwood City, CA).
Array data have been submitted to the Gene Expression Omnibus GSE42432.
Statistics
Kolmogorov-Smirnov normality test was performed to evaluate normality
distribution. Student’s paired t test was used to compare placebo and resveratrol
supplementation in normally distributed data; otherwise, Wilcoxon signed rank test
was used. A P value <0.05 was considered statistically significant. Data are
reported as mean ± SEM. Statistical analyses were performed using the statistical
program SPSS 16.0.
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Results
Subject characteristics
Eleven obese male volunteers aged 40-65 years and BMI between 28-36 kg/m2
participated in this study. As previously reported (5), 30 days of resveratrol
supplementation resulted in reduced plasma glucose (5.06 ± 0.13 mmol/l vs. 5.28 ±
0.15 mmol/l, P=0.05) and insulin concentrations (10.31 ± 1.25 U/l vs. 11.94 ± 1.11
U/l, P = 0.04) and a lower HOMA-IR compared with placebo (2.43 ± 0.24 vs. 2.80
± 0.20, P = 0.03), suggesting improved insulin sensitivity.
Resveratrol decreased abdominal subcutaneous adipocyte size
Mean adipocyte size was decreased after 30 days resveratrol (65.0 ± 4.4 m)
compared with placebo (74.7 ± 3.5 m) (Figure 1C). This was attributed by a shift
towards a lower proportion of large (70-89 μm) and very large adipocytes (>90 m)
and an increased proportion of small adipocytes (<50 m) (Figure 1D). A
representative image is shown in Figure 1A and 1B.
Figure 1. Adipocyte size measurement after placebo and resveratrol supplementation.
Representative adipose tissue sections after placebo (A) and resveratrol (B) supplementation (20x
magnification). (C) Mean adipocyte diameter. (D) Adipocyte size distribution. N=8. Values are means ±
SEM. # p<0.1, * p<0.05.
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Microarray analysis
From the 19,793 genes on the array, 12,676 genes were expressed in adipose
tissue. Resveratrol supplementation resulted in changed expression of 582 genes,
of which 290 were upregulated and 292 were downregulated.
Gene Set Enrichment Analysis
Gene sets that were downregulated by resveratrol belonged to pathways involved
in cell-cell junction, Wnt signaling, angiogenesis, G protein coupled receptors
(GPCRs) and Notch signaling (Figure 2A). Gene sets upregulated by resveratrol
were associated with lysosome, phagosome, inflammation, glucose/hexose
transport and cell cycle (Figure 2B). Upregulated pathways associated with
inflammation included interferon signaling, antigen processing and presentation, T
cell receptor signaling and NFκB activation.
Ingenuity pathway analysis
Besides GSEA, we analyzed the differentially expressed genes with Ingenuity
Pathway Analysis. The ten most upregulated pathways were involved in the
inflammatory processes, fibrosis (including fibronectin and matrix
metalloproteinases), cell proliferation (Rac signaling), stillbene biosynthesis and
lipid antigen presentation. The ten most downregulated pathways were involved in
Notch signaling, Wnt signaling, bone morphogenetic protein (BMP) signaling and
transforming growth factor- (TGF-) signaling (Figure 3). These pathways were
comparable with those of GSEA.
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Transcription factor analysis
Several transcription factors involved in interferon signaling were identified as
potentially activated (Table 1). Furthermore, the NFκB complex involved in
inflammation, peroxisome proliferator-activated receptor δ (PPARδ) and
transcription factor EB (TFEB), which links autophagy to lysosomal biogenesis,
were shown to be activated (7).
Transcription factors that were identified as inhibited belonged to the Notch, BMP
and TGF- signaling pathway including Notch 4 and mothers against
decapentaplegic homolog 4 (SMAD4) (Table 1). The transcription factor hypoxia
inducible factor 1α (HIF-1) was also inhibited.
Table 1. Transcription factor analysis using Ingenuity.
Transcription
Regulator Name
Predicted
Activation
State
z-
score P-value
IRF7 interferon regulatory factor 7 Activated 3.559 6.34E-05
STAT1 signal transducer and activator of transcription 1 Activated 2.903 1.11E-02
IRF1 interferon regulatory factor 1 Activated 2.844 1.76E-03
TFEB transcription factor EB Activated 2.508 3.48E-05
NFkB complex nuclear factor of kappa light polypeptide geneenhancer in B-cells Activated 2.470 2.90E-03
SIM1 single-minded homolog 1 Activated 2.210 3.07E-01
PPARD peroxisome proliferator-activated receptor delta Activated 2.178 3.74E-01
IRF5 interferon regulatory factor 5 Activated 2.147 7.47E-03
ZNF217 zinc finger protein 217 Activated 2.082 3.56E-02
CREB1 cAMP responsive element binding protein 1 Inhibited -2.034 3.80E-01
NOTCH4 notch 4 Inhibited -2.254 2.10E-04
PGR progesterone receptor Inhibited -2.272 5.22E-01
SMAD4 SMAD family member 4 Inhibited -2.471 1.15E-01
HIF1A hypoxia inducible factor 1, alpha subunit Inhibited -2.999 8.05E-03
TRIM24 tripartite motif containing 24 Inhibited -3.165 6.91E-05
Discussion
This is the first human study describing the effects of 30 days resveratrol
supplementation on adipose tissue morphology and gene expression patterns
using microarray analysis. Resveratrol significantly decreased adipocyte size, with
a shift towards a lower proportion of large and very large adipocytes and an
increased proportion of small adipocytes. This reduced mean adipocyte size may
underlie the previously reported improved insulin sensitivity, since adipocyte size is
an independent determinant of insulin sensitivity in humans (8). Microarray analysis
indicated an increase in adipogenesis and activation of the alternative pathway of
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lipid breakdown by lysosomes, which may explain the shift from large to small
adipocytes.
The Wnt signaling, Notch signaling and BMP/TGF- signaling pathway were all
downregulated after resveratrol supplementation. Inhibition of these signaling
pathways has shown to result in adipogenesis of preadipocytes and/or multipotent
precursor cells (9-12), although the exact role of these pathways in adipogenesis
needs to be further elucidated. Induction of differentiation also stimulates mitotic
clonal expansion. During this phase, growth-arrested preadipocytes reenter the cell
cycle and undergo one or two rounds of cell division (13). Indeed, in our study,
gene sets associated with cell cycle were upregulated by resveratrol. Overall, the
downregulation in Wnt, Notch and BMP/TGF- signaling and upregulation of gene
sets contributing to cell cycle after 30 days resveratrol supplementation suggest an
enhanced adipogenesis in obese subjects. This increased adipogenesis could
possibly explain the reduced adipocyte size after resveratrol. In contrast to our in
vivo observations, in vitro experiments performed in murine and human adipocyte
cell lines have shown that resveratrol inhibited proliferation and adipogenic
differentiation (14, 15). The discrepancy between in vitro results and the present
data may be explained by differences in resveratrol concentrations, acute in vitro
vs. chronic in vivo administration and the presence of stromal vascular cell types
(e.g. inflammatory cells) in the in vivo situation. Our data show that the
angiogenesis pathway was downregulated in human adipose tissue after
resveratrol supplementation. Furthermore, the transcription factor HIF-1 whose
activity is induced by hypoxia, insulin and nitric oxide was also downregulated (16).
These data are consistent with studies showing that resveratrol possesses anti-
angiogenic effects (17), but further research is necessary to determine the exact
role of resveratrol on angiogenesis in adipose tissue.
Besides a reduced expression of adipogenesis inhibiting pathways, activation of a
lysosomal pathway of lipid breakdown was demonstrated. Until recently,
mobilization of lipids by the classic lipolytic pathway has only been attributed to
lipid droplet associated proteins and lipases. Lately, an alternative pathway of lipid
metabolism has been proposed through the lysosomal degradative pathway of
autophagy. Major support for the involvement of autophagy, is the activation of
TFEB following resveratrol supplementation in the present study. TFEB controls
multiple crucial steps of the autophagic pathway (7). Studies in hepatocytes and
liver have demonstrated lipid breakdown by autophagy (18). Increased lysosome-
related proteolysis of the lipid droplet-associated protein perilipin (PLIN1) has been
proposed, which could facilitate adipose tissue lipolysis (19). In preadipocytes, it
has been shown that inhibition of autophagy may block adipogenesis, which was
evident from a decrease in PPAR and C/EBP (20). Therefore, in the present
study, the lysosome and phagosome pathways, may have contributed both to an
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induction of adipogenesis as well as to alternative lipid breakdown, possibly
contributing to the shift toward an increased proportion of small adipocytes after
resveratrol. Interestingly, autophagy may be induced upon starvation to deliver
intracellular proteins and organelles to lysosomes for degradation and use as an
energy source (21). Given the finding that resveratrol may partly mimic the effects
of calorie restriction, it is plausible to suggest that resveratrol may induce
autophagy, which has also been shown in cancer cells (22).
In the present study, several pathways involved in the immune response were
upregulated after resveratrol treatment. This may reflect an increase in cellular
stress induced by the reduction in adipocyte size caused by traction forces
between the adipocyte and the surrounding extracellular matrix. This in turn may
induce upregulation of inflammatory genes and pro-inflammatory adipokine
production, as shown after weight loss (23, 24). On the other hand, upregulation of
immune response pathways may be a physiological response to a higher lipid
turnover (i.e. lysosomal lipid breakdown). We previously observed a decrease in
plasma Il-6 and TNF- concentrations and a downregulation of genes sets
associated with immune response in skeletal muscle following resveratrol
supplementation in humans (5). These findings indicate that the increased immune
response in adipose tissue could represent a local rather than a systemic response
(5).
Our previously reported results showed an enhanced insulin-mediated suppression
of adipose tissue lipolysis and a slight improvement in insulin sensitivity
represented by a reduced HOMA-IR, which may suggest an increased glucose
uptake in adipose tissue (5). In line, the present results show that resveratrol
increased pathways in the adipose tissue involved in glucose and hexose transport
as evidenced by GSEA. However, in vitro data concerning the effects of resveratrol
on glucose transport are conflicting. In mature human adipocytes, resveratrol
stimulated basal and insulin stimulated glucose uptake (15). In contrast, in 3T3-L1
adipocytes resveratrol was found to decrease membrane-associated GLUT-4
protein levels and glucose uptake (25). It needs to be further established if the
observed increase in glucose/hexose transport pathway, translates into a functional
increase in glucose uptake.
In conclusion, resveratrol supplementation for 30 days induced a shift towards an
increased proportion of metabolic favorable small adipocytes. This phenotype was
accompanied by a gene expression profile indicative of increased adipogenesis
and an alternative pathway of lipid breakdown. Interestingly the latter process
seems to be mediated by pathways involving autophagy. These data suggest that
adipose tissue is an important target tissue for the effects of resveratrol in humans,
but further research is necessary to investigate whether it translates into an
improved adipose tissue function.
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Abstract
Background: Dietary fat quality may influence skeletal muscle lipid handling and
fat accumulation, thereby modulating insulin sensitivity.
Aim: The objective of the present study was to examine acute effects of meals with
various fatty acid (FA) compositions on skeletal muscle FA handling and
postprandial insulin sensitivity in obese insulin resistant men.
Methods: In a single-blind randomized crossover study, 10 insulin resistant men
consumed three high-fat mixed-meals (2.6MJ), which were high in saturated FA
(SFA), monounsaturated FA (MUFA) or polyunsaturated FA (PUFA). Fasting and
postprandial skeletal muscle FA handling were examined by measuring arterio-
venous concentration differences across the forearm muscle. [2H2]-palmitate was
infused intravenously to label endogenous triacylglycerol (TAG) and FFA in the
circulation and [U-13C]-palmitate was added to the meal to label chylomicron-TAG.
Skeletal muscle biopsies were taken to assess intramuscular lipid metabolism and
gene expression.
Results: Insulin and glucose responses (AUC) after the SFA meal were
significantly higher compared with the PUFA meal (p=0.006 and 0.033,
respectively). Uptake of TAG-derived FA was lower in the postprandial phase after
the PUFA meal as compared with the other meals (AUC60-240, p=0.02). Fractional
synthetic rate of the TAG, DAG and PL pool was higher after the MUFA meal as
compared with the SFA meal. PUFA induced less transcriptional down-regulation
of oxidative pathways compared with other meals.
Conclusion: PUFA reduced TAG-derived skeletal muscle FA uptake, which was
accompanied by higher postprandial insulin sensitivity, a more transcriptional
oxidative phenotype and altered intramyocellular lipid partitioning and may
therefore be protective against the development of insulin resistance.
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Introduction
Increased fat storage in non-adipose tissues like skeletal muscle (ectopic fat
accumulation) is a strong indicator of insulin resistance (1). Conditions
characterized by insulin resistance are often accompanied by adipose tissue
dysfunction and a reduced lipid buffering capacity, which may lead to an increased
supply of triacylglycerol (TAG) and free fatty acids (FFA) to non-adipose tissues
(lipid overflow hypothesis) (1, 2). Together with an impaired capacity of skeletal
muscle to oxidize fat (3-6), lipid overflow may cause excess fat storage in skeletal
muscle. Increased lipid accumulation in skeletal muscle, in particular the
accumulation of lipid metabolites like diacylglycerol (DAG), long-chain fatty acyl-
CoA and ceramides, may reduce insulin action by interference with insulin
signaling (7-10). Dietary intervention, in particular a reduction of saturated fat
(SFA), may improve insulin sensitivity (11-13), possibly through effects on lipid
overflow and skeletal muscle FA handling. Polyunsaturated FA (PUFA) may reduce
lipid overflow in the circulation by increasing lipid uptake and storage in adipose
tissue by inducing adipocyte differentiation (14). Furthermore, it has been found in
human muscle cell lines that SFA accumulate preferentially as DAG, thereby
activating protein kinase C and inhibiting insulin signaling, whilst unsaturated FA
are readily converted to TAG (15). Furthermore, oleic acid accumulates to a lesser
extent as DAG or TAG than palmitic acid and is more directed towards oxidation
(16). The underlying mechanisms for the differential effect of FA on metabolism
may relate to intracellular pathways that are differently tuned by FA subtypes. It
has been shown that PUFA may regulate gene transcription within minutes, acting
as agonists of peroxisome proliferator-activated receptors (PPARs) and sterol
regulatory element-binding protein 1c (SREBP1c) (17). However, human in vivo
studies investigating the effects of meals with different FA composition on skeletal
muscle FA handling are lacking. Recently, a unique dual stable isotope tracer
approach was validated to study skeletal muscle FA metabolism in detail. This
offers, in combination with measurements of arterio-venous concentration
differences across the forearm muscle (6, 18), the possibility of differentiation
between the metabolic fate of dietary versus endogenous FA. The hypothesis of
the present study was that a meal high in unsaturated FA may acutely improve
insulin sensitivity by reducing lipid overflow and shifting FA partitioning within
muscle towards oxidation as compared with a meal high in SFA in obese insulin
resistant subjects. The objective of the present study was to examine the acute
effects of meals with various FA compositions on forearm muscle FA handling and
postprandial insulin sensitivity in obese insulin resistant men using the dual stable
isotope technique. Furthermore, baseline and postprandial skeletal muscle
biopsies were collected for assessment of intramuscular FA handling and the
transcriptional regulation of FA metabolism.
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Methods
10 insulin resistant men (age 50–70 years; BMI 29-39 kg/m2; HOMAIR >2.5)
participated in a single-blind randomized cross-over study (Table 1). Exclusion
criteria were weight change of >3 kg within the last 3 months before the study;
diabetes; chronic inflammatory conditions; kidney or liver dysfunction; use of
hypolipidemic or anti-inflammatory medication; use of -blockers; use of aspirin >1
per week; highly-trained athletes; and alcohol abuse. All subjects were informed
about the nature of the study and written informed consent was obtained before
study participation. The local Medical Ethical Committee of Maastricht University
Medical Centre approved the study protocol.
Table 1. Subject characteristics.
NGT (n=10)
Age (yrs) 61.5 ± 1.6
Body weight (kg) 98.1 ± 2.8
BMI (kg/m2) 33.8 ± 3.8
Body fat (%) 31.6 ± 0.9
Fat free mass (kg) 70.3 ± 1.8
Fat mass (kg) 28.1 ± 1.6
Waist-hip ratio 1.04 ± 0.01
FPG (mmol/L) 5.6 ± 0.1
2h PG (mmol/L) 6.2 ± 0.4
Fasting insulin (U/L) 13.7 ± 1.3
HOMAIR 3.5 ± 0.4
M-value (mol*kgBW-1*min-1) 3.4 ± 0.8
HbA1c (%) 5.7 ± 0.2
Values are mean ±SEM. NGT, normal glucose tolerant; FPG, fasting plasma glucose; PG, plasma glucose
Experimental design
The design of the study was a randomized cross-over design with three different
treatments. On four occasions, subjects arrived at the university after an overnight
fast. On the first day, subjects completed anthropometric measurements, a fasting
blood sample was collected, and a hyperinsulinaemic–euglycaemic clamp was
performed to measure insulin sensitivity, using a modification of the method
described by DeFronzo et al. (19). On the other three days (2-3 weeks between
measurements, in randomized order), subjects were studied under baseline
conditions and for 4 hours after the ingestion of a liquid high-fat mixed-meal, which
was high either in SFA, MUFA or PUFA. A dual stable isotope technique was used,
to study the contribution of dietary TAG (labeled with [U-13C]-palmitate), and
endogenous TAG, i.e. VLDL, and circulating FFA (both labeled with [2H2]-palmitate)
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to lipid overflow and skeletal muscle FA handling, as reported previously (6, 18,
20).
Test meal composition
The liquid test meal provided 2.6 MJ, consisting of 61 E% fat, 33 E%
carbohydrates and 6.3 E% protein. Subjects were asked to drink the test meal
within 5 min. The FA composition of the test meals is presented in Table 2. The
MUFA meal consisted out of 40g olive oil and the PUFA meal contained 20g
safflower oil and 20g fish oil (18% EPA/12% DHA) (Bioriginal, Den Bommel, The
Netherlands).
Table 2. Fatty acid composition of test meals.
SFA MUFA PUFA
Protein (E%) 6.3 6.5 6.5
CH (E%) 32.6 32.3 32.3
Fat (E%) 61.2 61.2 61.2
SFA (E%) 35.5 11.6 14.4
MUFA (E%) 18.8 42.2 11.9
PUFA (E%) 1.7 4.6 34.8
CH, carbohydrate; SFA, saturated fatty acid; MUFA, monounsaturated; PUFA, polyunsaturated fatty acid; FFA, free
fatty acids.
Tracer infusion study
Subjects arrived at the university after an overnight fast and were asked to refrain
from drinking alcohol and to perform no strenuous exercise 24h before the study
day. In addition, they were asked to avoid food products naturally enriched with
[13C] (i.e corn or pineapple) during the whole study period. Skeletal muscle
metabolism was studied in the forearm muscle, using arterio-venous concentration
differences corrected for blood flow. Three catheters were inserted before the start
of the experiment. One catheter was placed retrogradely into a superficial dorsal
hand vein, which was heated in a hot-box (60ºC) to obtain arterialized blood. In the
same arm another catheter was placed in an antecubital vein for the infusion of the
[2H2]-palmitate tracer. A third catheter was placed retrogradely in a deep
antecubital vein of the contralateral forearm to sample venous blood draining the
forearm muscle. After taking an arterialized and deep venous background sample
at t-90 (i.e., 90min before meal ingestion), a continuous intravenous infusion of the
stable isotope tracer [2H2]-palmitate (97% enrichment, Cambridge Isotope
Laboratories, Andover, MA) complexed to albumin was started (0.035 mol*kg
body weight−1*min−1). Baseline blood sampling was started after 1h of tracer
infusion to allow for isotopic equilibration to occur. Blood samples were taken
simultaneously from the dorsal hand vein and the deep muscle vein at three time
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points during fasting (t-30, t-15, t0), and six time points postprandial (t30, t60, t90,
t120, t180, t240) after consumption of a high-fat mixed-meal (t0) containing 200 mg
[U-13C]-palmitate (98% enrichment, Cambridge Isotope Laboratories). Forearm
blood flow was measured before each blood sampling as described previously
(21). Skeletal muscle biopsies were taken during fasting conditions (after placing
the three catheters and before the background blood sampling) and at the end of
the postprandial measurement period (t240).
Indirect calorimetry
Energy expenditure and whole-body substrate utilization were measured using an
open-circuit ventilated hood system (Omnical, Maastricht University, The
Netherlands) under fasting conditions and after meal ingestion (t30, t60, t90, t120,
t180 and t240) (22). Gas analyses, which occurred every 15 seconds, were
performed by dual paramagnetic O2 analyzers and dual infrared CO2 analyzers
(type 1156, 1507, 1520; Servomex, Cowborough, Sussex, UK), similar to the
analysis system described by Schoffelen et al. (23). Nitrogen excretion was
calculated based on the assumption that protein oxidation represents ~15% of total
energy expenditure. Energy expenditure was calculated using the formula of
Weir (24).
Biochemical analyses
Blood was collected in EDTA tubes, centrifuged (1000g, 10min, 4ºC) and plasma
was immediately frozen in liquid nitrogen and stored at −80ºC until analysis.
Plasma FFA was analyzed using standard enzymatic techniques automated on a
Cobas Fara centrifugal spectrophotometer (Roche Diagnostics, Basel,
Switzerland). Plasma TAG, glycerol, glucose, and lactate were analyzed
enzymatically on a Cobas Mira automated spectrophotometer. Plasma insulin was
measured with a double antibody radioimmunoassay (Linco Research, St Charles,
MO). Hematocrit was determined in heparinized blood using a microcapillary
system. To determine isotope enrichment of plasma FFA and TAG, total lipids were
extracted from the plasma using chloroform-methanol 2:1 (vol/vol). The FFA and
TAG fractions were separated by thin-layer chromatography and derivatized to
their methyl esters for the analysis of plasma palmitate. Plasma fractions were
analyzed for the 13C-to-12C ratio on a gas chromatography continuous-flow isotope
ratio-mass spectrometer (Finnigan MAT-252 GC-IRMS, Bremen, Germany) and for
enrichment of [2H2] (Finnigan Incos-XL GC-MS). The methyl ester of palmitate
contains 17 carbon atoms and therefore, the tracer/tracee ratio (TTR) of palmitate
was corrected for the extra methyl group. Plasma palmitate concentrations
(mol/L) were analyzed on an analytical GC with ion flame detection using
heptadecanoic acid as internal standard.
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Skeletal muscle biopsy
Skeletal muscle biopsies were taken at baseline (after placing the three catheters
and before the background blood sampling) and at the end of the postprandial
measurement period (t240). Biopsies were obtained from the vastus lateralis
muscle under local anesthesia of the skin and fascia using the Bergström method
with suction (25), cleaned from any visible fat and blood, immediately frozen in
isopentane at its melting point, and stored at −80ºC until analysis. The biopsies
were taken to determine intramuscular TAG, DAG, FFA, and phospholipid (PL)
content, their degree of saturation, as well as the fractional synthetic rate (FSR) of
TAG, DAG, and PL (see skeletal muscle lipids). We investigated gene expression
profiles using microarray.
Skeletal muscle lipids
Skeletal muscle biopsies were lyophilized and dissected free of extramyocellular
lipid, blood, and connective tissue. Total lipids were extracted from 10 to 20mg
muscle sample using chloroform-methanol (2:1 vol/vol) and internal standards, and
thereafter evaporated under nitrogen at 37°C. The extracted lipids were separated
into TAG, DAG, FFA, and PL by thin-layer chromatography and transferred into
tubes for methylation. The TAG and DAG fractions were methylated by adding 1
mL of toluene-methanol-(BF3-methanol 14%) (20%-55%-25% vol/vol) and
incubated in capped tubes for 30min at 100 ºC. The PL fraction was methylated by
adding 1 mL of (BF3-methanol 14%) and incubation in capped tubes for 90 min at
100ºC. The FFA fraction was methylated by adding 1 mL of methanol-(BF3-
methanol 14%) (50%-50% vol/vol) and incubation in capped tubes at room
temperature for 15min. After incubation, 2mL pentane was added to the samples,
vortexed, and centrifuged (1000g, 5min, 20ºC), followed by isolation of pentane
extracts (upper phase) and evaporation under nitrogen at 30ºC. Finally, the
residues were dissolved in iso-octane and concentrations of FA in the fractions
were determined using an analytical GC. Stable isotope enrichment of the lipid
fractions was determined by measuring the 13C-to-12C ratio on a gas
chromatography continuous-flow isotope ratio-mass spectrometer (Finnigan MAT-
252).
Skeletal muscle gene expression
RNA extraction
Total RNA was extracted from frozen skeletal muscle specimens using TRIzol
reagent (Invitrogen, Breda, the Netherlands). RNA quantity was measured with the
ND-100 spectrophotometer (Isogen Life Science, Ijsselstein, the Netherlands), and
RNA integrity was analysed on an Agilent 2100 BioAnalyzer (Agilent Technologies,
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Amsterdam, The Netherlands) using nanochips according to manufacturer’s
instructions.
Microarray processing
Total RNA (100 ng/sample) was labeled by using Whole Transcript Sense Target
Assay and hybridized to human whole-genome Affymetrix Gene 1.0 ST arrays
targeting 19,793 unique genes (Affymetrix, Santa Clara, CA). Sample labeling,
hybridization to chips, and image scanning were performed according to the
manufacturers’ instructions.
Microarray data analysis
Quality control was performed and fulﬁlled the criteria for array hybridization
suggested by the Tumor Analysis Best Practices Working Group (26). Microarrays
were analyzed by using the reorganized oligonucleotide probes as described by
Dai et al (27). All individual probes for a gene were combined, which allowed the
possibility of detecting overall transcription activity on the basis of the latest
genome and transcriptome information instead of on the basis of the Affymetrix
probe set annotation. Expression values were calculated with the Robust Multichip
Average (RMA) method and normalized by using quantile normalization (28, 29).
Only probe sets with normalized signals >20 on >4 arrays were deﬁned as
expressed and selected for analysis. Individual genes were deﬁned as changed
when comparison of the normalized signal intensities showed a false discovery rate
(FDR) (30) Q value <0.05 in a 2- tailed paired t test with Bayesian correction
(Limma) (31). Data were analyzed with the use of Ingenuity Pathway Analysis
version 6.0 (Ingenuity Systems, Redwood City, CA). Our analysis identiﬁed
canonical pathways that were most signiﬁcant to the data set. The analysis was
performed for up- and down-regulated gene sets together. Array data have been
submitted to the Gene Expression Omnibus GSE31901.
cDNA synthesis and quantitative real-time polymerase chain reaction
Real-time quantitative Polymerase Chain Reaction (PCR) was used to analyze
RNA samples. Total RNA was reverse-transcribed in a 20 l reaction using the
iScript cDNA synthesis Kit (Bio-Rad,Veenendaal, the Netherlands) according to the
manufacturer’s instructions. Primers (available upon request) were designed using
Beacon designer or were obtained by using Primer Bank. Real-time PCR was
carried out in an icycler thermal cycler upgraded with a MyIQTM Single Color Real-
Time PCR detection system (Bio-Rad, Veenendaal, the Netherlands). Gene
expression levels were normalized using housekeeping genes -actin and -2
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microglobulin (2M). GeNorm was used to test the stability of the housekeeping
genes (32).
Calculations
The homeostasis model assessment for insulin resistance (HOMAIR) was
calculated according to Matthews et al. (33). The M-value from the
hyperinsulinaemic–euglycaemic clamp was calculated as described by DeFronzo
(19). Glucose and insulin AUC in response to the meal and
AUCglucose*AUCinsulin*10–6 (Plasma Glucose Index, PGI) were used as indices of
postprandial insulin sensitivity (34, 35). Lower values of PGI are indicative of better
insulin sensitivity. The net flux of metabolites (labeled and unlabeled) across the
forearm muscle was calculated by multiplying the arterio-venous concentration
difference by forearm plasma flow. Plasma flow was calculated by multiplying
forearm blood flow with (1-hematocrite)/100. A positive flux indicates net uptake
across forearm muscle, whereas a negative flux indicates net release. Fractional
extraction of metabolites (%) was calculated as the arterio-venous concentration
difference divided by the arterialized concentration. As a measure of efficiency of
substrate removal from the circulation, clearance across forearm muscle was
calculated by multiplying the fractional extraction with forearm plasma flow. Fasting
rate of appearance of FFA (RaFFA) (µmol*kg-1*min-1) was calculated with Steele’s
equation for steady-state, whereas Steele’s single-pool non-steady-state equations
adapted for use with stable isotopes was used to calculate RaFFA in the
postprandial state (36). Labeled FFA and TAG concentrations were calculated as
the product of TTR of [2H2]- and [U-13C]-palmitate and the concentration of
palmitate in FFA and TAG. Fractional extraction of [U-13C]-palmitate derived from
the hydrolysis of [U-13C]-palmitate in TAG (i.e., percentage “entrapment”) across
forearm muscle was calculated as described previously, with the assumption that a
proportion of FA derived from TAG hydrolysis may not be taken up by skeletal
muscle (6, 18).
The FSR of skeletal muscle TAG, DAG, and PL were calculated using skeletal
muscle FFA as the precursor pool for lipid synthesis (37). The increase in TTR of
[U-13C] from fasting to 4h postprandial was divided by the enrichment of skeletal
muscle FFA and expressed as percentage per hour (%/h). The degree of
saturation of skeletal muscle TAG, DAG, PL, and FFA (%) was calculated by
dividing the sum of SFA by the total amount of FA in a fraction. Δ9-desaturase
activity was estimated as the proportion palmitoleic acid (C16:1n-7) to palmitic acid
(C16:0), and as the proportion oleic acid (C18:1n-9) to stearic acid (C18:0). Total
skeletal muscle TAG, DAG, FFA, and PL contents were estimated as the sum of
the particular FA content of the assessed fraction. Postprandial AUC of metabolites
and substrate fluxes were calculated using the trapezoidal rule. Besides the total
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AUC (0–4 h after meal ingestion), also the “early” (0–2 h), and “mid” (2–4 h) AUC
was calculated to obtain more detailed information about the time course of
postprandial responses.
Statistics
Differences between the diets were examined using repeated-measures ANOVA
(using AUC). When a significant diet by time interaction was observed, Bonferroni
post-hoc testing was performed. Statistical analyses were performed using SPSS
19.0 for Mac (SPSS Inc., Chicago, IL, USA). All data are presented as mean ±
standard error of the mean (SEM). Statistical significance was set at p<0.05.
Results
Arterialized metabolites, forearm blood flow and forearm muscle
metabolism
Fasting arterialized plasma glucose (Figure 1A) and insulin (Figure 1B)
concentrations were comparable between the different meal test days. The
postprandial arterialized plasma glucose and insulin concentrations were higher
after the SFA meal then after the PUFA meal (Glucose: p=0.006 and insulin:
p=0.033, Table 3) with intermediate values after the MUFA meal. AUC for glucose
and insulin, and the product of AUCglucose*AUCinsulin*10–6 (PGI) were used as
indices of insulin sensitivity. The PGI after the SFA meal (12.8 ± 1.5 PGI) was
significantly higher as compared with the PUFA meal (8.5 ± 0.8 PGI, p=0.02). Net
glucose flux (Figure 1C), arterialized lactate concentrations (Figure 1D) and net
lactate flux (data not shown) were not different after intake of the different meals
(Table 3).
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Figure 1. Postprandial arterialized glucose, insulin and lactate response. (A) Arterialized glucose,
(B) arterialized insulin, (C) the net flux of glucose and (D) arterialized lactate concentrations under
fasting conditions (t=0) and after consumption of a high-fat mixed-meal. Values are mean ± SEM. n=10.
Repeated measures ANOVA were performed with Bonferroni post-hoc testing using the integrated
responses (AUC) (Table 3).
Whole-body and forearm muscle FFA metabolism
Whole-body FFA metabolism
Postprandially, arterialized FFA concentrations decreased during the first 2h and
returned to fasting values after 4h in all conditions (Figure 2A). FFA concentrations
tended to be lower after the SFA meal in the mid phase (2-4h) compared with the
PUFA meal (p=0.086, Table 3). [2H2]-labeled palmitate was infused intravenously
and mixed with the plasma FFA pool. The tracer/tracee ratio (TTR) reached a
steady state during fasting measurements (Figure 2B). Consistent with these
findings, the RaFFA in the circulation decreased after the meals, which is indicative
of suppression of whole-body lipolysis (Figure 2C). The RaFFA was more reduced
after the SFA meal in the postprandial phase as compared with the PUFA meal
(p=0.044, Table 3). [U-13C]-labeled palmitate (resulting from spillover of FA derived
from chylomicron-TAG hydrolysis) appeared in the plasma FFA pool from 60min
after meal ingestion and concentrations increased throughout the postprandial
period. There were no differences in arterialized concentrations of [2H2]- or [U-13C]-
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labeled palmitate in FFA after the three high-fat mixed-meals at any time (data not
shown). The TTR of [2H2]-labeled palmitate in FFA was higher in arterialized versus
deep venous plasma after all high-fat mixed-meals (SFA: p=0.004, MUFA:
p=0.002, PUFA: p=0.001), indicating dilution of the [2H2]-tracer in the plasma FFA
pool across forearm muscle (Figure 2B). The TTR of [U-13C]-palmitate in FFA was
not different in arterialized versus deep venous plasma after the three high-fat
mixed-meals (Figure 2D).
SFA MUFA PUFA
ANOVA
p-value
Post-hoc
SFA
vs
MUFA
SFA
vs
PUFA
MUFA
vs
PUFA
Arterialized Glucose (mmol/L per min)
Postprandial (0-4h) 5.77 ± 0.13 5.59 ± 0.14 5.48 ± 0.12 0.003 0.139 0.006 0.301
Early 5.94 ± 0.15 5.79 ± 0.15 5.74 ± 0.13 0.040 0.474 0.013 1.000
Mid 5.61 ± 0.14 5.39 ± 0.15 5.22 ± 0.15 0.002 0.179 0.011 0.174
Arterialized Insulin (U/mL per min)
Postprandial (0-4h) 38.7 ± 4.5 34.5 ± 4.1 27.0 ± 2.5 0.028 0.681 0.033 0.387
Early 46.3 ± 6.2 42.2 ± 5.3 34.7 ± 4.3 0.182 NA NA NA
Mid 31.0 ± 3.9 26.8 ± 3.6 19.3 ± 2.0 0.006 0.243 0.021 0.305
Net Glucose Flux across forearm muscle (mol*100mL-1*min-1 per min)
Postprandial (0-4h) 0.59 ± 0.09 0.52 ± 0.06 0.51 ± 0.11 0.228 NA NA NA
Early 0.70 ± 0.14 0.51 ± 0.06 0.58 ± 0.14 0.075 0.107 0.254 1.000
Mid 0.48 ± 0.05 0.52 ± 0.09 0.43 ± 0.09 0.289 NA NA NA
Arterialized Lactate (mmol/L per min)
Postprandial (1-4h) 1.08 ± 0.06 1.00 ± 0.09 1.02 ± 0.08 0.366 NA NA NA
Early 1.12 ± 0.06 1.14 ± 0.11 1.20 ± 0.09 0.244 NA NA NA
Mid 1.04 ± 0.08 0.87 ± 0.07 0.83 ± 0.09 0.048 0.068 0.145 1.000
Arterialized FFA (mmol/L per min)
Postprandial (0-4h) 336 ± 17 377 ± 33 377 ± 26 0.193 NA NA NA
Early 374 ± 28 360 ± 33 350 ± 29 0.704 NA NA NA
Mid 297 ± 16 393 ± 36 403 ± 29 0.019 0.142 0.086 1.000
Rate of appearance FFA (mol*kg-1*min-1 per min)
Postprandial (0-4h) 4.60 ± 0.40 5.29 ± 0.42 5.62 ± 0.28 0.019 0.202 0.044 1.000
Early 5.09 ± 0.43 5.71 ± 0.47 5.86 ± 0.36 0.174 NA NA NA
Mid 4.11 ± 0.42 4.88 ± 0.46 5.37 ± 0.25 0.021 0.357 0.029 0.717
Dietary fatty acids and insulin sensitivity
121
Arterialized TAG (mol/L per min)
Postprandial (0-4h) 1716 ± 192 1727 ± 183 1424 ± 180 0.377 NA NA NA
Early 1359 ± 179 1274 ± 162 1125 ± 148 0.656 NA NA NA
Mid 2073 ± 209 2181 ± 208 1724 ± 218 0.141 NA NA NA
[2H2]-labeled palmitate in TAG (mol/L per min)
Postprandial (0-4h) 9.8 ± 0.9 8.8 ± 0.8 8.0 ± 0.8 0.036 0.208 0.176 0.496
Early 6.0 ± 0.6 5.5 ± 0.5 5.3 ± 0.6 0.224 NA NA NA
Mid 13.6 ± 1.3 12.0 ± 1.2 10.6 ± 1.1 0.025 0.185 0.125 0.445
[U-13C]-labeled palmitate in TAG (mol/L per min)
Postprandial (0-4h) 4.0 ± 0.4 7.0 ± 1.0 3.8 ± 0.5 0.024 0.149 1.000 0.079
Early (1-2h) 13.3 ± 3.2 22.2 ± 10.2 7.5 ± 2.5 0.249 NA NA NA
Mid 5.6 ± 0.8 9.9 ± 1.7 5.4 ± 1.0 0.019 0.107 1.000 0.069
Postprandial data are expressed as AUC/min and based on postprandial period (0-4h after meal ingestion) unless
otherwise stated. Early is 0-2h after meal ingestion and mid is 2-4h after meal ingestion. SFA, saturated fatty acid;
MUFA, monounsaturated; PUFA, polyunsaturated fatty acid; FFA, free fatty acids; TAG, triacylglycerol; NA, not
applicable. Values are mean ± SEM. n=10. p-value represents overall p-value of the repeated measures ANOVA.
Post-hoc testing was performed using the Bonferroni correction.
Forearm muscle FFA metabolism
The net flux of plasma FFA across forearm muscle (arterio-venous concentration
difference multiplied by forearm plasma flow) was not different after the high-fat
mixed-meals  (Table 4). At the same time, a consistent uptake of [2H2]-labeled
palmitate FFA was observed after all high-fat mixed-meals (Table 4), with no
differences between meals.
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Figure 2. Postprandial whole body free fatty acid (FFA) metabolism. (A) Arterialized plasma free
fatty acid (FFA) concentrations, (B) the tracer-tracee ratio (TTR) of [2H2]-palmitate, (C) the rate of
appearance of FFA (Ra FFA) and (D) TTR of [U-13C]-palmitate. Values are mean ± SEM. n=10. Repeated
measures ANOVA were performed with Bonferroni post-hoc testing using the integrated responses
(AUC) (Table 3). For figure B and D also paired student’s t-test were performed to analyze the
difference in TTR between arterialized and deep venous plasma. (B) The TTR of [2H2]-labeled palmitate
in FFA was higher in arterialized versus deep venous plasma after all high-fat mixed-meals (iAUC: SFA:
p=0.004, MUFA: p=0.002, PUFA: p=0.001). (D) The TTR of U-13C]-labeled palmitate was not different in
arterialized versus deep venous plasma after the three high-fat mixed meals. (B and D) There were no
differences between the three high fat mixed meals. White symbols: arterialized plasma concentration
(ART); Black symbols: deep venous plasma concentration (DV).
Whole-body and forearm muscle TAG metabolism
Whole-body TAG metabolism
Arterialized plasma TAG concentrations were similar between groups under fasting
conditions and after ingestion of a high-fat mixed-meal (Figure 3A and Table 3).
The [2H2]-palmitate tracer could be measured in plasma TAG from the first baseline
sample onward, reflecting incorporation of the intravenously infused tracer into
VLDL-TAG (Figure 3B). The [U-13C]-palmitate tracer, given with the meal,
appeared in plasma TAG from 60min after meal ingestion, representing
chylomicron-TAG in the circulation (Figure 3B). Both labeled TAG fractions
increased up to 4h postprandial, whilst the [U-13C]-labeled palmitate in TAG tended
to increase more pronounced after the MUFA meal as compared with the PUFA
meal (p=0.079, Figure 3B and Table 3). The increase in [2H2]-labeled palmitate in
TAG was most pronounced after the SFA meal (p=0.036, Figure 3B and Table 3).
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Forearm muscle TAG metabolism
Fractional extraction of [U-13C]-labeled palmitate in TAG across forearm muscle
was consistently greater than the fractional extraction of [2H2]-labeled palmitate in
TAG throughout the whole postprandial period (data not shown). There were no
significant differences in extraction of [2H2]-labeled palmitate in TAG after the three
high-fat mixed-meals (Table 4). Extraction of [U-13C]-labeled palmitate in TAG
tended to be reduced after the PUFA meal compared with the MUFA meal in the
early phase (p=0.06, Table 4). The (unidirectional) uptake of FA derived from TAG
hydrolysis across forearm muscle was reduced after the PUFA meal as compared
with the SFA meal (p=0.02, Figure 3C and Table 4).
Table 4. Fasting and postprandial FFA and TAG metabolism and forearm blood flow
SFA MUFA PUFA P-value
Forearm blood flow (ml*100mL-1*min-1)
Fasting 3.28 ± 0.53 2.74 ± 0.29 2.65 ± 0.21 0.189
Postprandial (0-4h) 3.25 ± 0.41 2.95 ± 0.26 2.59 ± 0.26 0.859
Early 3.28 ± 0.48 2.90 ± 0.27 2.77 ± 0.26 0.725
Mid 3.10 ± 0.26 2.87 ± 0.23 3.01 ± 0.23 0.628
Figure 3. Postprandial whole triacylglycerol
(TAG) metabolism. (A) Arterialized plasma
triacylglycerol (TAG) concentrations, (B) [2H2]-
palmitate in TAG and [U-13C]-palmitate in TAG,
and (C) total uptake of TAG-derived FA during
fasting (t=0) and after consumption of a high-fat
mixed-meal. Values are mean  SEM. n=10.
Repeated measures ANOVA were performed
with Bonferroni post-hoc testing using the
integrated responses (AUC) (Table 3 and 4).
Black symbols are [2H2]-palmitate and white
symbols are [13C]-palmitate in panel C.
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Net FFA flux across forearm muscle (nmol*100mL-1*min-1)
Fasting 14.3 ± 80.9 20.4 ± 61.2 11.5 ± 60.1 0.937
Postprandial (0-4h) 26.7 ± 37.2 47.2 ± 29.6 20.0 ± 32.7 0.375
Early -14.0 ± 52.2 6.7 ± 39.1 -20.2 ± 35.0 0.195
Mid 67.3 ± 24.0 87.6 ± 22.0 64.5 ± 37.5 0.601
[2H2]-palmitate FFA net flux across forearm muscle (nmol*100mL-1*min-1)
Fasting 2.19 ± 0.47 1.78 ± 0.40 1.80 ± 0.34 0.504
Postprandial (0-4h) 1.80 ± 0.37 1.58 ± 0.23 1.68 ± 0.29 0.703
Early 1.78 ± 0.40 1.49 ± 0.32 1.48 ± 0.32 0.271
Mid 1.83 ± 0.38 1.66 ± 0.32 1.89 ± 0.33 0.826
[13C]-palmitate FFA net flux across forearm muscle (nmol*100mL-1*min-1)
Fasting NA NA NA
Postprandial (1-4h) 7.53 ± 3.64 9.87 ± 3.97 3.69 ± 4.56 0.448
Early 0.07 ± 0.10 -0.07 ± 0.12 0.02 ± 0.03 0.505
Mid 0.06 ± 0.03 0.08 ± 0.03 0.03 ± 0.04 0.408
Net TAG flux across forearm muscle (nmol*100mL-1*min-1)
Fasting 58.0 ± 35.5 21.6 ± 9.7 44.8 ± 21.5 0.365
Postprandial (0-4h) 81.4 ± 9.9 70.3 ± 55.0 48.7 ± 16.3 0.526
Early 85.6 ± 33.8 47.6 ± 10.8 44.6 ± 16.3 0.904
Mid 74.4 ± 25.2 87.2 ± 24.1 68.9 ± 15.3 0.647
[2H2]-palmitate TAG net flux across forearm muscle (nmol*100mL-1*min-1)
Fasting 0.05 ± 0.27 0.12 ± 0.21 0.38 ± 0.14 0.479
Postprandial (0-4h) -0.08 ± 0.30 -0.35 ± 0.20 0.18 ± 0.18 0.277
Early 0.13 ± 0.24 0.31 ± 0.19 0.34 ± 0.23 0.678
Mid -0.28 ± 0.53 -1.02 ± 0.31 0.02 ± 0.36 0.255
[13C]-palmitate TAG net flux across forearm muscle (nmol*100mL-1*min-1)
Fasting NA NA NA NA
Postprandial (0-4h) 0.35 ± 0.18 -0.18 ± 0.18 0.12 ± 0.30 0.256
Early 0.19 ± 0.07 0.30 ± 0.10 0.04 ± 0.02
#
0.103
Mid 0.43 ± 0.26 -0.43 ± 0.31 0.16 ± 0.45 0.214
Unidirectional uptake of fatty acids derived from TAG hydrolysis (nmol*100mL-1*min-1)
Postprandial (1-4h) 271.5 ± 41.9 250.3 ± 61.4 147.3 ± 41.8* 0.082
Early 237.3 ± 28.2 146.5 ± 46.9 119.8 ± 40.4* 0.069
Mid 288.6 ± 51.5 302.3 ± 76.0 161.1 ± 46.1* 0.094
Postprandial data are expressed as AUC/min and based on postprandial period (0-4h after meal ingestion) unless
otherwise stated. Early is 0-2h after meal ingestion and mid is 2-4h after meal ingestion. SFA, saturated fatty acid;
MUFA, monounsaturated; PUFA, polyunsaturated fatty acid; FFA, free fatty acids; TAG, triacylglycerol; NA, not
applicable. Values are mean ± SEM. n=10. p-value represents overall p-value of the repeated measures ANOVA.
Post-hoc testing was performed using the bonferroni correction. * SFA versus PUFA p<0.05. # MUFA versus PUFA
p<0.1.
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Energy expenditure and whole-body substrate metabolism
Whole-body energy expenditure, respiratory quotient, carbohydrate oxidation and
fat oxidation during fasting and after meal ingestion were comparable between the
different meals (data not shown).
Intramuscular lipid metabolism
Muscle lipid content and composition
The content of skeletal muscle TAG, DAG, FFA, and PL did not change after the
three high-fat mixed-meals (data not shown). The saturation of muscle TAG, DAG,
PL and FFA was not different after the ingestion of the different meals (data not
shown). Also the individual FA in the different muscle lipid pools did not change
after the three meals (data not shown).
Incorporation of [U-13C]-labeled palmitate in muscle lipids (FSR).
The fractional synthetic rate (FSR) of skeletal muscle DAG (p=0.015) was higher
after the MUFA meal and tended to be higher in the TAG (p=0.067) and PL fraction
(p=0.08) as compared with the SFA meal (Figure 4). After the PUFA meal, FSR
values were of similar magnitude as after the MUFA meal but were not statistically
different as compared with the SFA meal. This may indicate that a higher
proportion of palmitate from the intramuscular FFA pool was directed toward the
muscle lipid pools after the unsaturated FA meals.
Figure 4. Fractional synthetic rate after
the high-fat mixed-meals. The FSR in (A)
TAG, (B) DAG and (C) PL after
consumption of a high-fat mixed-meal.
DAG, Diacylglycerol; FSR, fractional
synthetic rate; TAG, triacylglycerol. Values
are mean ± SEM. n=8. Paired student’s t-
tests were performed.
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Microarray analysis
Microarray analysis was performed on skeletal muscle tissue before and 4 hours
after consumption of a high-fat mixed-meal consisting of SFA, MUFA or PUFA.
During 2 skeletal muscle biopsy procedures, we could not obtain enough biopsy
material for further analysis From the 19,793 genes present on the array, 14,424
genes were defined as expressed in skeletal muscle (Figure 5A). Genes that
showed comparable regulation after the three meals (5,429 genes) were not taken
into account for further analysis (Figure 5B). About 66% of the genes that were
changed after the SFA and MUFA meal were down-regulated, whereas 60% of the
genes were down-regulated after the PUFA meal.
Figure 5. Gene selection procedures and criteria. (A) Flow chart of gene selection and number of
genes changed in the microarray analysis. (B) Venn diagram of selected genes with a q-value < 0.05.
Overlapping genes were regulated in the same manner after the three meals and were not taken into
account for further analysis. MUFA, monounsaturated fatty acid; PUFA, polyunsaturated fatty acid;
RMA, robust multichip average; SFA, saturated fatty acid.
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To obtain further insight into the physiological relevance of these genes, pathway
analysis was performed. The top 10 most significantly regulated pathways after
each meal are listed in Figure 6. The pathways that were affected the most after
consumption of the SFA and MUFA meal were those involved in ubiquinone
biosynthesis, mitochondrial dysfunction and oxidative phosphorylation, which
consisted of genes involved in complex I-V of the respiratory chain. Consumption
of the SFA meal resulted in significantly decreased expression of 33 out of 96
OXPHOS genes, while 28 genes were down-regulated after the MUFA meal and 7
after the PUFA meal. Thus, there were less genes significantly down-regulated
after the PUFA meal, indicating less down-regulation of mitochondrial function
(data not shown). To confirm gene expression changes revealed by microarray
analysis, qPCR was used. We selected genes involved in complex I-V of the
respiratory chain. All genes were significantly down-regulated after the SFA meal,
which confirmed the microarray analysis. NDUFA1, NDUFB3, COX17 and ATP5J
were less down-regulated after the PUFA meal, so the change in expression of
genes showed the same direction of change as the microarray, but the relatively
small differences in expression of individual genes did not reach statistical
significance between meals (data not shown).
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Discussion
The present study examined postprandial skeletal muscle FA handling in obese
insulin resistant men consuming three high-fat mixed-meals with different FA
composition. Ingestion of the PUFA meal resulted in an improved postprandial
insulin sensitivity compared with SFA, which was accompanied by a reduced
muscle TAG-derived FA uptake, and a tendency towards increased intramuscular
lipid turnover.
Arterialized plasma insulin and glucose concentrations were higher after the SFA
meal as compared with the PUFA meal, with intermediate values for the MUFA
meal. Since there were no differences in net glucose flux between meals, this
implies higher postprandial insulin sensitivity after the PUFA meal (as evidenced by
data of the PGI). Our data are in line with previous studies, showing that a PUFA
meal improved insulin sensitivity as compared with a SFA meal (38, 39), We found
that the effect of MUFA was intermediate between the SFA meal and the PUFA
meal, which is in agreement with studies that have shown beneficial effects of
MUFA on insulin sensitivity as compared with SFA (39-42).
This differential effect on insulin sensitivity of PUFA versus SFA was accompanied
by differences in skeletal muscle FA metabolism. The uptake of TAG-derived FA by
forearm muscle decreased after the PUFA meal in the postprandial period as
compared with the SFA and MUFA meal. Circulating TAG concentrations were not
significantly lower after the PUFA meal compared to the other meals, suggesting
that a reduced TAG supply is not responsible for the reduced PUFA-induced TAG
extraction. The reduced TAG extraction may be related to the decreased
postprandial insulin concentrations, which may have resulted in reduced muscle
lipoprotein lipase (LPL) activity (35). Furthermore, the FA transporter CD36 is
acutely upregulated during insulin stimulation (34). Thus, reduced CD36 content in
skeletal muscle may also have contributed to the lower TAG extraction after the
PUFA meal.
Beside the reduced uptake of TAG-derived FA with PUFA, it seemed that there
was a higher fractional synthetic rate of the TAG, DAG and PL pool after the MUFA
meal compared with the SFA meal. The fractional synthetic rate of the lipid pools
was comparable after the PUFA and MUFA meal but values after the PUFA meal
were not significantly different from the SFA meal. These data should be
interpreted with caution, since skeletal muscle biopsies were taken 4h hours after
ingestion of the high-fat mixed-meal, when a steady-state has not yet been
reached. Nevertheless, these data hint towards a higher incorporation of dietary [U-
13C]-labeled palmitate from the muscle FFA pool in the different lipid fractions in
skeletal muscle with unsaturated FA compared with SFA. Additionally, there was a
lesser down-regulation of the mitochondrial oxidative genes after the PUFA
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compared with the SFA or MUFA meal, suggesting that overall lipid turnover is
higher after the PUFA compared with the SFA meal. The finding that a PUFA-
induced improvement in postprandial insulin sensitivity is accompanied by a higher
intramuscular lipid turnover is consistent with a recent study, demonstrating that
obese prediabetic insulin resistant subjects have a reduced fractional synthetic rate
of intramuscular TAG compared with controls (43). Overall, our data support the
concept that not the TAG concentration per se but rather lipid turnover may
determine insulin sensitivity.
Human studies examining the short-term effect of dietary FA on postprandial lipid
profile suggest that the FA composition of the meal may influence the absorption,
synthesis, and secretion of dietary TAG as well as the size of the chylomicron
particles (44-46). This study showed that postprandial circulating chylomicron
concentrations were highest after the MUFA meal. Other studies also found
increased TAG concentration after a MUFA meal (44, 47-49). De Bruin et al. (48)
found that the removal rate of olive oil chylomicron remnants was lower, which may
be explained by a reduced endothelial LPL action due to their TAG content or
greater particle number. This may imply that MUFA-chylomicrons have to rely on
an alternative route for their removal from the circulation. Indeed, it has been
suggested that hepatic lipase plays a significant role in the removal of MUFA-
enriched particles (48, 50).
It should be noted that we measured responses in the acute postprandial period. It
remains to be established if improvement in insulin sensitivity after the PUFA meal
due to lower lipid uptake (and possible less accumulation of fat in the muscle) is
relevant in the acute postprandial period. In fact, the increase in insulin sensitivity
after the PUFA meal may also be explained by other mechanisms beside lower
lipid uptake. For example, differences in the secretion of gut hormones (glucagon-
like peptide 1 and cholecystokinin) could potentiate differential insulin secretion
and insulin sensitivity according to FA composition of the meals (41, 46). Thus, the
exact mechanisms responsible for the differential postprandial insulin sensitivity
should be elucidated in future studies. Furthermore, it remains to be established
whether these acute effects may contribute to findings after long-term dietary
intervention. It has become clear from dietary intervention studies that long-term
isocaloric replacement of SFA has no major effects on insulin sensitivity (51).
In conclusion, the present study demonstrated that dietary FA have an acute effect
on postprandial insulin sensitivity. Replacing SFA with PUFA may induce a
reduced TAG-derived FA uptake, and a tendency toward a higher lipid turnover as
reflected by a more transcriptional oxidative phenotype and altered intracellular
lipid partitioning. These data suggest that the effects of replacement of SFA by
PUFA may contribute to lower uptake of lipids in skeletal muscle and may be
therefore protective against the development of insulin resistance in humans.
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Abstract
Background: High fiber diets offer several beneficial health effects.
Aim: The objective of the present study was to investigate whether replacement of
30% of available carbohydrates with polydextrose (PDX) or soluble corn fiber
(SCF) at breakfast and lunch would result in an increased fat oxidation rate and
satiety, which may be of relevance for body weight control and diabetes prevention.
Methods: In a single-blind randomized crossover study, 18 overweight men and
women underwent four different dietary interventions, which consisted of a PDX
diet, SCF diet and two control diets (full caloric and iso-caloric, comparable with
PDX with respect to grams or energy% of macronutrients, respectively). Glycemic
profile, energy expenditure and substrate oxidation were measured for 24 hours in
a respiration chamber. Circulating insulin, free fatty acids (FFA) and triacylglycerols
were determined over a 14-hour period during daytime. Appetite ratings were
assessed with visual analogue scales.
Results: Replacement of available carbohydrates with PDX or SCF reduced the
peak glucose response, which was accompanied by reduced postprandial insulin
responses. Moreover, higher levels of circulating FFA were observed after both
fiber diets, which was accompanied by an increased fat oxidation over 24 hours.
This effect was mainly attributed by the lower caloric value in the fiber diets and not
by the fibers per se. Beside the increase in fat oxidation there was a pronounced
suppressive effect on appetite ratings by PDX.
Conclusion: Replacing available carbohydrates by PDX may be of special interest
because of their beneficial effects on metabolic profile and may affect body weight
control in the long term.
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Introduction
The prevalence of obesity has increased rapidly worldwide and the importance of
developing dietary strategies to tackle the problem is widely acknowledged (1, 2).
Although it is well known that excess calorie intake is the primary dietary cause,
alterations in food patterns or nutrients must be considered (3). Consumption of
diets high in dietary fiber has been reported to result in a number of beneficial
health effects including a reduced risk of cardiovascular disease, diabetes,
hypertension, obesity and gastrointestinal disorders (4). High dietary fiber intake
may prevent weight gain by reducing appetite and energy intake (5, 6). Dietary
fibers may decrease intestinal passage time, leading to a more gradual nutrient
absorption and prolonged feelings of satiety. The slower nutrient uptake may result
in reduced postprandial glucose and insulin responses (7-11). The lower glucose
and insulin concentrations may, in turn result in a reduced inhibition of lipolysis,
higher circulating free fatty acid (FFA) concentrations and consequently increase
fat oxidation (12, 13). Additionally, dietary fibers can be fermented in the colon, with
the production of short chain fatty acids (SCFA) (acetate, butyrate and propionate)
and gases (hydrogen, methane and carbon dioxide), which may enhance satiety
and affect energy metabolism via various mechanisms (14). Epidemiological
evidence of these health-protective effects of dietary fiber has led to industrial
interest in developing novel dietary fibers that can be incorporated in a variety of
food products to increase fiber content. The question remains whether these
functional soluble fibers provide the same health benefits associated with
‘traditional’ dietary fibers. Only few soluble fibers can be used to be incorporated in
food products and beverages. The use of Polydextrose (PDX) and Soluble Corn
Fiber (SCF), also known as Soluble Gluco Fiber in Europe, seems a good option
since they have a higher digestive tolerance compared with other soluble fibers,
like for example inulin (15-17). PDX has randomly polymerized branched chains
and various types of glycosidic bonds (18). SCF is a fiber obtained from corn
starch, comprised of glucose oligosaccharides with digestion resistant glycosidic
linkages and contains minor amounts of mono and disaccharides (19). Both fibers
are poorly digested in the small intestine, but are partially fermented by the gut
microbiota (20). We hypothesized that replacement of available carbohydrates with
PDX or SCF may result in a reduced inhibition of postprandial fat oxidation rate and
increased satiety mediated through differences in glycemic and insulinemic and
FFA responses. A higher postprandial fat oxidation may have an impact on fat
storage and satiety, and may thereby translate in a negative energy balance in the
long term (21-23). Secondly, the higher postprandial fat oxidation may result in less
lipid accumulation in non-adipose tissues, thereby improving insulin sensitivity and
the metabolic profile in the longer term (24, 25). In the present study, we studied
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replacement of 30% of the total daily intake of available carbohydrates by PDX or
SCF provided at breakfast and lunch, on glycemic and insulinemic profile, energy
expenditure and substrate oxidation over a period of 24 hours.
Methods
Subjects
Eighteen overweight subjects (9 men and 9 women) between 20 and 50 years of
age participated in a single-blind randomized cross-over study. The men and
women were matched for age and body mass index (BMI) (Table 1). Additional
inclusion criteria were fasting plasma glucose < 6.1 mmol/L and a stable body
weight in the last 3 months (weight gain or loss < 3kg). None of the subjects were
on medication (except contraception) or were engaged in sports activities for more
than three hours per week. Body composition was determined by bio-impedance
(Bodystat Quadscan 4000, Bodystat Ltd, Douglas, DQ, British Isles). The study
protocol was reviewed and approved by the Medical Ethical Committee of
Maastricht University Medical Centre (MUMC+) and all subjects gave their written
informed consent before participating in the study.
Table 1. Subject characteristics.
men (n=9) women (n=9) p-value
Age (years) 32.4 ± 2.7 33.1 ± 3.5 0.883
Body weight (kg) 86.6 ± 2.3 81.1 ± 2.2 0.104
BMI (kg/m2) 27.3 ± 0.5 27.2 ± 0.4 0.910
Body fat (%) 18.4 ± 1.3 29.9 ± 2.0 0.000
Fat free mass (kg) 70.7 ± 2.4 56.8 ± 2.0 0.000
Fat mass (kg) 15.9 ± 1.0 24.3 ± 1.8 0.001
Waist-hip ratio 1.00 ± 0.01 0.91 ± 0.01 0.000
SBP (mmHg) 121 ± 3 111 ± 3 0.051
DBP (mmHg) 77 ± 2 72 ± 1 0.028
FPG (mmol/l) 5.1 ± 0.1 5.1 ± 0.2 0.932
HbA1c 5.4 ± 0.1 5.3 ± 0.1 0.352
Values are mean ± SEM. Men and women were compared using a 2-tailed Student’s t test for unpaired samples. BMI,
body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; FPG, fasting plasma glucose.
Study Design
The design of the study was a randomized single-blind cross-over design with four
different dietary interventions, including two fiber diets with polydextrose (PDX) or
Soluble Corn Fiber (SCF) also known as Soluble Gluco Fiber in Europe and two
control diets (full caloric and iso-caloric), with a 1 week washout period between
diets (see under Diet composition). The subjects were instructed not to change
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their lifestyle and dietary habits during the washout period. Before each test period,
subjects received a standardized meal (2385 kJ) at 19h00 the evening before they
entered the respiration chamber. Each respiration chamber visit started after the
continuous glucose monitoring system (CGMS) (Medtronic, MiniMed Inc., Sylmar,
CA, USA) was inserted in the peri-umbelical region at the abdomen of the subject
at 20h00 and ended 36 hours later at 8h00. The CGMS was calibrated four times
per day against finger-stick glucose determinations. In the first 12 hours, the
subjects could accustom to the chamber and during the first night, the sleeping
metabolic rate (SMR) was assessed to estimate total energy intake. The SMR was
calculated as the lowest energy expenditure (EE) (measured in 30 minutes
intervals) over three consecutive sleeping hours (26). Based on the SMR
(multiplied with a physical activity index of 1.55 (27)), total energy intake was
estimated. Subjects were fed in energy balance in all situations, since the
difference between 24 hour EE and energy intake was less than 10% deviation
(27).  For standardization of the measurements, the humidity in the respiration
chamber was fixed, clothing was standardized and physical activity was prescribed
by means of a standardized physical activity protocol (28). In the morning at 7h30
an indwelling cannula was inserted into an anticubital vein for the withdrawal of the
first fasting blood samples. Thereafter, subjects received one of the four different
diets in randomized order. During the day they received a breakfast at 8h, a lunch
at 12h and dinner at 17h30 and three snacks at 10h, 15h30 and 20h30. Water and
tea (except green tea) were available ad libitum. Profile of glucose, FFA,
triacylglycerols (TAG) and insulin were determined over a 14-hour period during
daytime from 8h00 until 21h30. Blood sampling was performed immediately before
ingestion of the three meals (breakfast, lunch and dinner) at t=0 min, and 30, 60,
120 and 240 minutes postprandially. The hydrogen concentration was measured in
end-expiration (alveolar) breath samples every 2h from 8h00 until 22h00 and again
at 8h00 the next morning using a gastrolyzer (Bedfont Scientific Ltd., The
Netherlands), as a marker for colonic fermentation. Visual analogue scales and
well-being questionnaires were completed 19 times throughout the test day as
described in detail below.
Diet composition
The four different dietary interventions consisted of two fiber diets (Sta-
lite®Polydextrose (PDX) and Promitor™ Soluble Corn Fiber (SCF), manufactured by
Tate & Lyle) and two control diets (full caloric and iso-caloric). In the PDX and SCF
diet, 30% of the available carbohydrates at breakfast and lunch of the full caloric
control diet were replaced by respectively PDX (56.7±0.9 g/day) or SCF (54.6±0.9
g/day). Logically, both fiber diets had a lower caloric value than the full caloric
control diet. To correct for the lower caloric value we also compared the PDX diet
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with a second control diet with the same caloric intake as the PDX diet (iso-caloric
control). The full caloric control diet, PDX and SCF diet consisted of approximately
the same macronutrient composition in grams. The iso-caloric control diet and PDX
diet had approximately the same macronutrient composition in energy percentage
(en%) (Table 2). The food products consisted of test products provided by Tate
and Lyle (Innovation Centre, France) and fresh and packed products bought at a
convenience store in the Netherlands. The test products provided by Tate and Lyle
included breakfast cereals, pudding and two instant drinks (powder mix for a hot
cocoa instant drink and a powder mix for an orange drink), all containing PDX or
SCF. In the full caloric and iso-caloric diet, placebo test products were given which
consist of full available carbohydrates with no PDX or SCF added. The fresh and
packed products consisted of semi-skimmed and full milk, high fat quark (type of
yoghurt), wheat bread, cheese, salami, margarine, apples, spaghetti bolognese and
salted peanuts. An overview of the diet composition is given in table 2. Besides the
fiber test products, which were only given in the PDX and SCF condition, the
remainder of the diet consisted of 19.1 ± 0.3g fiber in the full caloric condition, 16.0
± 0.3g fiber in the iso-caloric condition and 14.6 ± 0.2g fiber in both the PDX and
SCF condition.
Table 2. Diet composition.
Iso-caloric diet Full caloric diet PDX diet SCF diet
Energy (MJ) 9.5 ± 0.2 10.4 ± 0.2 9.5 ± 0.2 9.7 ± 0.2
Energy (kcal) 2261.2 ± 35.3 2489.3 ± 38.9 2261.2 ± 35.3 2323.8 ± 36.3
Protein (En%) 15.4 ± 0.2 14.9 ± 0.2 16.4 ± 0.3 15.9 ± 0.2
Protein (g/day) 87.0 ± 1.4 92.7 ± 1.5 92.9 ± 1.5 92.5 ± 1.5
Carbohydrate (En%) 46.5 ± 0.7 49.7 ± 0.8 46.5 ± 0.7 48.1 ± 0.8
Carbohydrate
(g/day)
262.7 ± 4.1 309.3 ± 4.8 249.4 ± 3.9 252.8 ± 4.0
PDX (g/day) / / 56.7 ± 0.9 /
SCF (g/day) / / / 54.6 ± 0.9
Fat (En%) 39.2 ± 0.6 35.8 ± 0.6 39.5 ± 0.6 38.3 ± 0.6
Fat (g/day) 98.5 ± 1.5 99.1 ± 1.6 99.2 ± 1.6 98.9 ± 1.5
Values are mean ± SEM.
24h energy expenditure (EE)
The 24h EE and substrate oxidation as well as the pattern of these parameters
over day and night were calculated from 7h30 to 7h30. Metabolic rate was
calculated from VO2 (l/min) and VCO2 (l/min) according to the equations of Frayn
(29). Energy expenditure was calculated using the formula of Weir (30). During the
stay in the respiration chamber 24-hour urine was collected from 8h00 to 8h00.
Subjects emptied their bladder at 8h00 before starting the collection. Urine volume
and nitrogen concentration were measured, the latter using a nitrogen analyzer
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(Heraeus, type CHN-O-Rapid). SMR of the second night was defined as the lowest
mean EE measured over three consecutive hours between 00h00 and 07h00 and
was used in further calculation. Diet-induced thermogenesis (DIT) and activity-
induced energy expenditure (AEE) were calculated as described previously (31).
Questionnaires
The Visual Analogue scale questionnaire (VAS, on a 100mm scale) contains
questions about feelings of hunger, fullness, satiety and desire to eat (32).
Opposing extremes were described at either end of a 100 mm horizontal line and
subjects marked the line to indicate how they felt at that moment. Well-being was
determined using a questionnaire on the occurrence of complaints (nausea,
abdominal bloating, stomach- intestinal cramps, diarrhea, and other symptoms).
Symptoms were graded on a 10-point scale with grade 1 representing ‘not present’
to grade 10 ‘strongly present’. Subjects were asked to mark how they felt at the
moment. For the analysis of the well-being questionnaire, a symptom was
considered present if the grade was scored >5.
Biochemical analysis
Blood was collected in pre-cooled tubes containing 0.2M EDTA (Sigma, Dorset,
UK). After collection, blood samples were centrifuged immediately at 4° C for 10
min at 1000g and frozen at -80° C until analysis. Plasma glucose, FFA and TAG
were analyzed using standard enzymatic techniques automated on a Cobas Fara
centrifugal spectrophotometer (Roche Diagnostics, Basel, Switzerland). Plasma
insulin was measured with a double antibody radioimmunoassay (Linco Research,
St Charles, MO).
Statistical analysis
Differences between the diets were examined using repeated-measures ANOVA.
First, PDX was compared with the full and iso-caloric diet, thereafter SCF was
compared with the PDX and full caloric diet. When a significant diet by time
interaction was observed, LSD post-hoc testing was performed. Postprandial area
under the curve (AUC) was calculated using the trapezoidal rule for all plasma
metabolites, energy and substrate metabolism and appetite scores. Data are
reported as mean ± SEM. A P-Value < 0.05 was considered statistically significant.
Statistical analyses were performed using the statistical program SPSS 16.0 for
Mac OS X.
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Results
Interstitial and plasma glucose and plasma insulin responses
There were no differences in integrated interstitial glucose response between the
four dietary interventions over 24 hours (Figure 1A). This was also reflected in
plasma, since there were no differences in plasma glucose over the day (Figure
1B). The peak glucose response after breakfast was lower after both fiber diets
compared with the full caloric diet (Full vs. PDX p=0.06, Full vs. SCF p=0.03). After
lunch, the peak glucose response was lower after the SCF diet compared with the
full caloric diet (Full vs. SCF p=0.03) (Figure 1B). During the night, PDX showed
the highest glucose response (AUC night p=0.02 and p=0.03, post-hoc Full vs.
PDX p=0.007, ISO vs. PDX p=0.08, SCF vs. PDX p=0.05) (Figure 1A). After
breakfast and lunch, the insulin response was significantly lower in the PDX and
SCF diet compared with the full caloric diet (AUC breakfast (8h-10h) p=0.04 and
p=0.001, post-hoc Full vs. PDX p=0.02, Full vs. SCF p=0.003; AUC lunch (12h-
14h) p=0.04 and p=0.01, post-hoc Full vs. PDX p=0.03, Full vs. SCF p=0.01). Over
the whole day, the reduced insulin response was only significant for the SCF diet
(Figure 2).
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Figure 1. Postprandial glucose responses. (A) Interstitial glucose response measured with a
continuous glucose monitoring system over 24 hours. (B) Plasma glucose response measured during
daytime. Repeated measures ANOVA were performed with LSD post-hoc testing using the integrated
responses (AUC). n=18. Data are mean ± SEM.
Figure 2. Postprandial insulin responses. Insulin response measured over time and AUC insulin
measured during daytime. Repeated measures ANOVA were performed with LSD post-hoc testing
using the integrated responses (AUC). n=18. Data are mean ± SEM. * p<0.05.
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FFA and TAG responses
During the day, the integrated FFA response was significantly higher in the PDX,
SCF and iso-caloric diet compared with the full caloric diet indicating that the higher
FFA response was due to the lower amount of calories in the diets rather than a
specific response to PDX or SCF (Figure 3A-B). For both fiber diets, the lower
concentrations of insulin in the postprandial state may reduce the inhibition of
lipolysis and may explain the higher FFA response, which was observed. There
were no differences in TAG response between all diets (Figure 3C-D).
Figure 3. Postprandial FFA and TAG responses. (A) FFA response measured over time. (B) AUC
FFA measured during daytime. (C) TAG response measured over time. (D) AUC TAG measured during
daytime. Repeated measures ANOVA were performed with LSD post-hoc testing using the integrated
responses (AUC). n=18. Data are mean ± SEM. * p<0.05, ** p<0.01.
Energy expenditure
Energy expenditure over 24 hours was not significantly different between the four
diets (Figure 4A-B). There were also no differences in sleeping metabolic rate
(SMR) during the second night, diet-induced thermogenesis (DIT) and activity
induced energy expenditure (AEE) (Figure 4C-E). On average, subjects were in
energy balance on the full caloric diet (+ 0.19 ± 0.17 MJ/d, p=0.3) and were in
negative energy balance on the PDX (- 0.83 ± 0.17 MJ/d, p=0.000), iso-caloric (-
0.78 ± 0.17 MJ/d p=0.000) and the SCF diet (- 0.60 ± 0.18 MJ/d p=0.003). There
was a significant difference in energy balance between the full caloric diet and the
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three other diets (iso-caloric, PDX and SCF diet) (p=0.000, post-hoc Full vs. PDX:
p=0.000, Full vs ISO: p=0.000, Full vs SCF: p=0.000). This may be explained by
the lower amount of calories in both fiber diets and the iso-caloric diet.
Figure 4. Energy expenditure measured over 24 hours in a respiration chamber. (A) Energy
expenditure measured over time. (B) Energy expenditure measured during 24 hours. (C) Sleeping
metabolic rate (SMR) of the second night measured during 24 hours. (D) Diet induced thermogenesis
(DIT) measured during 24 hours. (E) Activity energy expenditure (AEE) measured during 24 hours.
Repeated measures ANOVA were performed with LSD post-hoc testing. n=16. Data are mean ± SEM.
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Substrate oxidation
Over 24 hours, carbohydrate oxidation was reduced during the PDX and SCF diet
as compared with the full caloric diet (Figure 5A-B). Fat oxidation was increased in
both fiber diets and the iso-caloric diet as compared with the full caloric diet over 24
hours (Figure 6A-B). This indicates that the higher fat oxidation is due to the lower
amount of calories in the diets rather than a specific response to PDX or SCF. The
effect on substrate oxidation was mainly observed during the day (Figure 5C and
6C). During the night, the iso-caloric diet showed a lower carbohydrate oxidation
and a higher fat oxidation as compared with the full caloric and PDX diet (Figure
5D-6D).
Figure 5. Carbohydrate oxidation (CHO) measured over 24 hours in a respiration chamber. (A)
CHO measured over time. CHO measured during 24 hours (B), daytime (C), and night time (D).
Repeated measures ANOVA were performed with LSD post-hoc testing. n=16. Data are mean ± SEM. #
p<0.1, * p<0.05, ** p<0.01.
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Figure 6. Fat oxidation measured over 24 hours in a respiration chamber. (A) Fat oxidation
measured over time. Fat oxidation measured during 24 hours (B), daytime (C), and night time (D).
Repeated measures ANOVA were performed with LSD post-hoc testing. n=16. Data are mean ± SEM. *
p<0.05, ** p<0.01.
Hydrogen excretion
The concentration hydrogen was significantly higher after the PDX diet over 24
hours compared with both control diets (Figure 7). The SCF diet also showed a
higher breath hydrogen concentration compared with the full caloric diet. This
indicates a higher colonic fermentation after both fiber diets. There was no
difference between both fiber diets. The higher breath hydrogen response after the
PDX and SCF diets decreased after dinner and showed the same response as the
control diets.
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Figure 7. Breath hydrogen measurement over 24 hours. Upper right corner: AUC hydrogen over 24
hours. Repeated measures ANOVA were performed with LSD post-hoc testing using the integrated
responses (AUC). n=18. Data are mean ± SEM. * p<0.05, ** p<0.01.
VAS and well-being questionnaires
Desire to eat and the feeling of hunger were significantly lower after the PDX diet
compared with both control diets over 24 hours (Figure 8A and 8B). So, the
reduced desire to eat and feeling of hunger was due to the effect of the PDX fibers
per se. Feeling of fullness and satiety feelings were higher after the PDX diet
compared with both control diets over 24 hours, but this effect was only observed
in women (Figure 8C and 8D). The effect on appetite was only seen with the PDX
fibers since the SCF fibers showed a higher desire to eat (p=0.09) and less satiety
feelings (p=0.002) compared with the PDX diet.
Subjects scored no feelings of nausea, burping, headache, vomiting and dizziness
during all conditions. Only 1 male subject reported abdominal bloating in all
conditions. The same subject reported stomach-intestinal cramps in all conditions
except PDX. Diarrhea was scored present by 1 female in the PDX condition, 1
female in the SCF condition and 1 male in both fiber diets (Figure S1). The urge to
defecate was the highest in the SCF condition with an average score of 1.9 ± 0.3
on a total score of 10 measured over 24 hours compared with 1.5 ± 0.2 in both the
PDX and Full caloric condition (diet p=0.02, post-hoc Full vs. SCF p=0.05, PDX vs
SCF p=0.01).
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Figure S1. Diarrhea score measured over time. n=16. Data are mean ± SEM.
Discussion
Food components with health promoting properties have gained widespread
interest. The present study shows that replacing available carbohydrates by the
soluble fibers PDX and SCF reduced the peak glucose response, which was
accompanied by a reduction in postprandial insulin responses. Furthermore,
increased circulating FFA concentrations and concomitant a higher fat oxidation
were observed. This was mainly attributed by the lower caloric value and the more
negative energy balance of the high fiber diets and not the fibers per se.
Nevertheless, PDX showed favorable effects on appetite, which appeared to be a
specific characteristic of PDX independent of energy balance. The effects on
appetite and fat oxidation can be regarded as a beneficial change in metabolic
profile in relation to body weight control and insulin sensitivity if these effects
persist over longer periods of time under ad libitum feeding conditions.
Replacing available carbohydrates by PDX or SCF reduced insulin responses in
the postprandial state translating in a reduced insulin response over the whole day
for SCF. However, no major effects on interstitial and plasma glucose responses
were observed after both fiber diets, only the peak glucose responses after
breakfast and lunch were lower. Several studies reported no effect of PDX on
plasma glucose or insulin kinetics when PDX was given pure or as a drink with a
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mixed meal (33, 34). However, other studies reported a lower glucose response
when PDX was incorporated in chocolate, sweetened dried cranberries and
strawberry jam (35-37). Kendall et al. showed lower postprandial glucose and
insulin responses for SCF when given as a lemonade drink (11). These studies
investigated postprandial glucose and insulin concentrations after a single meal
over a limited period of time rather than after three meals (breakfast and lunch
contained PDX or SCF) during daytime in this study.
Furthermore, we investigated the effect of both fibers on substrate oxidation and
energy expenditure. For the PDX and SCF diet, a higher fat oxidation and lower
carbohydrate oxidation was observed compared with the full caloric diet. As
indicated above, this increased fat oxidation was accompanied by reduced insulin
responses (only significant for SCF over the whole day) and consequently higher
FFA concentrations confirming our initial hypothesis that a fiber induced reduction
in insulin concentrations may result in increased circulating FFA thereby increasing
fat oxidation. Nevertheless, the increased fat oxidation was mainly attributed by the
lower caloric value and not the fibers per se, since the iso-caloric control also
showed a higher fat oxidation compared with the full caloric diet. Sparti et al.
studied the effect of two different isoenergetic diets containing high or low
unavailable carbohydrates on 24-hour substrate oxidation in lean subjects.
However, total substrate oxidation did not differ between the two diets (38). In
another study, substrate oxidation was measured for 5 hours after ingestion of
meal containing resistant starch or rapidly digestible starch, with a difference of 103
kJ in energy content between the former and the latter meal. Resistant starch
intake was followed by a lower glucose oxidation and a greater fat oxidation (39). In
line with our results, the difference in energy content between both meals may
have contributed to the increase in fat oxidation.
There were no differences in 24-hour energy expenditure between the diets. In
previous studies in which the meal or diet was supplemented with dietary fibers,
also no differences in 24-hour energy expenditure were reported (38, 40-42). DIT,
AEE and SMR were not different between the fiber and control diets. There is still a
lot of controversy about the effect of dietary fibers on DIT. Some studies reported
no effect of dietary fibers on DIT (39, 43), while others showed a reduced DIT (44,
45). The explanation for the discrepant results is not entirely clear but may relate to
differences in the methodology for determining DIT, subject characteristics and
different fiber characteristics.
Commensal bacteria ferment dietary fibers. The gases produced by fermentation
are absorbed into the circulation and diffused into the pulmonary alveolus.
Therefore, measurement of hydrogen in the breath reflects the anaerobic bacterial
fermentation of dietary fiber in the colon (14, 46). In this study, we indeed showed
that the concentration of hydrogen in the breath was significantly higher after the
PDX and SCF diet compared with both control diets. This indicates a higher colonic
Chapter 6
152
fermentation after both fiber diets. There were no differences in hydrogen
concentration between both fiber diets. Because colonic fermentation is an
incomplete combustion, disregarding the fermentation process could lead to errors
in estimating substrate oxidation from indirect calorimetry data (47, 48). However,
in an experiment designed to quantify the measurement error in substrate oxidation
due to the presence of fermentation, Poppitt et al. estimated the maximal error in
carbohydrate oxidation after ingestion of 58g unavailable carbohydrates to be 2%.
(49). Also, Heresbach et al. showed that when the additional excretion of breath
hydrogen is < 20ppm, the magniture of error in VCO2 measurement is small on
average (47). Although it is important to measure hydrogen excretion in whole-
body calorimetry studies in which fermentable carbohydrates are part of the diet,
the effects on the calculation of energy expenditure and fuel selection in humans
are small (40) and have had no impact on the conclusions of the present study.
Furthermore, the effect of both fibers on several measures of appetite were
investigated. In our study, desire to eat and feeling of hunger were lowest after the
PDX diet as compared to all other diets. Feeling of fullness and satiety feelings
were higher after the PDX diet compared with both control diets, but this was only
shown in women. Gender differences in satiety responses have been noted in
previous studies, in which women reported higher post-meal satiety ratings and
showed a reduced food intake (50, 51). The effect on appetite was not seen for
SCF.
Peripheral fatty acid oxidation has long been implicated in the control of eating
(52). Nevertheless, since the favourable effects on appetite were a specific
characteristic of PDX while the increased fat oxidation was mainly determined by a
negative energy balance, other mechanisms may be responsible for the PDX-
induced reduction in appetite. Several factors may influence appetite like, the
intrinsic physical properties of dietary fiber (bulking, gel formation and viscosity),
modulation of gastric motor function, increased mastication, changes in gut
hormones (ghrelin or GLP-1) and blunting of postprandial glucose and insulin
responses (53-55). Additionally, it has been hypothesised that colonic fermentation
resulting in increased production of SCFA could stimulate colonic L-cells to
produce several appetite-regulating hormones such as PYY and GLP-1 (55). The
responsible mechanisms remain to be elucidated.
In conclusion, replacement of available carbohydrates with PDX or SCF reduced
the peak glucose response, reduced postprandial insulin responses and increased
circulating FFA concentrations, which was accompanied by an increase in fat
oxidation after both fiber diets. This effect was mainly attributed by the lower caloric
value and not the fibers per se. Interestingly, PDX incorporated in food products
may be of special interest since it has a suppressive effect on appetite control,
which may have a significant effect on body weight control and improved metabolic
health in the long term.
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Obesity and insulin resistance
Obesity is increasing in epidemic proportions throughout the whole world (1). This
alarming increase in obesity is associated with a lower age of onset and an
increased incidence and prevalence of obesity-related comorbidities like type 2
diabetes mellitus (T2DM) (2). Changes in lifestyle are considered to play an
important role in the etiology of obesity and T2DM. Manipulation of diet and
physical activity are the first-choice treatment for these metabolic diseases (3).
Lifestyle intervention programs combining dietary advice and an increased physical
activity have been shown to be effective in the prevention of T2DM (4, 5). However,
more than 30% of the high risk subjects do not respond to the intervention
indicating the need for additional preventive strategies. Metabolic inflexibility,
defined as an impaired capacity to increase fat oxidation in the fasted state and to
suppress fat oxidation after a meal may contribute to the accumulation of lipids and
lipid metabolites within the skeletal muscle (6). The accumulation, composition and
localization of bioactive lipid metabolites may interfere with insulin signaling,
thereby promoting the development of insulin resistance and T2DM (7, 8).
Identification of foods, which could influence specific physiological targets to
improve metabolic flexibility may be helpful in the prevention and management of
overweight and obesity as well as insulin resistance. Therefore, in this thesis we
investigated the effects of several dietary interventions on body weight control as
well as the prevention and/or reversal of insulin resistance by modulation of fat
metabolism.
Fatty acid handling in the prediabetic state
The underlying metabolic and molecular mechanisms responsible for the
impairment in metabolic flexibility  in the insulin resistant or prediabetic state are
not completely understood (9). It has been suggested that the metabolic profile of
the insulin resistant muscle is more directed towards fat storage than towards
oxidation (9, 10).
It has been shown that T2DM subjects have a significantly elevated ACC-2 mRNA
expression in skeletal muscle (11). This increase in ACC-2 may promote malonyl-
CoA formation which in turn leads to inhibition of CPT-1, a lower transport of FFA
into the mitochondria and a decreased fat oxidation (12). Also a set of genes
involved in oxidative phosphorylation including PGC1, has been shown to be
coordinately downregulated in the skeletal muscle of T2DM patients (13, 14). In
chapter 2 we investigated whether the prediabetic state is accompanied by
changes in the expression of genes involved in fatty acid handling during fasting
and insulin-mediated conditions. We observed no differences in expression of
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genes involved in lipogenesis and lipid oxidation between the impaired glucose
tolerant (IGT) and normal glucose tolerant (NGT) state. This may be explained by
the fact that differences in the degree of insulin resistance between the subject
groups were less extreme than in previous studies (11, 13-15). After the
hyperinsulinemic clamp, several genes were upregulated, including PGC1,
SREBP-1c, SREBP-2 and ACC-2. Interestingly, the clamp-induced increase in
SREBP-2 gene expression was more pronounced in IGT men as compared to NGT
men. This may reflect an increased activation of the novo membrane synthesis to
repair the mitochondrial membrane damage possibly induced by an increased lipid
peroxidation in the prediabetic state (16). However, further research is necessary
to elucidate the exact role of SREBP-2 in skeletal muscle.
Calorie restriction
Calorie restriction has consistently been proven to produce weight loss and to have
beneficial health effects like an improved insulin sensitivity (17, 18), possibly
mediated via modulation of fat metabolism. Previous studies have reported that
weight loss showed either an improvement (19) or no change (20) in fasting fat
oxidation. After weight loss, obese prediabetic subjects have been shown to
improve their capacity to switch from fat oxidation to carbohydrate oxidation after a
meal (19). Altogether, there are clear indications that weight loss is able to partly
reverse postprandial impairments in substrate oxidation, whereas with respect to
the fasting condition, improved regulation of fat oxidation could not be confirmed in
all studies. To elucidate the effect of weight loss on fasting skeletal muscle fat
metabolism, we investigated in chapter 2 the impact of weight loss on fatty acid
metabolism-related gene expression in obese IGT subjects. After the 12 week
VLCD, the obese IGT man lost approximately 15kg of body weight, which was
accompanied by an increase of 71% in insulin sensitivity and a tendency towards
an increase in muscle oxidative capacity as evidenced by CS activity.
Nevertheless, no changes in skeletal muscle gene expression of several target
genes (PGC1, PPAR, ACC-2, SREBPs and ChREBP) were observed. This is
consistent with Simoneau et al. (9) who also did not detect changes in several
different markers of skeletal muscle FA metabolism in obese NGT men after a
weight loss intervention based on a VLCD, but is not consistent with all other
studies showing an upregulation of genes involved in lipid oxidation (21-23). Our
results may imply that changes in the postprandial state possibly play a larger role
in lipid-induced insulin resistance. However, gene expression changes do not
necessarily translate into functional proteins so it could be that some key steps in
lipid metabolism are involved in the improvement in insulin sensitivity, in particular
since we observed a tendency towards an increased oxidative capacity.
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Furthermore, we cannot exclude that small differences in gene expression after
weight loss may have been missed because of the relatively small sample size,
and the results need confirmation in future studies.
Resveratrol: a potential calorie restriction mimetic?
Several beneficial effects of resveratrol have been described including anti-
inflammatory, antioxidant, cardio-protective and anti-aging actions (24). Although
originally the focus was mainly directed towards anti-oxidant properties of
resveratrol (25), more recently cellular effects on fatty acid metabolism and
mitochondrial function have been described. Resveratrol has been shown to exert
favourable effects in rodents fed a high-calorie diet. The animals were less prone to
develop insulin resistance, which was related to the induction of genes for oxidative
phosphorylation and increased mitochondrial biogenesis (26). By reversing
disturbances in fat metabolism resveratrol may be able to improve the success of
lifestyle interventions with respect to insulin sensitivity and body weight control. In
chapter 3, we investigated the effect of 30 days resveratrol supplementation on
energy metabolism and metabolic profile in 11 healthy obese men. The hypothesis
was that an improvement in mitochondrial function together with an increased
mitochondrial biogenesis improves skeletal muscle metabolic flexibility and (fat)
oxidative capacity. This may reduce bioactive lipid metabolite accumulation and
may improve insulin sensitivity. Our microarray data clearly suggested strong
involvement of mitochondrial function in the beneficial effects of resveratrol.
Therefore, we performed more detailed analyses of mitochondrial function which
revealed that resveratrol had beneficial effects on mitochondrial respiration when
octanoyl-carnitine was used as a substrate, but not when only glutamate was used.
These data suggest that resveratrol specifically improves muscle fat oxidative
mitochondrial capacity. The underlying molecular mechanisms contributing to the
improvement in mitochondrial activity may be mediated by AMPK which was
activated by resveratrol. This resulted in increased protein content of the AMPK
downstream effector SIRT1 as well as the mitochondrial master regulator PGC1,
accompanied by increased citrate synthase activity. The fact that mtDNA copy
number, OXPHOS protein content, and PCr recovery were not changed in
resveratrol treated subjects suggests that 30 days resveratrol treatment mostly
affects mitochondrial efficiency, not abundance. It is possible that more long-term
treatment would cause these parameters to change as well.
Furthermore, we investigated whether this improvement in mitochondrial efficiency
would be reflected on whole body level. Over 24 hours we observed a higher RQ in
the resveratrol group especially apparent after periods of feeding suggesting an
improved metabolic flexibility. This was confirmed in the postprandial test were we
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showed an improvement in insulin mediated suppression of postprandial adipose
tissue lipolysis and a more pronounced reduction in whole body fat oxidation after
resveratrol supplementation as compared to placebo. This suggests an improved
switch in substrate oxidation after a meal.
With respect to energy metabolism, subjects showed a lower sleeping metabolic
rate after resveratrol supplementation, without changing 24 hour energy
expenditure. It should be noted that sleeping metabolic rate is the component of
human energy metabolism that is most sensitive to metabolic changes—as it is not
affected by physical activity—and small differences in sleeping energy expenditure
can be detected with high accuracy. In line, we observed that basal and
postprandial energy expenditure were also lower after 30 days of resveratrol
supplementation. The 2%–4% reduction in energy expenditure upon resveratrol
treatment may reflect an increased metabolic efficiency and is consistent with the
effects observed after calorie restriction (6% reduction) (27, 28). Long-term
supplementation of resveratrol may thus contribute to weight gain if energy intake
is not adjusted to the reduction in energy expenditure. An approach to overcome
this lower energy expenditure is by supplementing resveratrol together with other
food components that can stimulate energy expenditure like caffeine, capsaicin or
green tea extract (29, 30). However, this has to be further investigated in long-term
human studies.
Since our data showed that resveratrol clearly induced a shift in mitochondrial
substrate selection and an improvement in metabolic flexibility, we investigated
whether this was also reflected in liver and skeletal muscle lipid accumulation.
Intrahepatic lipid content was lower after 30 days of resveratrol supplementation
compared with placebo. This was paralleled by lower plasma ALAT values, both
indicating improved liver function. In contrast, intramyocellular lipid (IMCL) content
was markedly increased, but since this was concomitant with an improvement in
muscle fat oxidative capacity, this may hint towards endurance training-like effects
of resveratrol (31, 32). Endurance athletes have elevated IMCL levels but are
extremely insulin sensitive because of their high muscle oxidative capacity (33).
Furthermore, insulin sensitivity was also improved after resveratrol as evidenced by
a lower HOMA-index. Several human intervention studies reported the insulin-
sensitizing effect of resveratrol. Crandall et al. treated 10 IGT patients for 4 weeks
with resveratrol and observed a reduction in postprandial glucose levels without an
increase in insulin production (34). In T2DM patients, 4-weeks resveratrol
supplementation improved insulin sensitivity based on HOMA-IR and delayed the
glucose peak following a standardized meal (35). However, Ghanim et al. did not
show an effect on fasting glucose, insulin and HOMA-IR scores following 6 weeks
resveratrol supplementation (in P. cuspidatum extract) in healthy individuals (36).
From these interventions it can be concluded that subjects with IGT or T2DM may
be most susceptible to resveratrol supplementation and may therefore benefit the
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most from this intervention.
Pronounced effects of resveratrol have also been reported on lipolysis,
adipogenesis and inflammation in isolated adipocytes and on adipose tissue of
murine animals (37). These effects may possibly modulate adipose tissue function
and contribute to a reduced body fat accumulation and improved insulin sensitivity
(26, 38). However, data on the effects of resveratrol on adipose tissue function in
the human in vivo situation are lacking. Therefore, in chapter 4 the effect of
resveratrol on adipose tissue morphology and the underlying mechanisms involved
were investigated using microarray analysis. Resveratrol significantly decreased
adipocyte size, with a shift towards a lower proportion of large and very large
adipocytes and an increased proportion of small adipocytes. This reduced mean
adipocyte size may underlie the improved insulin sensitivity as reported in chapter
3, since adipocyte size is an independent determinant of insulin sensitivity in
humans (39). Microarray analysis revealed downregulation of pathways like Wnt,
Notch and BMP/TGF- signaling and upregulation of gene sets contributing to cell
cycle, which suggest an enhanced adipogenesis after resveratrol supplementation.
This increased adipogenesis could possibly explain the reduced adipocyte size
after resveratrol. Furthermore, GSEA revealed an increase in gene sets associated
with activation of a lysosomal pathway of lipid breakdown (autophagy). Until
recently, mobilization of lipids by the classic lipolytic pathway has only been
attributed to lipid droplet associated proteins and lipases. The involvement of
autophagy in lipid degradation was first reported by Singh et al. (40) who
demonstrated that clearance of lipid droplets is mediated by lipid specific
autophagy in hepatocytes and liver. Major support for the involvement of
autophagy in our study was also the activation of the transcription factor EB (TFEB),
which has been shown to control multiple steps of the autophagic pathway and to
ensure prolonged and sustained activation of autophagy (41). The finding that the
lysosomal degradative pathway is a critical regulator of hepatocyte lipid metabolism
opens the possibility that it may function in a similar way in adipose tissue. Studies
to date have not determined the effect of autophagy on differentiated adipocytes. In
preadipocytes, it has been shown that inhibition of autophagy may block
adipogenesis (42). Therefore, in the present study, the lysosome and phagosome
pathways, may have contributed both to an induction of adipogenesis as well as to
alternative lipid breakdown. These data suggest that autophagy may serve as an
important target for the treatment of metabolic diseases like obesity and T2DM and
that resveratrol may be an interesting therapeutic tool to induce this process but
this needs to be further elucidated.
Furthermore in chapter 4, several gene sets involved in the immune response
were upregulated in adipose tissue after resveratrol treatment. This may reflect an
increase in cellular stress induced by the reduction in adipocyte size caused by
traction forces between the adipocyte and the surrounding extracellular matrix (43).
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This in turn may induce upregulation of inflammatory genes and pro-inflammatory
adipokine production, as shown after weight loss (44, 45). On the other hand,
upregulation of immune response pathways may be a physiological response to a
higher lipid turnover (i.e. lysosomal lipid breakdown). As reported in chapter 3, we
also observed a decrease in circulating plasma Il-6 and TNF- concentrations and
a downregulation of gene sets associated with immune response in skeletal muscle
in these subjects following resveratrol supplementation. These findings indicate
that the increased immune response in adipose tissue could represent a local
rather than a systemic response. Further studies in humans are necessary to
investigate the tissue specific effects of resveratrol supplementation on
inflammation.
In summary, 30 days resveratrol supplementation clearly improved muscle fat
oxidative mitochondrial capacity and metabolic flexibility. Moreover, resveratrol
induced a shift towards an increased proportion of metabolic favorable small
adipocytes. This phenotype was accompanied by a gene expression profile
indicative of increased adipogenesis and an alternative pathway of lipid breakdown
which may contribute to an increased lipid buffering capacity of the adipose tissue.
This may reduce the supply of lipids to non-adipose tissues and together with the
increased oxidative capacity may contribute to a reduction in ectopic lipid
accumulation as was observed in the liver. The reduced intrahepatic lipid content
together with an efficient lipid turnover in skeletal muscle may have contributed to
the improvement in insulin sensitivity. From this we can conclude that resveratrol
has considerable potential to improve health and prevent chronic disease in
humans. However, it is not yet certain if long-term resveratrol supplementation will
maintain these physiological benefits.
Dietary fatty acids
An overconsumption of saturated fats has been implicated as a causative factor for
the development of insulin resistance, whereas certain monounsaturated fats and
PUFAs and, particularly n-6 fatty acids, appear to have no adverse effects or even
fairly positive effects on the action of insulin (46). However, the underlying
mechanisms how dietary fatty acids may affect insulin sensitivity and how the risk
or severity of insulin resistance can be modulated by fat quantity and quality are
currently under debate. A change in dietary fat quality (an increase in unsaturated
fatty acids) may differentially modulate circulating lipids, skeletal muscle fatty acid
handling and fuel partitioning within the muscle towards less accumulation of lipid
metabolites and increased oxidative capacity which may contribute to an improved
insulin sensitivity. Therefore, in chapter 5, the objective was to examine the acute
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effects of meals with various fatty acid compositions on skeletal muscle FA
processing and postprandial insulin sensitivity in obese, insulin-resistant men. The
meals consisted of SFA (35.5 En%), MUFA (42.2 En%) or PUFA (34.8 En%). The
PUFA meal contained n-6 safflower oil and n-3 fish oil with a ratio of 1:1. Ingestion
of the PUFA meal resulted in an improved postprandial insulin sensitivity compared
with SFA. Our data are in line with those of previous studies, showing that a PUFA
meal improved insulin sensitivity as compared with an SFA meal (47, 48).
Furthermore, we found that the effect of MUFA was intermediate between the SFA
meal and the PUFA meal, which agrees with studies that have shown beneficial
effects of MUFA on insulin sensitivity as compared with SFA (49-51). Moreover,
underlying mechanisms for the improvement in insulin sensitivity after the PUFA
meal were investigated by using a dual stable isotope technique. With this
technique, the contribution of dietary fat (CM-TAG) vs. endogenous fat (FFA and
VLDL-TAG) to in vivo skeletal muscle fatty acid metabolism could be investigated
by using two different labels. [U-13C]-palmitate was added to a high fat mixed meal
to label CM-TAG in the circulation and [2H2]-palmitate was infused intravenously to
label the endogenous pool of FA. As [2H2]-palmitate can be incorporated into TAG
in the liver, [2H2]-labelled TAG represents VLDL-TAG in the circulation. Moreover,
this stable isotope technique was combined with measurements of arterio-venous
concentration differences across the forearm muscle to investigate skeletal muscle
FA handling and the specific contribution of the different fat sources.
We observed a reduced uptake of TAG-derived FA by the forearm muscle in the
postprandial period after ingestion of a meal high in PUFA as compared with the
SFA meal.  Furthermore, we showed a higher incorporation of dietary [U-13C]-
palmitate from the muscle FFA pool in the different lipid fractions (higher fractional
synthetic rate [FSR]) in skeletal muscle with unsaturated fatty acids compared with
saturated fatty acids, indicating an increased muscle lipid turnover. Moreover,
microarray analysis of skeletal muscle revealed a lesser downregulation of the
mitochondrial oxidative genes after the PUFA meal than after the SFA or MUFA
meal. Together, these data indicate that a PUFA-induced improvement in
postprandial insulin sensitivity may be accompanied by a lower lipid uptake and
possibly less accumulation of fat in the muscle and a higher intramuscular lipid
turnover as compared to SFA. This is consistent with the findings of a recent study,
which showed that insulin resistance is associated with a reduced lipid turnover as
evidenced by a lower FSR of intramuscular TAG (52). Nevertheless, we cannot
exclude that the increase in insulin sensitivity after the PUFA meal may also be
explained by other mechanisms. For example, differences in the secretion of gut
hormones (glucagon-like peptide 1 and cholecystokinin) could potentiate
differential insulin secretion and insulin sensitivity according to the fatty acid
composition of the meals (51, 53). Thus, the exact mechanisms responsible for the
differential postprandial insulin sensitivity should be further elucidated in future
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studies. Furthermore, it remains to be established whether these acute effects may
contribute to findings after long-term dietary intervention. Three large long-term
intervention studies, KANWU study, LIPGENE study and the RISCK trial, did not
find major effects on insulin resistance when SFA were replaced by an equal
amount of MUFA (54-56). However, substitution of SFA with MUFA did improve
insulin sensitivity in the KANWU study when total fat intake was below 38 En% (54).
These data suggest that dietary fat quality is only of importance for insulin
sensitivity with a total fat intake equal or lower than 35-40 % of total energy intake.
Moreover, in the LIPGENE study, insulin sensitivity significantly improved in
women on the high MUFA diet, but only when the habitual fat intake before the
start of the study was below 36 En% (unpublished results). There is also a lot of
controversy with respect to the long-term effect of PUFA on insulin sensitivity. A
recent meta-analysis showed that n-3 PUFA consumption did not affect insulin
sensitivity (57).
Overall, total fat intake alone probably does not have a major effect on insulin
sensitivity but the possible interaction between fat quality and quantity needs
further investigation. Also heterogeneity in subject characteristics like gender and
initial metabolic profile may mask the effect of the dietary intervention. Therefore, a
more personalized dietary approach is necessary to increase the intervention
success.
Dietary fibers
Fiber is a major component of carbohydrate that is generally considered beneficial
for health and can decrease the energy density of a diet. High fiber foods take
longer to eat and have a reduced absorption rate thereby increasing fullness and
satiety. They may also stimulate the release of gut peptides that modify eating
behavior (277,278). High fiber intake may thus prevent weight gain by reducing
energy intake and appetite (58, 59). Furthermore, the decreased intestinal passage
time and more gradual nutrient absorption may contribute to a reduction in
glycemic and insulinemic responses (60-64). These lower glucose and insulin
concentrations may, in turn result in a reduced inhibition of lipolysis, higher
circulating FFA concentrations and consequently increased fat oxidation (65, 66). A
greater postprandial fat oxidation may attenuate fat accumulation in non-adipose
tissues, leading to an improvement in insulin sensitivity (67). A higher postprandial
fat oxidation may also translate in a negative energy balance in the long term.
These health-protective effects raised interest of the industry to develop functional
fibers, which could be incorporated in food products to replace carbohydrates like
glucose and sucrose but with a similar sweetness and taste. However, it still needs
to be investigated if these functional fibers deliver the same known health benefits
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as “traditional” fibers. Therefore, in chapter 6 we investigated whether replacement
of 30% of the total daily intake of available carbohydrates by polydextrose (PDX) or
soluble corn fiber (SCF) at breakfast and lunch would result in an increased fat
oxidation rate and satiety, which may be of relevance for body weight control and
diabetes prevention. Logically, both fiber diets had a lower caloric value than the
full caloric control diet. To correct for the lower caloric value we also compared the
PDX diet with a second control diet with the same caloric intake as the PDX diet
(iso-caloric control). The full caloric control diet, PDX and SCF diet consisted of
approximately the same macronutrient composition in grams. The iso-caloric
control diet and PDX diet had approximately the same macronutrient composition
in energy percentage. In this way, we could distinguish whether the effects
observed were attributed by the fibers per se or the lower caloric content of the
fiber diets. Replacing available carbohydrates by PDX and SCF reduced the peak
glucose response, which was accompanied by a reduction in postprandial insulin
responses. Furthermore, increased circulating FFA concentrations and
concomitant a higher fat oxidation were observed. This was mainly attributed by
the lower caloric value and the more negative energy balance of the high fiber diets
and not the fibers per se. Nevertheless, PDX showed favorable effects on appetite,
which appeared to be a specific characteristic of PDX independent of energy
balance. Several factors may influence appetite like, the intrinsic physical
properties of dietary fiber (bulking, gel formation and viscosity), modulation of
gastric motor function, increased mastication, changes in gut hormones (ghrelin or
GLP-1) and blunting of postprandial glucose and insulin responses (68-70).
Additionally, it has been hypothesised that colonic fermentation resulting in
increased production of SCFA could stimulate colonic L-cells to produce several
appetite-regulating hormones such as PYY and GLP-1 (70). The responsible
mechanisms remain to be elucidated.
The reduced energy content of PDX together with its suppressive effects on
appetite may lead to a negative energy balance, which has been shown to
increase fat oxidation. The intake of food products in which part of the available
carbohydrates is replaced by PDX could be of benefit to individuals aiming to
reduce overall energy intake to achieve and maintain a healthy body weight.
Furthermore, an increase in fat oxidation may reduce fat accumulation in non-
adipose tissues, which may lead to improvements in insulin sensitivity. However,
this has to be investigated in a long-term study with ad libitum food intake.
Possibly, the energy reduction is unlikely to engender a major reduction in body
weight but could contribute to preventing weight gain or weight regain (58).
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Conclusion and future perspectives
The studies described in this thesis provide insight in the effects of several dietary
interventions on body weight control as well as insulin sensitivity by modulation of
fat metabolism. The main outcomes and future directions of this thesis are
summarized below:
1. A very low calorie diet program induced an initial large decrease in weight,
which was accompanied by an improvement in insulin sensitivity. The
underlying mechanism for this improvement could not be explained by
changes in skeletal muscle fatty acid metabolism related gene expression
in the fasted state. This may imply that changes in the postprandial state or
other processes possibly play a larger role in lipid-induced insulin
resistance. Further research is necessary and should not only focus on
skeletal muscle but also explore the other organs in a broader whole-body
perspective.
2. Resveratrol supplementation for 30 days reduced adipocyte size and the
accompanying gene expression profile hinted towards an improved lipid
buffering capacity of the adipose tissue. This together with the
improvement in muscle fat oxidative mitochondrial capacity and metabolic
flexibility and reduced liver fat accumulation may be underlying
mechanisms for the improvement in insulin sensitivity. Studies
investigating long-term supplementation of resveratrol are necessary to
further explore whether these calorie-restriction like effects remain over
time. Secondly, it remains to be determined whether the reduction in
energy expenditure, which was observed, will contribute to weight gain
making this supplement less attractive for the prevention of metabolic
complications.
3. Acute ingestion of a PUFA meal consisting of n-3 fish oil and n-6 safflower
oil (ratio 1:1) has shown to improve postprandial insulin sensitivity
compared with an SFA meal. Potential underlying mechanisms for this
improvement may be the reduced uptake of TAG-derived FA by the
forearm muscle and a higher intramuscular lipid turnover. However, long-
term effects of SFA replacement by PUFA on insulin sensitivity may be
more complex and may also involve total fat intake. Possibly, also a more
personalized dietary approach is preferred to increase the intervention
success.
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4. Food products with incorporated functional fibers like PDX and SCF
reduced the peak glucose response, which was accompanied by a
reduction in postprandial insulin responses. Furthermore, increased
circulating FFA concentrations and concomitant a higher fat oxidation were
observed. This was mainly attributed by the lower caloric value and the
more negative energy balance of the high fiber diets and not by the fibers
per se. Nevertheless, PDX showed favorable effects on appetite, which
appeared to be a specific characteristic of PDX independent of energy
balance. Long-term studies are needed to investigate the effect of these
products in an ad libitum setting on body weight control and insulin
resistance.
To conclude, the “ideal’ diet for obese insulin resistant subjects should include
those dietary components that induce satiating and metabolic properties that are
effective for body weight control and improvements in the metabolic profile. A
reduction in daily energy intake is usually part of dietary treatment. Increased
consumption of food products/food supplements like resveratrol, more unsaturated
fatty acids and an increase in certain dietary fibers may improve the metabolic
flexibility of fat metabolism, which can contribute to intervention success and long
term maintenance of beneficial metabolic effects. However, further research is
necessary to evaluate the long-term benefits of these components. Moreover, the
study of complete dietary patterns, rather than isolated foods or nutrients, may be
the most adequate approach to assess the role of diet on obesity and the insulin
resistant state. This because synergistic or antagonistic effects may exist between
the different components of the diet. Besides dietary recommendations also regular
physical activity should be included in any health promotion and disease
prevention strategy. Receiving guidelines about the “ideal’ personal diet should
always be in accordance with the persons’ own preferences and accompanied by
behaviour modifications since the intrinsic motivation of the subject plays an
important role to enhance compliance with the diet. Furthermore, governmental
actions are needed to modify the food environment. Consumption of unhealthy
food should be discouraged by making the costs of it higher and alternatively
healthier diets should be promoted by making these products cheaper.
The challenge for the future is to further investigate the link between nutrition and
obesity as well as obesity-related health complications to eventually develop the
most successful personalized dietary approach to tackle these diseases.
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SUMMARY
The global epidemic of overweight and obesity is rapidly increasing throughout the
world. This alarming increase in obesity is associated with a lower age of onset and
an increased incidence and prevalence of obesity-related comorbidities like type 2
diabetes mellitus (T2DM). Changes in lifestyle are considered to play an important
role in the etiology of obesity and T2DM but there is a need for additional
preventive strategies to increase the effectiveness of dietary programs. The
identification of food and food ingredients that could influence specific physiological
targets like increasing fat oxidation and restoring metabolic flexibility may be helpful
in the prevention and treatment of obesity as well as diabetes. Therefore, in this
thesis we investigated the effects of several dietary interventions on body weight
control as well as the prevention and/or reversal of insulin resistance by modulation
of fat metabolism.
The effects of calorie restriction on insulin sensitivity may be mediated by changes
in skeletal muscle fatty acid handling but the underlying mechanisms need to be
further elucidated. Therefore, in chapter 2 we investigated the effect of a 12-week
weight loss intervention on insulin sensitivity and on skeletal muscle fatty acid
metabolism-related gene expression in obese subjects with impaired glucose
tolerance (IGT). The very low calorie diet induced a large decrease in body weight
of approximately 15kg, which was accompanied by an improvement in insulin
sensitivity. No changes in baseline expression of genes involved in muscle fatty
acid handling (PGC1, PPAR, ACC-2, SREBPs and ChREBP) could be
observed, despite a tendency towards an increase in muscle oxidative capacity.
This may imply that changes in the postprandial state possibly play a larger role in
lipid-induced insulin resistance. However, the number of genes determined in the
present study was limited. Further research is necessary and should focus on a
more complete transcriptomic and functional profile of skeletal muscle but also
explore the other organs in a broader whole-body perspective.
Polyphenolic compounds, such as resveratrol are currently an area of intense
investigation due to their ability to mimic metabolic effects of calorie restriction.
Although originally the focus was mainly directed towards anti-oxidant properties of
resveratrol, more recently cellular effects on fatty acid metabolism and
mitochondrial function have been described. However, human data were still
lacking. Chapter 3 and 4 described the first human study that systematically
examined the metabolic effects of resveratrol in healthy obese men. In a
randomized cross-over study, resveratrol supplementation (150mg/day) for 30 days
clearly improved muscle fat oxidative and mitochondrial capacity and metabolic
flexibility. Moreover, resveratrol induced a shift towards an increased proportion of
metabolically favorable small adipocytes. This phenotype was accompanied by a
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gene expression profile indicative of increased adipogenesis and an increased lipid
breakdown by the alternative pathway of autophagy. Furthermore, intrahepatic lipid
content was decreased which may have contributed together with the improved
skeletal muscle oxidative capacity to the improvement in insulin sensitivity.
Moreover, a 2%-4% reduction in energy expenditure was observed upon
resveratrol treatment which may reflect an increased metabolic efficiency and is
consistent with the effects observed after calorie restriction. Overall, we can
conclude that resveratrol has considerable potential to improve health and prevent
chronic disease in humans. However, it is not yet certain if long-term resveratrol
supplementation will maintain these physiological benefits. Therefore, further
research is necessary to explore whether these calorie-restriction like effects
remain over time and if the reduction in energy expenditure, which was observed,
will contribute to weight gain making this supplement less attractive for the
prevention of metabolic complications.
The underlying mechanisms how dietary fatty acids may affect insulin sensitivity
and how the risk or severity of insulin resistance can be modulated by fat quantity
and quality are currently under debate. Therefore, in chapter 5, the objective was
to examine the acute effects of meals with various fatty acid compositions on
skeletal muscle fatty acid processing and postprandial insulin sensitivity in obese,
insulin-resistant men using the dual-stable fatty acid isotope technique in a
randomized cross-over design. With this technique, the contribution of dietary fat
(chylomicron-TAG, CM-TAG) vs. endogenous fat (FFA and VLDL-TAG) to in vivo
skeletal muscle fatty acid metabolism could be investigated by using two different
labels. [U-13C]-palmitate was added to a high fat mixed meal to label CM-TAG in
the circulation and [2H2]-palmitate was infused intravenously to label the
endogenous pool of fatty acids. Acute ingestion of a high fat mixed meal, high in
polyunsaturated fatty acids (PUFA) consisting of n-3 fish oil and n-6 safflower oil
(ratio 1:1) improved postprandial insulin sensitivity compared with a high saturated
fatty acid (SFA) meal. Potential underlying mechanisms for this improvement may
be the reduced uptake of TAG-derived fatty acids by the skeletal muscle, a higher
incorporation of dietary [U-13C]-palmitate from the muscle FFA pool in the different
lipid fractions (higher fractional synthetic rate [FSR]) in skeletal muscle and a lesser
downregulation of the mitochondrial oxidative genes. These data indicate an
impaired muscle fatty acid handling and turnover of in particular SFA. However,
long-term effects of SFA replacement by PUFA on insulin sensitivity may be more
complex and may also involve total fat intake.
Fiber is a major class of carbohydrates and has been reported to result in several
health effects. High fiber intake may decrease glycaemic and insulinemic
responses, which may favour lipolysis and fat oxidation rather than storage and
may attenuate fat accumulation in non-adipose tissues leading to improved insulin
sensitivity. A higher postprandial fat oxidation may also translate in a negative
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energy balance in the long term. This has led to industrial interest in developing
dietary fibers that can be incorporated in a variety of food products. However, the
question remains if these fibers provide the same health benefits as traditional
dietary fibers. For that reason, we studied in chapter 6 in a randomized crossover
study, whether replacement of 30% of the total daily intake of available
carbohydrates by polydextrose (PDX) or soluble corn fiber (SCF) at breakfast and
lunch would result in an increased fat oxidation rate and satiety in eighteen
overweight men and women. This may be of relevance for body weight control and
diabetes prevention. Logically, both fiber diets had a lower caloric value than the
full caloric control diet. To correct for the lower caloric value we also compared the
PDX diet with a second control diet with the same caloric intake as the PDX diet
(iso-caloric control). In this way, we could distinguish whether the effects observed
were attributed by the fibers per se or the lower caloric content of the fiber diets. A
diet with incorporated functional fibers like PDX and SCF reduced the peak glucose
response, which was accompanied by a reduction in postprandial insulin
responses. Furthermore, increased circulating FFA concentrations and
concomitant a higher fat oxidation were observed. This was mainly attributed by
the lower caloric value and the more negative energy balance of the high fiber diets
and not the fibers per se. Nevertheless, PDX showed favorable effects on appetite,
which appeared to be a specific characteristic of PDX independent of energy
balance. Long-term studies are needed to investigate whether the positive short
term effects of these products translate into long term benefits on body weight
control and insulin resistance in an ad libitum setting. Possibly, the energy
reduction is unlikely to engender a major reduction in body weight but could
contribute to preventing weight gain or weight regain.
It is obvious that the “ideal’ diet for obese insulin resistant subjects should include
those dietary components that induce health benefits and satiating properties that
are effective for body weight control and improvements in insulin sensitivity.
Increased consumption of food products/food supplements like resveratrol, more
unsaturated fatty acids and an increase in certain dietary fibers may improve the
metabolic flexibility of fat metabolism, which may contribute to intervention success
and long term maintenance of beneficial metabolic effects. However, further
research is necessary to evaluate the long-term benefits of these components.
Moreover, the study of complete dietary patterns, rather than isolated foods or
nutrients, may be the most adequate approach to assess the role of diet on obesity
and the insulin resistant state. This is because synergistic or antagonistic effects
may exist between the different components of the diet. The challenge for the
future is to further investigate the link between nutrition and obesity as well as
obesity-related health complications to eventually develop the most successful
personalized dietary approach to tackle these diseases.
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De epidemie van overgewicht en obesitas verspreidt zich in snel tempo over de
hele wereld. Deze alarmerende toename van obesitas is geassocieerd met een
verhoogde incidentie en prevalentie van co-morbiditeiten zoals type 2 diabetes
mellitus (T2DM). Bovendien komt overgewicht op steeds jongere leeftijd voor,
waarbij veranderingen in leefstijl een belangrijke rol spelen. Het volgen van een
dieet kan hulp bieden, maar er is duidelijk behoefte aan extra preventieve
strategieën om de effectiviteit van dieet programma’s te verhogen. Onderzoek naar
bepaalde voedingsmiddelen en voedselingrediënten die fysiologische processen
kunnen beïnvloeden zoals het verhogen van de vetverbranding en het herstellen
van metabole flexibiliteit, kan een belangrijke rol spelen bij de preventie en
behandeling van obesitas en T2DM. In dit proefschrift werd onderzocht wat de
effecten waren van verschillende voedingsinterventies op het lichaamsgewicht en
het voorkomen en/of omkeren van insuline resistentie door het beïnvloeden van de
vetstofwisseling.
De effecten van calorie restrictie op de insulinegevoeligheid kan worden
gemedieerd door veranderingen in de vetstofwisseling van de skeletspier, maar de
onderliggende mechanismen moeten verder worden onderzocht. Daarom hebben
we in hoofdstuk 2 het effect bestudeerd van een 12 weken durend dieet op
insuline gevoeligheid en op genen betrokken bij de vetstofwisseling in de
skeletspier bij obese proefpersonen met een verstoorde glucose tolerantie (IGT).
Het dieet was gebaseerd op een zeer lage inname van calorieën wat leidde tot een
grote daling in het lichaamsgewicht van ongeveer 15kg en een verbetering van de
insulinegevoeligheid. Er werden geen veranderingen waargenomen in
verschillende genen betrokken bij de vetstofwisseling (PGC1, PPAR, ACC-2,
SREBPs en ChREBP) in de skeletspier in nuchtere toestand. Desondanks trad er
toch een verbetering op in de verbrandingscapaciteit van de spier. Dit kan
betekenen dat veranderingen in de postprandiale toestand een grotere rol spelen
in lipide-geïnduceerde insulineresistentie. Het aantal genen dat we bepaald
hebben in deze studie was echter gelimiteerd. Verder onderzoek is noodzakelijk en
moet zich meer richten op het volledige transcriptoom en het functionele profiel van
de spier, maar moet daarnaast ook de andere organen hierbij betrekken om alles
in een breder perspectief te kunnen zien.
Polyfenolen zoals resveratrol kunnen de metabole effecten van calorie restrictie
nabootsen. Hoewel oorspronkelijk de aandacht gericht was op de
antioxidantwerking van resveratrol is er recentelijk meer aandacht voor het effect
van resveratrol op de vetstofwisseling en de mitochondriële functie. In hoofdstuk 3
en 4 hebben we de eerste humane studie beschreven die systematisch de
metabole effecten van resveratrol heeft onderzocht bij gezonde obese mannen. In
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een gerandomiseerde cross-over studie waarbij resveratrol (150mg/dag) werd
toegediend gedurende 30 dagen verbeterde de verbrandingscapaciteit van vet in
de mitochondriën van de spier en de metabole flexibiliteit. Daarnaast was er ook
een toename in de proportie van kleine, metabool gunstige vetcellen. Dit fenotype
ging gepaard met een genexpressieprofiel dat wees op een verhoogde
adipogenese en een alternatieve pathway van vetafbraak (autofagie). Verder werd
een verminderde vetstapeling in de lever gevonden die samen met een efficiëntere
omzetting van vetten in de spier kan hebben geleid tot de verbetering in
insulinegevoeligheid. Verder was er een reductie in energieverbruik van 2%-4% na
resveratrol supplementatie wat overeenkomt met effecten die aangetoond zijn na
calorie restrictie en wat kan wijzen op een verhoogde metabole efficiëntie. Uit deze
resultaten kunnen we concluderen dat resveratrol potentieel heeft om de
gezondheid te verbeteren en chronische ziekten te voorkomen. Het is echter niet
zeker of deze gunstige fysiologische effecten behouden kunnen worden op lange
termijn. Verder onderzoek is nodig om te onderzoeken of de vermindering in
energieverbruik die waargenomen werd, zal bijdragen aan een gewichtstoename,
wat dit supplement minder aantrekkelijk zou kunnen maken als preventief middel
tegen metabole complicaties.
De onderliggende mechanismen die verklaren hoe vetten in de voeding de insuline
gevoeligheid kunnen beïnvloeden en hoe de hoeveelheid en de kwaliteit van het
vet het risico op de ontwikkeling van insulineresistentie kunnen beïnvloeden, staan
momenteel nog ter discussie. Het doel van hoofdstuk 5 was om de acute effecten
van maaltijden rijk aan vet maar met verschillende vetzuursamenstellingen op de
vetstofwisseling in de skeletspier en de postprandiale insulinegevoeligheid te
onderzoeken bij obese, insulineresistente mannen. Dit werd gedaan met behulp
van twee verschillende isotopen van het vetzuur palmitaat in een gerandomiseerde
cross-over studie. Met deze techniek werd de bijdrage van vetten uit de voeding
(chylomicron-triacylglycerol, CM-TAG) of vetten reeds aanwezig in het lichaam
(vrije vetzuren en VLDL-TAG) onderzocht. [U-13C]-palmitaat werd toegevoegd aan
een gemengde maaltijd rijk aan vetten om de CM-TAG in de circulatie te labelen en
[2H2]-palmitaat werd intraveneus geïnfuseerd om de endogene pool van vetzuren
te labelen. De acute inname van een maaltijd met meervoudig onverzadigde vetten
(PUFA) die bestond uit n-3 visolie en n-6 saffloerolie (ratio 1:1) verbeterde de
postprandiale insuline gevoeligheid in vergelijking met een maaltijd met verzadigde
vetten. Dit ging gepaard met een verminderde opname van vetzuren afkomstig van
triglyceriden door de spier, een hogere opname van voedingsvetzuren in de
verschillende lipide fracties van de spier (hogere fractionele synthetische snelheid)
en een verminderde downregulatie van mitochondriële oxidatieve genen in
vergelijking met de maaltijd met veel verzadigd vet. Deze gegevens wijzen op een
hogere lipiden turnover na inname van PUFA in vergelijking met verzadigde vetten,
wat één van de verklaringen kan zijn voor de verhoogde postprandiale insuline
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gevoeligheid. Echter, het effect van het vervangen van verzadigde vetten door
meervoudig onverzadigde vetten op de insulinegevoeligheid op de lange termijn is
complex en mogelijk speelt hier de totale vetinname ook een belangrijke rol.
Vezels zijn een belangrijke component van koolhydraten en kunnen bijdragen aan
positieve gezondheidseffecten. Een hoge inname van vezels kan de glucose- en
insulinerespons doen afnemen en kan zo bijdragen aan een verbeterde afbraak en
oxidatie van vet en verminderde vetopslag. Hierdoor zullen er minder vetten
stapelen in ectopische weefsels wat kan leiden tot een betere insulinegevoeligheid.
Een hogere postprandiale vetverbranding kan zich ook vertalen in een negatieve
energiebalans op de lange termijn. Hierdoor is de interesse van de industrie
gewekt om vezels te produceren die toegevoegd kunnen worden aan verschillende
voedingsmiddelen. De vraag is echter of deze vezels dezelfde positieve effecten
bieden voor de gezondheid als de traditionele voedingsvezels. Om die reden
onderzochten we in hoofdstuk 6 in een gerandomiseerde cross-over studie of de
vervanging van 30% van de totale dagelijkse inname van beschikbare
koolhydraten door polydextrose (PDX) of oplosbare maïsvezels (SCF) bij het ontbijt
en de lunch zou resulteren in een verhoogde vetverbranding en verzadiging bij
achttien mannen en vrouwen met overgewicht. Dit zou het lichaamsgewicht onder
controle kunnen houden en diabetes kunnen voorkomen. Beide vezel diëten
hadden een lagere calorische waarde dan het dieet met de controle
voedingsmiddelen. Om te corrigeren voor deze lagere calorische waarden werd het
PDX dieet ook vergeleken met een tweede controle dieet met hetzelfde aantal
calorieën (iso-calorische controle). Op deze manier kon er worden onderzocht of
de effecten door de vezels zelf veroorzaakt werden of door de lagere calorische
inhoud van de vezel diëten. Een dieet met deze functionele voedingsvezels
verminderde de piekwaarde van de postprandiale glucoserespons, wat gepaard
ging met een vermindering in postprandiale insulinerespons. Bovendien namen de
circulerende vrije vetzuurconcentraties toe en gelijktijdig werd een hogere
postprandiale vetverbranding waargenomen. Dit werd voornamelijk veroorzaakt
door de calorische waarde en de meer negatieve energiebalans van het vezelrijke
dieet en niet door de vezels zelf. Desalniettemin vertoonde PDX gunstige effecten
op de eetlust, wat onafhankelijk was van de energiebalans. Er zijn echter lange
termijn studies nodig om het effect van deze producten te onderzoeken op de
regulatie van het lichaamsgewicht en de insulinegevoeligheid in een ad libitum
setting. Waarschijnlijk zal de reductie in energie geen groot effect hebben op het
verlies in lichaamsgewicht maar kan het wel bijdragen aan de preventie van
gewichtstoename en het jojo-effect.
Het is duidelijk dat het "ideale" dieet voor obese insulineresistente mensen dient te
bestaan uit die voedingscomponenten die een gezond voedingspatroon induceren
en verzadigende eigenschappen bezitten die effectief zijn voor verlaging en
handhaving van het lichaamsgewicht en die verbeteringen in insuline gevoeligheid
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induceren. Verhoogde consumptie van voedingsmiddelen/ voedingssupplementen
zoals resveratrol, meer onverzadigde vetzuren en een toename in bepaalde
voedingsvezels kunnen de metabole flexibiliteit van het vetmetabolisme verbeteren
en kunnen zo bijdragen aan leefstijlinterventie succes en lange termijn handhaving
van gunstige metabole effecten. Er is echter verder onderzoek nodig om de
langetermijn effecten van deze componenten te evalueren. Bovendien moet het
onderzoek gericht zijn op het bestuderen van volledige voedingspatronen, in plaats
van losse voedingsmiddelen of nutriënten, om zo het effect van voeding op
obesitas en insulineresistentie vast te stellen. Dit omdat er synergetische of
antagonistische effecten kunnen bestaan tussen de verschillende componenten
van het dieet. De uitdaging voor de toekomst is het verband tussen voeding en
obesitas, alsook obesitas gerelateerde ziektes verder te onderzoeken om
uiteindelijk het meest succesvolle persoonlijke dieet te ontwikkelen om deze
ziektes te voorkomen of aan te pakken.
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Coming together is a beginning,
keeping together is progress,
working together is
success!
~ Henry Ford ~
Een dankwoord schrijven geeft altijd een beetje een dubbel gevoel. Enerzijds een
gevoel van opluchting omdat het proefschrift klaar is en ik dit hoofdstuk eindelijk
kan afsluiten om me ten volle over te geven aan nieuwe uitdagingen die op mijn
pad liggen. Anderzijds een gevoel van gemis omdat ik hier 4 jaar intensief mee
bezig ben geweest en naast de minder leuke dingen ook onvergetelijke momenten
heb beleefd! Daarom wil ik graag iedereen bedanken die op wat voor manier dan
ook heeft bijgedragen tot dit succes!
Daarnaast verdienen nog een aantal mensen een speciaal woordje van dank.
Allereerst wil ik mijn promotoren Prof. dr. Ellen Blaak en Prof. dr. Edwin Mariman
bedanken voor de mogelijkheid die ik heb gekregen om een promotie onderzoek te
starten.
Beste Ellen, je deur stond altijd open en ik kon steeds bij je terecht met al mijn
vragen. Ik bewonder hoe je telkens de positieve kanten van mijn onderzoek naar
boven wist te brengen.
Beste Edwin, bedankt voor al de keren dat je zomaar even kwam binnenspringen
om een praatje te maken. Door deze gesprekken kreeg ik weer extra moed om er
keihard tegenaan te gaan en heb ik meer inzicht gekregen in het onderzoek.
Bedankt allebei voor de steun gedurende de afgelopen jaren en voor de talloze
revisies van de hoofdstukken en manuscripten om zo dit proefschrift naar een
hoger niveau te brengen.
Next, I would like to thank all members of the reviewing committee, Prof. dr. Wim
Saris, Prof dr. Karine Clément, dr. Jogchum Plat, Prof. dr. Casper Schalkwijk and
Prof. dr. Annemie Schols for taking the time to review my thesis and/or being
present at the official dissertation.
Anneke en Annemieke, de keuze was snel gemaakt om jullie als mijn paranimfen
te kiezen. Sinds de eerste dag bij HB had ik het geluk om bij jullie op de kamer te
mogen. Anneke, wat was het leuk om samen onze eerste humane studie te mogen
uitvoeren. We waren echt een superteam! Daarnaast hebben we ook nog vele fijne
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carpoolmomenten beleefd. Ik wens je nog het allerbeste toe en nog veel geluk met
je gezinnetje in jullie nieuwe huis!
Annemieke, wat vonden we het jammer toen Anneke bij ons weg ging. Het laatste
jaar hebben we dus met ons 2-tjes doorgebracht. Dit betekende echter niet dat het
minder gezellig was. Ik kon altijd bij je terecht al was het maar om af en toe eens te
klagen ;-) Ik wens je nog veel geluk in je verdere leven met Christiaan en hoop dat
we nog lang in contact blijven. Ook bedankt voor de laatste aanpassingen aan de
kaft. Hij is nu echt geworden zoals ik in gedachten had!
Met ons 3-en hebben we veel plezier gemaakt waardoor Ellen B. zich soms
afvroeg of er ook nog ooit werd gewerkt :-). Zo hielden we ons onder andere bezig
met lachwekkende photoboot momenten, het oefenen van de belt flip (en dat in
een overvolle kamer), jongleer oefeningen (braintraining…), het verzamelen van
AH en Plus gadgets, de snoeppot vullen en leeg eten (na een tijdje zijn we hier
maar mee gestopt in het kader van een gezonde leefstijl), bloemetjes zaaien, zelf
kleine experimenten opzetten, in de zomer ijsjes eten, lunchwandelingen, een tocht
door Maastricht om spullen te kopen voor het vezelonderzoek, het in leven
proberen houden van ons plantje dat bijna dood was doordat we alle drie in
dezelfde periode op vakantie gingen, en nog meer van deze ontspannende
activiteiten… Maar wees niet ongerust daarnaast werd er ook keihard gewerkt!
Kortom, we hebben samen zoveel beleefd dat ik niemand anders wilde als
paranimfen om mij bij mijn promotie bij te staan!
Chantalle, je hebt Anneke en mij de kneepjes van het vak geleerd. Zonder jou was
onze eerste studie niet zo een succes geweest. Ik zal nooit vergeten hoe goed jij
met de proefpersonen om kon gaan om het ze naar hun zin te maken. Het
eindeloos aantal cupjes schrijven en altijd opnieuw dezelfde films meekijken viel
uiteindelijk erg mee omdat het altijd zo gezellig was! Ook bedankt om deel te
nemen aan één van mijn studies.
Silvie, jij verdient ook een speciaal woordje van dank. De tweede humane studie
mocht ik namelijk met jou uitvoeren. Voor jou was het je eerste humane studie en
je hebt dit echt super goed aangepakt! Ondanks de vele weekends (inclusief
nachten) die je op de uni hebt doorgebracht bleef je op maandag nog tot in de late
uurtjes tot de testdag was afgelopen. Ik bewonder je doorzettingsvermogen en je
wetenschappelijk inzicht! Het was erg fijn om met je te mogen samenwerken!
Gijs, bedankt voor de ondersteuning bij de vele humane studies! Je stond altijd
klaar om te helpen met het plaatsen van infusen en probes en het afnemen van
spierbiopten. We konden altijd op je rekenen. Ook bedankt voor de vele
wetenschappelijke en minder wetenschappelijke discussies, dit heeft zeker
bijgedragen tot mijn inzicht in het onderzoek. Veel succes in je verdere loopbaan!
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Johan, je bent voor mij een echte diehard wetenschapper! Met al mijn labvragen
kon ik steeds bij jou terecht. Hoe dikwijls heb ik niet bij je op de kamer gestaan als
een western blot weer niet lukte. Je had steeds weer nieuwe ideeën om tot een
oplossing te komen. Ik hoop dat je nog vele kansen krijgt om jouw briljante ideeën
uit te werken want je verdient het om hierin verder te gaan!
Anneke VH en Eefje, de “oude garde” van het vetstofgroepje! Eefje, ook al had je
een nieuwe baan in het verre Groningen, ik kon steeds bij jou terecht met al mijn
vragen. Anneke VH, toen ik begon was jij in de afrondfase van je promotie, jij was
voor mij de expert in de stabiele isotopendata en jouw templates zijn voor velen
van ons nog goed van pas gekomen!
Dorien, Jasper, Emanuel en Rudi, de “nieuwe” garde van het vetstofgroepje!
Bedankt voor de leuke babbels en wetenschappelijke discussies. Veel succes nog
met jullie onderzoek en Dorien laat je niet doen door al die mannen ;-)
Hoewel we op het einde niet meer een gezamenlijk overleg hadden met het
groepje van Marleen wil ik ook graag jullie bedanken! Roel, Erik, Dorit en Karianna
bedankt voor de collegialiteit! Karianna nog eens extra bedankt om altijd voor me
klaar te staan als ik weer een vraag had over een statistische analyse. Je bent het
statistisch wonder van HB ;-)
Buurmannen Herman en Jonathan, bedankt voor de gezellige gesprekken, leuke
practica en het printen van mijn labels. Wat was ik blij toen ik niet meer al die
cupjes met de hand moest schrijven! Het heeft me heel wat tijd en werk bespaard!
Judith, Marjet en Paul, bedankt om mij te introduceren in de wondere wereld van
de respiratiekamer. Paul, als er iets mis was met de respiratiekamer stond je
steeds weer voor me klaar, zelfs in het weekend en de avonduren! Judith en
Marjet, dankzij jullie gingen mijn respiratiekamer metingen erg vlot omdat ik het van
de experts geleerd had ;-) Ook bedankt voor de gezellige avonden als we samen
een meting hadden!
Doordat ik een Mac en PC had, betekende het soms ook dat de problemen voor
twee telden. Loek, bedankt dat jij voor elk probleem wel een oplossing wist!
Laurens, ook jou mag ik niet vergeten. Als er iets was met de omnical, diskettes die
niet werkten (ja die bestaan nog bij HB) of bestanden die op mysterieuze wijze niet
wilden openen op mijn computer stond jij altijd voor me klaar.
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Claudia, Desiree en Jolanda, bedankt voor de hulp als ik mijn sleutel weer eens
vergeten was, met het fax- en scanapparaat en de administratie rond mijn
proefschrift.
Ook bedankt aan alle analisten, Wendy, Hasibe, Annemie, Yvonne en Jos voor het
uitvoeren van de vele analyses. Zonder jullie was het nooit gelukt!
Nog een speciaal woordje van dank aan Yvonne en Jos!
Yvonne, bedankt voor de hulp bij de analyses van de vet- en spierbiopten. Ik heb
erg veel van jou geleerd!
Jos, wat was het gezellig als je zoals gewoonlijk ’s avonds en in het weekend op
het werk was terwijl ik een respiratiekamermeting had! Hierdoor voelde ik me
tenminste niet alleen en had ik iemand om samen mee te eten, TV kijken en af en
toe een biertje (kriek Lindemans ;-)) te drinken. Hoewel de bitterballen helaas niet
meer mochten, zijn de borrels nog steeds een succes! Bedankt Jos, om de
organisatie steeds weer op jou te nemen en om iedereen te motiveren om op
vrijdag om 16u het werk neer te leggen en weekend te vieren!
Freek, Montserrat, Anja, Anke, Antoine, Johan S. en Johan R., bedankt voor de
gezelligheid op het lab tijdens het runnen van de vele PCR’s en western blots.
Jullie stonden steeds voor me klaar als ik weer een vraag had of een helpende
hand nodig had.
Dit proefschrift is mede tot stand gekomen door de samenwerking met
Wageningen voor het runnen van de micro-arrays . Bedankt Michaël, Mark en
Lydia voor de hartelijke ontvangst en de goede wetenschappelijke discussies. Ik
heb zeer veel van jullie geleerd tijdens de week dat ik bij jullie mocht werken om
me te verdiepen in de micro-array analyses. Al hadden we in het begin vele
hindernissen te overwinnen dit weerhield me niet om bij een volgende studie nog
eens voor deze techniek te kiezen 
Humane studies uitvoeren kan je niet zonder proefpersonen. Bedankt allemaal!
Bedankt aan alle collega’s voor de leuke congressen, het ontspannende citytripje
Istanbul, gezellige borrels, de fijne vakgroepuitjes, weekendje Ardennen en zoveel
meer waardoor ik weer extra energie kreeg om verder te gaan.
I also want to thank my new colleagues at Medtronic for the pleasant atmosphere
and for making me feel very welcome. Although we are located all over the world
we are really one team! It is great working with you all!
Er zijn uiteraard ook mensen die ervoor gezorgd hebben dat het leven niet alleen
uit onderzoek en het proefschrift bestond. Allereerst “de jeugd” van de harmonie.
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Ook al hebben sommigen onder ons een niet meer zo jeugdige leeftijd toch
noemen we ons nog steeds zo ;-) Door de leuke sfeer was ik meestal snel
vergeten dat ik op zondagochtend weer zo vroeg moest opstaan om klarinet te
spelen. Daarnaast hebben de vele uitstapjes (dag en nacht), repetitieweekenden
en de reis naar Praag voor onvergetelijke momenten gezorgd! Ik hoop dus nog
vele jaren bij de “jeugd “ te mogen horen. Nog een extra bedankje voor Sanne!
Zonder jou had ik nu niet zo een mooie kaft, het was erg leuk om samen het
voorbereidende werk te doen!
Ook bedankt aan iedereen van het Biomedische clubje. Ook al zie ik sommigen
van jullie meer dan anderen toch is het steeds gezellig als we weer een keertje
afspreken. Ik hoop dus dat we dit in de toekomst nog vaak kunnen doen. Kathleen,
ook al heeft ons Vietnamreisje misschien voor enige vertraging gezorgd in het
afmaken van mijn proefschrift. Ik heb er zeker geen spijt van want het was een reis
om nooit te vergeten!
Nele en Sarah, de etentjes en spelletjesavonden waren altijd zeer gezellig en nu
dat mijn proefschrift eindelijk klaar is heb ik terug meer tijd om vaker naar Leuven
af te zakken.
Het frisbeeteam, ook al was ik meestal meer actief naast het veld (als supporter)
dan op het veld, ik heb erg genoten van de vele tornooien in binnen- en buitenland
in de zon en de regen en zal de leuke verkleedfeestjes niet snel vergeten!
Ook het jaarlijkse weekendje met de “oud klasgenoten” van Fery en de
verscheidene activiteiten van A.S.G. hebben voor de nodige ontspanning gezorgd!
Familie en schoonfamilie, sommigen onder jullie vroegen zich af wanneer ik nu
eindelijk klaar zou zijn met studeren of wisten nooit helemaal precies wat ik deed.
Toch hebben jullie steeds voor de nodige interesse, afleiding en plezier gezorgd!
Mama en papa, ik neem aan dat jullie nog steeds niet goed begrijpen waar ik
eigenlijk de voorbije vier jaar mee bezig ben geweest. Desondanks hebben jullie
alles nauwlettend op de voet gevolgd en steeds geïnteresseerd geluisterd naar wat
ik te vertellen had. Ik wil jullie graag danken omdat jullie er steeds voor me zijn en
omdat ik altijd op jullie kan rekenen!
Als allerlaatste dan eindelijk de persoon die mijn dank het meeste heeft verdiend
en die ik waarschijnlijk niet genoeg kan bedanken. Fery, mijn liefje, er is niemand
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